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Chapter 1 
Effects of insulin on vascular tone and 
sympathetic nervous system. 
Introduction and Outline of the studies 
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I о Ι CHAPTER 1 
Introduction 
The last decade, an overwhelming amount of data has pointed to the relationship 
between insulin resistance/hyperinsulinemia and cardiovascular disease (1-5). A 
reduced sensitivity to the metabolic effects of insulin (insulin resistance) has been 
related to several disorders of which hypertension, obesity, dyslipidemia and non-
insulin-dependent diabetes mellitus (NIDDM) are the most common (6-8). 
Furthermore hyperinsulinemia has been directly associated with atherosclerosis 
and cardiovascular events (2,9). The nature of the relation between insulin 
resistance and cardiovascular morbidity and mortality is not clear. Insulin 
resistance is physiologically compensated by hyperinsulinemia, which also holds 
true in most patients with NIDDM (10-13). This has brought up the hypothesis 
that the relationship between insulin resistance and cardiovascular disease/ 
hypertension might be related to some cardiovascular effect of insulin itself (Μ­
Ι 6). These effects have indeed been described in-vitro as well as in-vivo in human 
individuals (17-19). 
This overview will focus on two aspects of these "extra-metabolic" actions of 
insulin: the effects on vascular tone, and the interaction with the sympatho­
adrenal system. Recent advances in the knowledge of physiological effects of 
insulin on the cardiovascular system and the sympathetic nervous system (SNS) will 
be described, and related to the pathophysiological condition of insulin 
resistance. This overview will principally be limited to in-vivo experiments 
performed in humans. 
Experimental conditions and methods 
In early experiments in humans, effects of insulin were mainly studied after an 
intravenous bolus of insulin, and are therefore hampered by the subsequent 
hypoglycemic event (20). Furthermore, under these circumstances, non-steady 
state conditions exist. Plasma insulin as well as glucose concentrations change 
continuously over time, biological effects are not linearly related to plasma 
concentration; both parameters mutually influence each other, but again not 
linearly. Therefore it is difficult to draw firm conclusions from these experiments. 
Nearly all studies on the relationship between insulin and vascular tone or SNS of 
the last decade have used the euglycemic hyperinsulinemic clamp, which allows 
that investigations can be performed under steady state insulin concentrations 
and euglycemia (21,22), as well as at various glycémie levels (23). However, it has 
to be emphasized that the clamp technique is far from truly physiological: 
systemic hyperinsulinemia is achieved by peripheral insulin infusion. In contrast to 
physiological conditions, portal insulin concentrations are therefore equal to 
systemic levels. Likewise, glucose is infused directly intravenously, and does 
INTRODUCTION AND OUTLINE OF THE STUDIES 11 
therefore not initially pass the gastro-intestinal tract and the portal circulation. 
Finally, at high insulin levels, arterio-venous differences in glucose concentrations 
will increase, and in case of euglycenoic clamping (of the arterial level), the actual 
deep venous plasma glucose concentration may reach unphysiological low values. 
Effects of insulin on vascular tone 
Acute effects of insulin 
In 1968, Miles and Hayter reported that intravenous insulin (followed later by 
intravenous glucose) induced a decrease in arterial pressure in the supine 
position. Four of eight subjects with sympathetic failure (predominantly patients 
with diabetes), lost consciousness in the upright posture (20). After intravenous 
glucose all subjects recovered. The authors suggested that insulin may cause a 
decreased arterial resistance, which might be compensated for by normal 
baroreceptor reflexes (20). In case of absent compensatory reflexes, fainting 
might result. These observations suggest a direct hypotensive effect of insulin, 
possibly by vasodilation in resistance arterioles. Indeed, hypotensive effects to 
insulin have been reported in patients with autonomic failure (24), and diabetic 
autonomic neuropathy (25). Apart from these and other reports (26), from 1990 
onwards, the vasodilator effect of insulin has been convincingly shown by several 
authors. With the use of prolonged hyperinsulinemic clamps, it was shown that 
systemic hyperinsulinemia induces an increase in leg blood flow (as determined by 
dye dilution), that was preceded by a rise in skeletal muscle glucose uptake (27). 
Because glucose uptake is determined by tissue extraction, but also by blood flow 
[Fick's principle], the insulin-induced vasodilation enhances insulin's own 
stimulatory effect on glucose uptake (27). An S-shaped dose-response relationship 
between plasma insulin concentration during the clamp and leg blood flow was 
reported, with the steepest part of the curve at high physiological insulin 
concentrations (27-29). It is important to emphasize that these results have been 
obtained using "stepped" clamps, in which sequential increasing insulin doses are 
infused during variable time intervals, with measurements at the end of each 
insulin dose. These long lasting experiments (up to more than 8 hours) do not 
rule out time or sequence effects. Several other groups have confirmed the 
vasodilator effect of insulin in skeletal muscle in man (17,30-35). Vasodilation in 
response to systemic insulin infusion has been demonstrated using a variety of 
invasive (dye dilution) (29-31) as well as non-invasive techniques 
(plethysmography) (32-35), in both forearm (33,35) and leg (29-32,34). 
Vasodilator action under conditions of insulin resistance 
Insulin-induced vasodilation has been reported to be diminished under conditions 
of insulin resistance, such as obesity (29,37,38), hypertension (15,33), NIDDM 
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(39,40), IDDM (41) and aging (42). Furthermore insulin-mediated influence on 
vascular tone is diminished when insulin resistance is induced in normal subjects 
by dexamethasone (43) or by infusion of triglycerides (34). It has been postulated 
that the decreased insulin-induced vasodilation explains part of the diminished 
glucose uptake and represents as such a novel mechanism for insulin resistance 
(15,29,30,44), but the significance of this effect has been refuted by others (45-
47). 
It has been claimed that insulin-induced blood flow increase is larger at higher 
plasma glucose concentrations (27,40), but these results have been reached by 
sequential stepped clamps of long duration, and are not confirmed by others. 
An area of major controversy exists regarding the effects of locally (direct intra-
arterially) infused insulin on skeletal muscle blood flow. Although several 
investigators do report an increase in blood flow in forearm or leg (30,48-53), 
others do not (54-60). Part of this controversy may be related to the dose of 
insulin, the duration of infusion and the forearm muscle content (35). 
The mechanism of insulin's vasodilator action is not completely understood. An 
interaction with the autonomic nervous system has been proposed; theoretically, 
both a decreased vascular sensitivity to α-adrenergic stimuli, or an augmented 
response to ß-adrenoceptor agonists, might explain insulin-induced vasodilation. 
Indeed, earlier reports seemed to point to a ß-adrenergic mediated vasodilation 
(51,61), but these results were not confirmed by others (32). Several investigators 
have adressed the interaction of insulin with a- or ß-adrenergic sensitivity. The 
studies however show many differences in design, and the reported results are 
controversial; some studies show an exaggerated response to norepinephrine (62-
64) during systemic acute hyperinsulinemia, some a diminished response 
(54,56,60) during local hyperinsulinemia, and some report no change (48,50,65,66) 
during local or systemic insulin administration. 
More recent reports have indicated that insulin-induced vasodilator action seems 
to be nitric oxide (NO) related (53,67). However, novel in vitro experiments 
disagree with these findings, and suggest involvement of potassium channels (68). 
Furthermore, interactions between insulin and Na*-K*-ATPase might induce 
hyperpolarization and subsequent vasodilation (19,69). Hence, the exact 
mechanism of insulin-induced vasodilation requires further investigation. 
Effects of insulin on the sympatho-adrenal system 
Methods of investigation 
The activity of the sympathetic nervous system (SNS) in humans is difficult to 
investigate. The relationship between insulin and the sympathetic nervous system 
has been studied by several techniques (70). Activation of sympathetic nerves will 
lead to release of norepinephrine in the synaptic cleft, most of which will 
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undergo re-uptake (71). An amount of the released norepinephrine is extra-
neuronally inactivated by Catechol-O-Methyl Transferase (COMT) to 
normetanephrine. Part of the norepinephrine however leaks ("spills over") to the 
extracellular fluid and plasma compartment (72). Venous norepinephrine 
concentration is therefore an indirect, crude, measure of sympathetic nerve 
activity, as is urinary norepinephrine excretion. Venous norepinephrine 
concentration is determined by total body norepinephrine spillover and clearance 
on the one hand, local (forearm) spillover and removal on the other hand, as well 
as by blood flow. Norepinephrine concentration in arterial blood is a more precise 
estimate of synaptic norepinephrine spillover (73). With the use of tracer 
norepinephrine infusion (74,75) an even more detailed estimate of sympathetic 
neural activity is possible (70). 
Direct measurement of sympathetic nerve traffic to muscle by microneurography 
offers a powerful tool for studying the activity of the human SNS in vivo (76). 
Muscle sympathetic nerve activity (MSNA) has been shown to be closely related to 
plasma norepinephrine spillover (70,77). The MSNA technique has besides 
advantages also drawbacks: It is technically demanding and in a proportion of 
cases unsuccessful. Moreover neural outflow at one location does not necessarily 
reflect global sympathetic activity (70). 
Finally, power spectral analysis of diurnal blood pressure and heart rate have 
been used for estimating sympathetic activity (70). The value and validation of 
these techniques, however remains uncertain up to now. 
Effect of acute insulin administration on 5N5 activity 
The relationship between insulin and the SNS originates in the relation between 
food intake / meal composition and subsequent change in sympathetic nervous 
activity (78,79). In laboratory animals it has been shown that fasting inhibits 
whereas overfeeding stimulates SNS activitiy (7,80). Similar observations were 
obtained in humans: A sympathetic response as measured by MSNA was observed 
after ingestion of carbohydrates (81). Subsequently, evidence emerged that 
carbohydrate-induced insulin secretion might be responsible for the observed 
changes (82). 
One of the first studies showing a direct relationship between insulin and the SNS 
was a study of Rowe et al. They demonstrated an increase in plasma 
norepinephrine concentrations during insulin infusions under clamp conditions for 
150 minutes. The increase was most prominent at fairly high doses of insulin (83). 
The group of Anderson has extended and repeated these experiments with the 
use of microneurography. During two sequential one-hour periods of insulin 
infusion, leading to physiological and supra-physiological plasma insulin 
concentrations, MSNA gradually increased (17). Plasma norepinephrine 
concentrations rose concurrently (17). These results were confirmed by by Berne 
et al., again demonstrating an increase in MSNA during hyperinsulinemic clamp 
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(84), although a sequential two step clamp did not show a clear dose-response 
relationship. Also in another study no clear dose-response relationship was 
observed (43). The largest part of the increment in SNS activity seems to occur 
already during the lower insulin dose (37,85). 
There are no studies specifically addressing time-relationships although in some 
studies with constant insulin infusion, most changes occur in the first hour 
(37,43,62). The increase in plasma norepinephrine concentration is due to 
increased systemic spillover (and hence probably increased sympathoneural 
release), as can be derived from norepinephrine kinetic studies (58). 
It is of importance to stress that at least two groups (84,85) have performed 
control studies and reported that the observed changes during insulin, were not 
found during placebo, although one report claimed that neural activation could 
be due to the clamp procedure itself (86). 
Mechanism of sympathetic activation 
It has been mentioned earlier that activation of the sympathetic nervous system 
must be ascribed to hyperinsulinemia and not to glucose infusion (81,82). During 
euglycemic clamps, hypoglycemic episodes are avoided, which means that 
sympathetic activation cannot be due to glycopenia. Local (forearm) 
hyperinsulinemia does not activate SNS (58), suggesting that only systemic 
hyperinsulinemia is able to induce sympathoneural activation. The observed 
sympathetic activation could be baroreceptor-mediated as a concequence of a 
slight, insulin-induced decline of blood pressure. In acute experiments in humans, 
insulin infusion exerts a vasodilator effect as mentioned earlier in this chapter 
(17,29). The concept in which vasodilation and sympathetic stimulation are 
coupled is supported by the fact that in patients with autonomic failure insulin 
induces hypotension (24,25). In addition, in conditions characterized by insulin 
resistance such as obesity (37), and after dexamethasone (43), both insulin-
induced vasodilation and sympathetic activation are blunted. However, in earlier 
reports, a lack of parallelism between the course of both parameters was noticed 
(17). Also two recent reports suggesting a dissociation of the sympathoexcitatory 
action of insulin and its vasodilator effect (85,87) seem to argue against this 
concept. An already longer suggested mechanism is stimulation at the level of the 
central nervous system leading to both activation of the SNS and vasodilation in 
skeletal muscle vascular beds (7,88). Further studies are necessary to unravel the 
mechanism of sympathoadrenal stimulation by insulin. 
Basal and insulin-stimulated sympathetic activity under conditions of insulin 
resistance 
Disorders characterized by insulin resistance such as obesity, hypertension and 
NIDDM (1,4), can be viewed as a continuous exposure to hyperinsulinemia. 
Therefore it is an important question, whether this chronic hyperinsulinemia 
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affects the (basal) activity of the SNS. Recent reports have indeed established a 
clear correlation between baseline MSNA and body mass index. A higher body 
mass was associated with a higher basal sympathetic activity (78,89). It is not 
surprising that across the same group of individuals with a large range in body 
mass, an association was found between insulin concentration and MSNA (78). 
The higher SNS activity in obese subjects as compared to leans, decreased to a 
nearly normal level following a very low calory diet for 8 weeks (90,91). It is well 
known that both low energy intake and weight loss also improve insulin 
sensitivity (92). In insulin resistant obese subjects, the sympathoexcitatory effect 
of acute hyperinsulinemia seems to be lost (37). Two hour insulin infusions 
induced a gradual increase in MSNA in lean individuals, but the increase was 
abolished in obese subjects (37). However it has to be emphasized that the basal 
values of the obese group were considerable elevated, as compared to the lean 
control group. This means that a substantial insulin-induced increase in 
sympathetic outflow in the lean would still have resulted in values comparable to 
those observed in the obese at baseline. The increase in sympathetic nerve traffic 
after glucose ingestion in obese subjects is reported to be blunted too (93). 
In hypertension, an established insulin resistant state (6), a normal basal and 
insulin-stimulated MSNA (94,95), an elevated basal MSNA (96), and an 
exaggerated response to insulin with respect to norepinephrine spillover (58) 
have all been reported. Basal MSNA was not higher in hypertensive obese subjects 
compared to normotensive obese controls (97). 
In insulin-dependent diabetes (IDDM), regarded as an insulin resistant state 
(45,46), especially when complicated by nephropathy (98), the situation is more 
complex. It is beyond any doubt that chronic hyperinsulinemia does exist in IDDM, 
partly as a result of the unphysiologic route of insulin administration. In a group 
of uncomplicated IDDM, Hofmann and coworkers have reported a decreased 
instead of an increased basal SNS activity, which could be normally stimulated by 
superimposed acute hyperinsulinemia (99). The authors attributed this lower basal 
MSNA to a subclinical autonomous neuropathy, although no other tests indicated 
autonomic disturbances, and therefore this interpretation has been critized (100). 
The decreased MSNA levels normalized after intensive diabetes treatment (101); 
the mechanism of this effect remains unclear. 
An interesting observation has recently been published. Resting MSNA in a patient 
with an insulinoma and an approximately 4 times above normal elevated plasma 
insulin concentration, was normal and similar to basal MSNA after resection of the 
tumor. Sympathetic responsiveness to cold stress and to a Valsalva maneuvre was 
normal before and after removal of the tumor. After surgery, elevation of plasma 
insulin concentration to the preoperative level was associated with clear 
sympathetic activation (102). The lack of sympathetic activation in this patient 
before surgery, therefore seems to be related to reversible down-regulation of 
receptors or post-receptor pathways due to sustained hyperinsulinemia. 
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Effects of acute or chronic hyperinsulinemia on responsiveness of the SNS 
Many different sympathetic and pharmacological tests have been performed 
before and during systemic or local hyperinsulinemia. However, studies show 
large differences in design and report conflicting results, as stated before. 
The responses to sympathetic stimuli as reported in insulin resistant obese 
subjects are controversial too. In obesity it has been reported that the 
sympathetic responses to cold stress (37,89) or to a Valsalva maneuvre (37) were 
normal. Sympathetic responses to hypoglycemia were increased (103). Pressor 
sensitivity to infusion of norepinephrine was found to be augmented in obesity 
(64), but on the other hand, changes in MSNA induced by infusion of 
phenylephrine or nitroprusside appeared to be smaller in obese subjects (89). 
Despite lower basal sympathetic nerve activity, the responses to the sympathetic 
stimuli of hypoglycemia (49) and cold pressor test (99) were similar in 
uncomplicated IDDM, compared to the responses in the control groups. Therefore, 
responsiveness to sympathetic stimuli in IDDM seems to be intact, depite the 
existence of insulin resistance. In NIDDM, the response to sympathetic stimuli has 
not been studied in great detail. 
Opposite to the crucial and important effect of epinephrine for the recovery from 
hypoglycemia, up to now, very little attention has been paid to the effect of 
acute or chronic euglycemic hyperinsulinemia on adrenomedullary function in 
humans. 
Summary 
In acute experiments in normal human individuals, hyperinsulinemia induces a 
vasodilator response in the skeletal muscle vascular bed, in concert with activation 
of the sympathetic nervous system. These effects often, but not always, coincide. 
In addition, the lack of parallelism of both effects argues against a direct 
interrelationship. Insulin-induced vasodilation probably acts through a direct 
effect of insulin on the vessel wall, although the exact pathway has not been 
established yet. Under conditions of insulin resistance insulin-induced vasodilation 
is reduced, and this defect might be reversible. 
The mechanism of the sympathoexcitatory effect of insulin is largely unknown, 
and with the exception of obesity, disorders characterized by insulin resistance 
and chronic hyperinsulinemia seem not to be associated with a diminished 
sympathetic activator response to insulin, nor with a diminished response to 
"non-insulin" sympathetic stimuli. 
Chronic hyperinsulinemia might therefore induce continuous sympathetic 
stimulation, a condition which has been related to increased cardiovascular 
morbidity, and might in particular be relevant to the development of 
hypertension (104-106). 
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Aim of the present studies 
In the following chapters, a number of items concerning the effects of insulin on 
vascular tone and on the sympathetic nervous system will be further investigated. 
First, the direct effect of regional (forearm) insulin infusion on resting forearm 
blood flow will be explored, including possible relationships with insulin 
stimulated glucose metabolism. Secondly, the putative interaction of insulin with 
a- and ß-adrenoceptor responses will be investigated in more detail. 
Several data point to insulin's effect on ion transport in general (19) and on its 
effect on the sodium potassium pump in particular (69). In further exploring the 
mechanism of insulin's vasodilator action, we hypothesized that insulin-induced 
acivation of the enzyme Na*-K*-ATPase in the vascular wall might induce 
hyperpolarization and subsequent vasodilation. This would imply that inhibition 
of this enzyme by ouabain, might inhibit vasodilation. 
As stated earlier in this introduction, little attention has been given to the 
influence of insulin on adrenomedullary function, in the abscence of 
hypoglycemia. To gain more insight into this aspect, we combined insulin infusion 
(clamp technique) with epinephrine kinetic studies. 
Further studies were performed in groups of individuals with insulin resistant 
disorders: NIDDM, familial combined hyperlipidemia (FCH) and obesity. It was 
hypothesized that resistance to the effect of insulin on metabolic processes might 
not necessarily imply resistance to the vascular and neurohumoral actions of 
insulin. In some particular cases there could exist a dissociation between the 
effect on insulin on glucose homeostasis and other effector organs ("selective 
insulin resistance"). Therefore in lean subjects with an early NIDDM, to be 
considered an insulin resistant state and characterized by chronic 
hyperinsulinemia, effects of insulin on vascular tone and sympathetic nervous 
system were investigated. Also in familial combined hyperlipidemia, a disorder of 
which an association with insulin resistance had been suggested before, effects of 
insulin on glucose metabolism and vascular tone were investigated. Finally, 
assuming that insulin-induced vasodilation is related to insulin resistance, we 
investigated whether pharmacological improvement of insulin sensitivity, would 
improve vascular responses to insulin. 
The results of these studies are described in the following chapters, and add some 
knowledge to the up to now rather scanty and partly controversial findings. 
However further work has to be done, especially in the chronic situation to 
further unravel the relationship between insulin, vascular tone and sympathetic 
nervous system. 
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Abstract 
Systemic hyperinsulinemia induces vasodilation in human skeletal muscle. This 
effect is gradually in onset and at low insulin levels not maximal until at least 3 h. 
To investigate whether the vasodilator response to insulin results from a direct 
vascular effect, we infused insulin directly into the cannulated brachial artery 
(perfused forearm technique) in a total of 30 experiments in 20 healthy, lean, 
normotensive volunteers. Local, intra-arterial, infusion of insulin (180 min, 0.3 
mU· dL'forearm volume-min-1, n=15, forearm venous insulin concentration 
approximately 540 pmol-L ') induced a gradual increase in forearm blood flow 
(FBF; venous occlusion plethysmography) from 1.86±0.17 to 3.64±0.64 mL-dU-min1 
after 180 min (ANOVA P<0.001). Percentage increases of FBF after 60, 120 and 180 
min averaged: 14.4±5.9, 59.4±25.5 and 124.6±51.2% respectively. Forearm glucose 
uptake increased from 0.24±0.05 to a maximum of 1.98±0.28 μΓηοΙ^ΙΛιτυη1 
(P<0.001). Furthermore, insulin infusion increased forearm lactate release and 
potassium uptake. In 10 out of these 15 individuals, the forearm glucose-uptake 
was further increased in a second, separate, repeat experiment with concomitant 
intra-arterial infusion of glucose 5% (0.2 mLdL-1-min-1), resulting in forearm 
venous glucose concentrations of approximately 15 mmol-l-1. This combined 
infusion achieved a similar vasodilator response to the infusion of insulin alone. 
The individual vascular responses of the two paired experiments showed a strong 
correlation (r=0.87, /*<0.01). In five subjects time and vehicle control experiments 
were performed, showing no changes in FBF or metabolism during the 180 min. 
We conclude that the slow vasodilator response to insulin (as observed during 
systemic infusion) can, at least partly, be explained by a direct vascular effect of 
insulin. Insulin-mediated skeletal muscle glucose uptake precedes this effect, but 
seems not to be an important determinant of the vasodilator response to insulin. 
Introduction 
In acute experiments in humans, systemic insulin infusion with maintenance of 
euglycemia, exerts a vasodilator effect in skeletal muscle (1-3). This insulin-
induced vasodilation has been found to be reduced in disorders characterized by 
insulin resistance as obesity (1), hypertension (4) and non-insulin-dependent 
diabetes mellitus (NIDDM) (5). As insulin-mediated skeletal muscle vasodilation 
significantly contributes to the disposal of glucose, a diminished vasodilator 
capacity in itself explains part of the decreased insulin sensitivity in insulin-
resistant states (1,4,5). Therefore, further research on the phenomenon of insulin-
induced vasodilation may be of clinical importance. 
Controversy exists as to whether the vasodilator response to physiological 
hyperinsulinemia results from a direct effect of insulin on the vascular wall. 
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Whereas some authors have found an increase in blood flow in response to local 
insulin administration (6,7), others have not (8-10). Based on the latter findings it 
has been concluded that the insulin-induced vasodilation is centrally mediated 
(11,12). In the present study we have carefully investigated the effect of regional 
hyperinsulinemia on the putative vasodilation in the skeletal muscle vascular bed, 
with special attention to the time course. Until now very little attention has been 
given to the time course of the insulin-induced vasodilator effect, which may be 
an important clue with respect to the controversial observations in the literature. 
From data of Laakso et al. (1), it is obvious that the vasodilator effect of systemic 
insulin infusion (physiological plasma insulin concentrations) is not maximal until 
3 h of infusion, and that after 30 and 60 min, respectively, only approximately 
10% and approximately 30% of the maximum effect has been reached. Recently, 
even slower increases in blood flow in response to insulin have been reported 
(13,14). On the other hand, several studies where insulin was administered locally 
have used only 20-30 min of infusion time (9,10,15). 
Finally, as insulin-mediated glucose uptake may be an important determinant of 
the vasoactive effects of insulin (14,16), this parameter was measured throughout 
our studies and was artificially raised in a subgroup by regional glucose infusion. 
Methods 
Subjects 
The study group consisted of 20 healthy volunteers. All met the inclusion criteria: 
age between 18 and 35 years, non-smoking, absence of hypertension (office 
blood pressure <140/90 mmHg, measured after 5 min rest in the supine position), 
body mass index <25 kgm2. Participants used no medication, with the exception 
of oral contraconceptives. The participants were selected by advertisement and 
received a payment. All subjects had a negative family history of diabetes and 
hypertension. All participants gave written informed consent. The experimental 
protocol was approved by the hospital ethics committee. 
Procedures 
The experiments were performed with the subjects in supine position after an 
overnight fast, in a quiet, temperature-controlled room (23-24cC). Under local 
anesthesia (0.3-0.4 mL lidocaine HCl 20 mg-mL1), a 20-gauge catheter (Angiocath, 
Becton Dickinson, Sandy, UT, USA) was inserted into the left brachial artery and 
connected with an arterial pressure monitoring line (Viggo Spectramed, 5269-129) 
to a Hewlett Packard 78353B Monitor. Mean arterial pressure (MAP) was 
determined by the electronically integrated area under the brachial arterial pulse-
wave curve. The arterial line was kept patent with saline infusion (3 mLh' with 
2 U heparinmL' added). In the same arm a catheter (Venflon, 20 G, 32 mm) was 
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inserted retrogradely into a deep forearm vein to obtain venous blood samples. 
On the contralateral side an identical catheter was inserted into a large forearm 
vein for blood sampling. 
Forearm volume (FAV) was measured with the water displacement method. 
Forearm blood flow (FBF) was measured simultaneously in both arms, with the 
arms elevated just above heart level, using mercury-in-silastic strain-gauge venous 
occlusion plethysmography as previously described (17). FBF was expressed in 
mL-dL 'FAVmin ', and in the text abbreviated to mL-dL 'min \ One minute before 
the start of the measurements, a wrist cuff was inflated to 100 mmHg above 
systolic blood pressure. The collecting cuff around the upper arm was inflated to 
a pressure of 40 mmHg during 8 heart cycles using a Hokanson E20 rapid cuff 
inflator. The strain gauges were connected with the Hokanson EC4 
Plethysmographs. During a measurement period, 8-10 measurements of FBF were 
performed, each lasting approximately eight heart cycles. 
Net uptake or release of glucose, lactate and potassium was calculated by 
simultaneous arterial and venous blood sampling (see calculations). Venous blood 
was sampled while the wrist cuffs remained inflated. Samples for insulin, 
potassium, lactate and pyruvate were taken at hourly intervals. 
Protocols 
Insulin (I) experiments. In 15 individuals, after complete instrumentation, at least 
30 min of rest were included to obtain a steady state, after which baseline 
measurements were performed and repeated after 15 min. When FBF was stable, 
insulin (Actrapid, Novo-Nordisk, Denmark) was infused into the brachial artery, at 
a dose of 0.3 mU-dL'-min1 (volume 50 pL-dL'-min1) and continued for 180 min. 
Insulin 50 UmL"1 was twice diluted in 100 mL of 0.9% NaCI each time with the 
addition of 2 mL of human albumin 20% (Central Laboratory of Blood 
transfusion, Amsterdam). FBF was measured after 5, 15 and thereafter every 15 
min until 180 min. 
Insulin + Glucose (l+G) experiments. In 10 individuals, randomly selected out of 
the 15 who had participated in the first protocol, the entire experiment was 
repeated after at least 4 weeks, but now with the addition of 0.2 mL-dL '•min'1 
glucose 5% infusion. 
Control (C) experiments. In 5 different individuals, time and vehicle control 
experiments were performed, following exactly the same protocol, but now saline 
with the addition of albumin 20% (as mentioned above) was infused into the 
brachial artery for 180 min. 
Analytical methods. Plasma glucose was measured in duplicate using the glucose 
oxidation method (Beekman Glucose Analyzer 2, Beekman Instruments, Fullerton, 
CA, USA). 
Plasma insulin was measured with an in-house double antibody radioimmunoassay 
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(¡nterassay coefficient of variation 6.2%). For quantification of L-lactate (and 
pyruvate) in deproteined blood (6% perchloric acid) an enzymatic assay (Lactate 
UV-kit; Boehringer Mannheim, Mannheim, Germany) with L-lactate 
dehydrogenase (L-LDH; EC 1.1.1.27) was performed. Because pyruvate 
concentrations remained at or below detection limit, these results were not used 
for further analyses. Potassium was measured with a standard procedure using a 
Ю-іоп selective electrode with a Hitachi 747 auto-analyzer (Boehringer 
Mannheim). 
Calculations and data analysis. Forearm vascular resistance (FVR) was calculated by 
dividing MAP and FBF, and expressed in arbitrary units (AU). To correct for the 
increased fluid infusion in the second protocol, 0.2 was subtracted from the 
calculated FBF. For every 30-min period the mean of the previous 30-min 
measurements was calculated and used in the subsequent analyses. Forearm 
balances were calculated as: 
(ConcentrationARTERiAL-ConcentrationvENous) χ FPF 
Forearm plasma flow (FPF) = FBF χ (1-hematocrit). 
Effects of insulin on hemodynamic parameters were analysed using one-way 
repeated measures ANOVA, with insulin as independent factor. Post hoc t-tests 
were performed to test differences of the various time points from baseline. The 
effect of insulin alone was compared with the effect of insulin + glucose with the 
use of a two-way ANOVA for paired observations, with insulin and 
insulin+glucose as independent variables. All other (mainly metabolic) data met 
requirements of normality and were statistically analysed with the use of 
Student's ί test. Correlations were calculated using Spearman's rank correlation 
tests. For the relation between venous insulin concentrations and forearm glucose 
extraction [(GA-GV)/GA], linear regression was performed and the coefficients of 
regression were used for further analysis. All statistical analyses were performed 
using the SPSS personal computer software package. 
Results in tables and figures are expressed as mean ± SEM, unless otherwise 
indicated. Statistical significance was set at a value less than 0.05 (two-sided). NS 
means not significant. 
Results 
Baseline characteristics 
Baseline characteristics of the three study groups are given in Table 1. Participants 
were lean, young, normotensive and had a strictly normal fasting glucose level. 
Vascular responses to local hyperinsulinemia 
Insulin infusion led to deep venous forearm insulin concentrations of 549±43, 
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Table 1. Characteristics of participants (mean±SD) 
Number (M:F) 
Age (yr) 
BMI (kg.m2) 
Systolic BP (mmHg) 
Diastolic BP (mmHg) 
Fasting Glucose (mmolL') 
Arterial 
Venous 
Insulin alone 
15(7:8) 
22.5 ± 4.5 
20.7 ±1.5 
120.5 ± 12.7 
76.9 ± 7.6 
4.72 ±0.19 
4.47 ± 0.23 
Insulin-t-glucose 
10 (4:6) 
22.8 ± 4.5 
20.9 ± 1.5 
117.9 ± 12.9 
74.5 ± 5.4 
4.73 ±0.18 
4.28 ± 0.24 
Control 
5 (2:3) 
23 ±1.2 
20.9 ± 0.8 
119.5 ±11.4 
73.5 ±7.6 
4.66 ±0.21 
4.36 ± 0.39 
497±53 and 404±50 pmol-L·' after 60, 120 and 180 min respectively, whereas 
arterial levels did not increase: 57±5, 57±4, 54±4 and 49±4 pmol-L1 (baseline, 60, 
120 and 180 min respectively). 
Local infusion of insulin induced a highly significant increase in forearm blood 
flow over time, from 1.86±0.17 to 3.64±0.64 mLdL'min' (ANOVA P<0.001). This 
vasodilation did not occur before 15 min, and was significantly different from 
baseline after 30 min. As can be seen in Fig. 1, the increase in FBF was gradual 
and even after 180 min, FBF did not seem to have reached a steady state. The 
increase in flow was attended by a significant decrease in FVR from 49.4±3.6 to 
33.1±4.2 AU (ANOVA P<0.001). Also the control arm showed a slight increase in 
FBF over time (FBF from 1.57*0.16 to 2.30±0.42 mL-dl^-min', ANOVA P=0.061), 
but the FBFnpermwnui/FBFcontroi arm ratio increased significantly (from 1.26±0.09 to 
1.67±0.15, ANOVA P<0.001), proving a true regional effect of insulin infusion (18). 
ι , • •• -» • - , , , , , 
В 30 60 ΘΟ 120 150 180 
Time (min) 
Fig. 1. Time course of increase in forearm blood flow (AFBF) in both experimental and 
control arm (bottom), and of forearm arterial and venous glucose concentrations 
(top) during 180 min of intra-arterial insulin infusion. 
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Metabolic responses to local hyperinsulinemia 
Arterial forearm glucose values did not change, whereas venous forearm glucose 
levels decreased to trough levels at 30 min and increased slightly afterwards (see 
Fig. 1). Calculated forearm glucose uptake increased from 0.24±0.05 to a 
maximum of 1.98±0.28 /imoldL'min' (at 30 min, P<0.001) and decreased slightly 
afterwards to 1.29±0.19 after 180 min (P<0.01 vs. 30 min). 
Insulin infusion increased forearm lactate release (from baseline 70±27 to 340±52 
nmoldL'min ' after 120 min, P<0.01) and uptake of potassium (from -0.17±0.05 to 
0.24±0.15 μιηοΙ·αί1·Γηίη', P<0.05, see also Table 2). No significant correlations 
were found between changes in metabolic parameters and blood flow changes. 
Inherent to its metabolic effect, a positive relationship was observed between 
deep venous insulin concentrations and glucose extraction across the forearm 
vascular bed (P<0.01). 
Table 2. Lactate release and potassium uptake at different time points (mean±SE) 
Time 
(min) 
Lactate release (nmoldl 'min') 
l + G 
Potassium uptake (/jmoldl'min1) 
l + G 
0 
60 
120 
180# 
70±27 102±47 107±71 
257±65 793±194 113±68 
340±52 798±165 95±50 
-0.17±0.05 0.14±0.12 -0.05±0.03 
0.10±0.10 0.28±0.12 -0.07*0.13 
0.32±0.16 0.52±0.12 -0.00±0.09 
0.24*0.15 0.48±0.15 0.00±0.07 
Note: I: local hyperinsulinemia alone, l+G: combination of local hyperinsulinemia and 
hyperglycemia, C: sham experiment. 
# Lactate samples had to be processed immediately, which was not possible at the end of 
the test 
Effects of the addition of glucose 
Infusion of glucose into the brachial artery led to venous glucose concentrations 
of approximately 15 mmol-L1 (13.8±1.0, 14.2±1.0, 14.4±0.9, 15.9±1.6, 15.2±0.8 and 
15.6±1.8 mmolL', after 30, 60, 90, 120, 150 and 180 min respectively). Systemic 
venous glucose levels (measured at contralateral side) remained approximately 5 
mmolL' (4.7±0.1, 4.8±0.1 and 4.9±0.1 mmolL', after 60, 120 and 180 min 
respectively). Venous insulin levels were comparable with those in the first set of 
experiments (568±67, 637±67 and 566±89 pmol-L', after 60, 120 and 180 min 
respectively). The combination of hyperinsulinemia and hyperglycemia induced a 
significant increase in flow (FBFexperimemaia™ from 2.03±0.29 to 2.79±0.28 mLdL'min ' 
after 180 min, ANOVA P<0.01, see Fig. 2), whereas FBF in the control arm did not 
change (from 2.13±0.47 to 2.34±0.54 mLdL'min ', P=NS). 
Comparing the paired data sets of insulin alone vs. insulin + glucose infusion 
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(n=10), no significant difference in the FBF changes between the two experiments 
was observed (FBFnper.mwui.im, insulin alone (I): from 1.63±0.12 to 1.78±0.12, 
2.04±0.23, 2.66±0.32 mLdL'min'; insulin+glucose (l+G): From 2.03±0.29 to 
2.30±0.24, 2.53±0.23, 2.79±0.28 mLdL'min', values after 60, 120 and 180 min 
respectively). Also the percentage increases in FBF of both paired experiments 
were not significantly different between the two experiments (increase after 30 
min: I, 7.7±5.2% vs. I+G, 21.5±8.1% P=0.12; after 90 min: I, 24.9±12.0% vs. I+G, 
24.9±15.5% P=1.00; after 150 min: I, 40.8±17.2% vs. I+G: 40.3±14.9% P=0.97). 
During I+G, forearm lactate release (P=0.012) and potassium uptake (P=0.086) 
reached higher levels than during I alone (see Table 2), indicating a local increase 
of metabolic pathways. 
A significant correlation between the percentage increase in FBF during I alone 
and during concomitant I+G was established on various time points. In Fig. 3 the 
correlation at 90 min is shown: r=0.87, P=0.001. 
Vascular responses to sham procedure 
In the control experiment, FBF did not change during 180 min intra-arterial 
infusion of saline+albumin (2.25±0.41, 2.10±0.34, 1.85±0.23, 2.00±0.25, 1.83±0.22, 
1.76±0.18 and 1.9±0.21 mLdL'min', baseline, 30, 60, 90, 120, 150 and 180 min 
respectively). Arterial and venous glucose concentrations as well as forearm 
glucose uptake remained at fasting levels (data not shown). 
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Fig. 2. Time course of increase in forearm blood flow (AFBF), in the experimental arm 
during 180 min of insulin (I) or insulin+glucose (I+G) infusion into the brachial 
artery. 
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Fig. 3. Percentage change in forearm blood flow (FBF) after 90 min of either insulin (I) 
alone or insulin+glucose (l+G) infusion into the brachial artery. 
Discussion 
The major new finding of the present study is that local insulin administration in 
the vascular bed of the human forearm skeletal muscle, leading to forearm deep 
venous insulin levels in the physiological range, induces a moderate, but 
reproducible, degree of vasodilation. This, however, is slow in onset and preceded 
by maximal forearm glucose uptake. In fact, the time course of the vasodilation is 
very similar to that found with systemic insulin administration, leading to similar 
insulin levels (13). Furthermore artificial raising of glucose uptake by local 
hyperglycemia did not influence the vasodilator response to insulin. 
In recent years, various investigators, including ourselves, have shown the 
vasodilator capacities of insulin (1-3). Interestingly, in various related disorders 
such as obesity, hypertension and NIDDM, characterized by insulin resistance 
(19,20), a decreased insulin-induced vasodilation has also been reported (1,4,5). 
The mechanism by which insulin exerts vasodilator effects could therefore be of 
great importance. Although not fully understood up to now, recent data seem to 
point towards a nitric oxide-dependent mechanism of action (7,21). One of the 
controversies is whether the vasodilator response results from a direct effect on 
the vascular wall or from an indirect, possibly central mechanism (22). In favour of 
the latter hypothesis is the fact that several investigators were not able to show 
any vasodilation when insulin was infused locally (8-10,23). 
Until now little attention has been given to the time course of insulin-induced 
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vasodilation or to the relation between the speed of onset of the vasodilator 
effect and the insulin (and glucose) concentration. From the data available, it is 
clear that during euglycemic systemic hyperinsulinemia, insulin-induced 
vasodilation is slow in onset and takes at least 3 h to obtain its maximal effect at 
physiological concentrations (1,13). This is considerably longer than the time 
needed to reach maximal glucose uptake (1,16) and means that in studying blood 
flow responses to insulin, not only concentration, but also duration of infusion 
may be critical (which will also hold true for local infusion). In keeping with this, 
Lundgren et al. (24), reported an increase in calf blood flow from 2.3 to 3.2 after 
2 h, but even further to 4.4 mLdL'min ' after 6 hours of a fixed-dose insulin 
infusion. 
Therefore it is obvious that in studying local vasodilator effects of insulin, 
sufficient time should be taken to allow insulin to exhibit its full effects, as we 
did in this study. This fact could explain why some authors were not able to 
identify any local action of insulin, as a number of investigators infused insulin 
for only 20-30 min (9,10,15). Gelfand & Barrett (25) established a small increase in 
blood flow after 80 minutes, as did Neahring et al. (26), and Jern (27), using a 
paired study approach (2-h local insulin infusion). It can be speculated that at 
higher insulin concentrations the vasodilator effect will appear earlier, and hence 
be found after 15-30 min (6,7). 
In our study, the individual response to insulin, although reproducible, showed a 
high variability, ranging from no effect to more than doubling of the blood flow 
(Fig. 3). This high interindividual variation has also been reported by others and 
related to the relative forearm muscle content (14). Thus, studies with small 
sample sizes, have a considerable risk of a type 2 statistical error, which could 
have further contributed to the controversial findings up to now. 
Whereas we show in this study that at least part of insulin's vasodilator action can 
be explained by a local effect on the vascular wall, our study was not intended to 
explain the exact mechanism of insulin's effect. It seems that insulin-mediated 
glucose uptake precedes vasodilation in skeletal muscle, but this does not mean 
that these two actions are coupled. In our own study, the addition of extra 
glucose, which must certainly have accelerated glucose uptake (28), had no 
additional effect on the change in vascular resistance. Only Edelman et al. have 
reported that blood flow increased with higher glucose levels during a constant 
insulin concentration (16). Their results were, however, derived from complex, 
sequential ("stepped") clamps, with a duration of approximately 8 h. 
Theoretically it may be possible that the changes they observed were the 
consequence of prolonged exposure to insulin alone (24), and not of the higher 
glycémie level. Others have found no differences in flow in relation to different 
glycémie levels (28). Furthermore, Vollenweider et al. (29) have shown that insulin 
(with glucose) infusion induced vasodilation, but fructose infusion alone, which 
increased carbohydrate oxidation comparably but had only minor effects on 
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¡nsulinemia, did not stimulate skeletal muscle blood flow. As such it may be 
concluded that there is no firm evidence that hyperglycemia augments insulin-
induced vasodilation. 
In our study glucose uptake increased rapidly, but then slightly decreased during 
the subsequent experiment. During systemic hyperinsulinemia, this decrease in 
glucose uptake over time is not observed. This finding is probably related to our 
experimental approach; owing to the increase in blood flow and the fixed insulin 
infusion rate, forearm insulin concentrations decreased, leading to a decreased 
glucose extraction. In favour of this explanation is the fact that we found a 
significant, positive, intra-individual correlation between venous insulin 
concentrations and glucose uptake. Therefore this secondary decrease in forearm 
glucose uptake will be related to the experimental model, and hence although 
partly inevitable, unphysiological. 
During regional hyperinsulinemia, venous plasma glucose concentrations 
decreased to hypoglycemic levels. It is important to realize that this would also 
occur in euglycemic clamps. The term euglycemia refers to the arterial(ized) 
glucose concentration, but, owing to the stimulatory effect of insulin on glucose 
uptake, venous glucose concentrations will be considerably lower. Further, it has 
to be stressed that, because of the local approach, no systemic hypoglycemia 
occurred in our studies. 
We have found, as have others (30), that during local insulin infusion lactate 
release increases. However, there was no correlation established between lactate 
release and vasodilatation. Furthermore, during the combination of 
hyperglycemia and hyperinsulinemia, lactate release further increased, suggesting 
more active metabolic pathways, but the increase in blood flow was not affected. 
Also others have argued that it is unlikely that lactate increase accounts for 
insulin's vasodilator effect (1). 
In conclusion, we report that local hyperinsulinemia leading to physiological 
insulin levels in the human forearm induces a slow-onset local vasodilation, that is 
preceded by maximal tissue glucose uptake. The time course of the effect seems 
to be similar to that found in studies in which insulin is infused systemically and 
indicates that the insulin-induced vasodilator effect is mediated at least partly at 
the level of the skeletal muscle. 
Although insulin-mediated skeletal muscle glucose-uptake preceded the 
vasodilatory effect, it seems not to be an important determinant of the 
vasodilator response. 
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Regional hyperinsulinemia induces 
vasodilation but does not modulate 
adrenergic responsiveness in humans 
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Abstract 
The relationship between insulin resistance/hyperinsulinemia and cardiovascular 
disease may be related to one of the cardiovascular effects of insulin. In acute 
experiments in humans, systemic euglycemic hyperinsulinemia induced 
vasodilation in skeletal muscle. Furthermore, the sympathetic nervous system is 
activated, although this does not lead to increase in blood pressure (BP). We 
hypothesized that insulin could induce vasodilation either by reduction of a- or 
by augmentation of ß-adrenergic responsiveness. The effect of insulin infusion 
into the brachial artery (regional forearm hyperinsulinemia; venous insulin 
concentration approximately 500 pmolL') on forearm blood flow (FBF: 
plethysmography) was studied. Responses to the ct-adrenoceptor-mediated 
vasoconstrictor norepinephrine (NE: once with and once without the ß-
adrenoceptor antagonist propranolol, 2 χ n=12; 9 participated in both), and to 
the ß-adrenoceptor-mediated vasodilator isoproterenol (n=12) were measured 
before and during local hyperinsulinemia. Time/control studies (n=6) were 
performed. Insulin alone induced vasodilation, as indicated by an increase in FBF-
ratio (infused/control arm) from 1.2±0.1 to 1.6±0.2, P=0.009). Increasing dosages 
of NE (1.25 to 240 ngdL'min ') induced vasoconstriction that was more 
pronounced during concomitant propranolol infusion (P<0.001), indicating a dose-
dependent vasodilatory component in the effect of NE. Isoproterenol (ISO; 0.03 to 
10 ngdL'min1), a pure ß-adrenoceptor agonist, induced vasodilation. The 
percentage changes of FBF-ratio during NE+propranolol were similar and not 
significantly different before and during hyperinsulinemia. The same was true of 
the response to NE alone and the response to ISO. Neither was the intrinsic ß-
agonist component of NE influenced by insulin. Repeated NE infusion showed no 
time- or vehicle effect. We conclude that regional hyperinsulinemia in the 
physiological range induces local vasodilation in the skeletal muscle vascular bed, 
but this vasodilation is not mediated through modulation of a- or ß-adrenergic 
responsiveness. 
Introduction 
Hyperinsulinemia as a counterpart of insulin resistance is a prominent feature of 
associated cardiovascular risk factors as hypertension, obesity, dyslipidemia and 
non-insulin-dependent diabetes mellitus (1,2). The nature and significance of this 
association, an issue of considerable pathophysiological importance, is still unclear 
but may be related to the cardiovascular effects of insulin. Besides its key role in 
the regulation of carbohydrate metabolism (3), insulin has important 
cardiovascular effects (4,5). Despite earlier reports that insulin was in itself 
capable of inducing hypertension (6), most recent reports have failed to confirm 
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this (7,8). Indeed, in acute experiments in healthy subjects (9,10) as well as in 
patients with hypertension (11), insulin has been shown to induce a vasodilator 
effect and not to increase systemic blood pressure (BP). Furthermore, several 
groups of researchers, including ourselves, have shown that during acute 
hyperinsulinemia the sympathetic nervous system is activated (9,11-13). 
The mechanism of insulin's effect on vascular tone has not yet been clarified (4), 
but an interaction with the autonomic nervous system seems obvious because the 
insulin-induced stimulation of the sympathetic nervous system does not lead to 
increases in BP, at least not in acute experiments. Thus, insulin-induced 
vasodilation could be explained by a decreased sensitivity of the vascular bed to 
α-adrenergic stimuli or an increased responsiveness to ß-adrenoceptor agonists. 
Indeed, various investigators have reported a change in responses to adrenergic 
stimuli deemed to be a modulatory effect of insulin. The reported results, 
however, are extremely controversial and show various differences in design: 
Studies in humans vs. in animal (14,15), studies with systemic hyperinsulinemia 
(euglycemic clamp technique) vs. studies with regional hyperinsulinemia (16,17), 
systemic administration of vaso-active drugs vs. local administration (18,19), and a 
great variety in drugs administered: norepinephrine (NE) (14-17,20-22), 
phenylephrine (PE) (18,23), angiotensin II (All) (15,16,19), isoproterenol (ISO) 
(24,25) and epinephrine (26). Furthermore, studies are performed in healthy 
humans as well as in disease states characterized by insulin resistance (20,27-29). 
In the presence of hyperinsulinemia, attenuated (15,18,22,23,30) unchanged 
(14,20) and exaggerated (16,19,21) responses to the various vasoconstrictors have 
been reported, as have increased (24) and decreased (25) responses to the ß-
adrenergic vasodilator ISO. 
In the present study, we used the perfused forearm technique to investigate 
whether acute hyperinsulinemia affected vascular a- or ß-adrenoceptor 
responsiveness in humans. Studying these two aspects together may be 
advantageous, because at different levels significant interactions and cross-talks 
do exist: Both endogenous catecholamines NE and epinephrine exhibit a- and ß-
receptor affinity. Furthermore, stimulation of presynaptic a- and ß-receptors 
inhibits and stimulates NE release from sympathetic nerve endings, respectively 
(31). Finally, an eventual effect of insulin modulating the a-adrenoceptor-
mediated vasoconstriction could be counterbalanced by a change in ß-
adrenoceptor sensitivity. Our results convincingly show that insulin has local 
vasodilator properties itself but does not affect the responsiveness to a- or 3-
adrenoceptor stimulation. 
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Methods 
Subjects 
In all, 42 studies were performed in 33 healthy subjects (16 women, 17 men), 
aged 19-32 years (mean±SD, 23±3 years). All were normotensive [mean office BP 
after 5-min rest in the supine position: systolic BP (SBP) 125±11 mmHg and 
diastolic BP (DBP) 75±8 mmHg), and normoglycemic and had a normal weight 
(body mass index (BMI) 22.5 ± 1.7 kg-nr2). All individuals had a negative family 
history of diabetes mellitus and hypertension. The participants were recruited by 
advertisement and received a small remuneration. All gave written informed 
consent. The experimental protocol was approved by the local ethics committee. 
Measurements 
Forearm volume was measured by water displacement. Forearm blood flow (FBF) 
was measured simultaneously in both forearms by mercury-in-silastic strain-gauge 
venous occlusion plethysmography. The elbows and wrist were supported at or 
just above heart level. Strain gauges were attached around the forearm at the 
level of the maximal diameter. One minute before the start of the FBF 
measurements, a pediatric cuff around the wrists was inflated to 100 mmHg 
above the SBP level to ensure that the measurements referred only to the skeletal 
muscle vascular bed of the forearm. The collecting cuff around the upper arm was 
inflated to a supravenous pressure of 40 mmHg during eight heart cycles with the 
Hokanson E20 rapid cuff inflator (ECG-triggered). This cycle was repeated three to 
four times each minute. The strain gauges were connected with Hokanson's EC4 
Plethysmographs, and FBF was determined in mm/100 mL forearm volume per min 
from the mean vertical deflection per minute divided by a 1% electrical 
calibration signal. FBF was expressed as milliliters per minute per decilitre forearm 
volume. In addition, the ratio of the FBF in the infused arm to that in the control 
arm was calculated for each measurement (FBF ratio). 
All experiments were performed in a temperature-controlled room (22°-24°C). 
Before, after 30 min, and after 60 min of local hyperinsulinemia, arterial and 
venous blood samples were taken for determination of glucose and insulin. 
Plasma glucose was measured by the glucose oxidation method (Beckmann 
Glucose analyzer 2, Beekman Instruments, Fullerton, CA, USA); plasma insulin 
concentration by a double-antibody in-house radioimmunoassay (RIA) with an 
interassay coefficient of variation of 6.2% . 
Protocols 
After a 12-h overnight fast, subjects came to the laboratory. Under local 
anaesthesia [0.3-0.4 mL lidocaine HCl 20 mg-mL' (Xylocaine 2%, Astra)], a 20-
gauge, 2-inch catheter (Angiocath, Becton Dickinson, Sandy, UT, USA) was inserted 
in the brachial artery and connected with an arterial pressure monitoring line 
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(Viggo Spectramed, 5269-129) to a Hewlett Packard 78353B monitor. Mean 
arterial pressure (MAP) was determined by an electronically integrated area under 
the brachial arterial pulse-wave form. The line was kept patent with saline 
infusion (3 mL-h1 with 2 U heparinmL' added). The dosages of drugs 
administered were calculated per deciliter of forearm volume (ng-dL '-min1). 
Moreover, a catheter (Venflon, 20 gauge, 32 mm) was retrogradely inserted in a 
deep ipsilateral forearm vein to obtain venous blood samples. 
Effect of insulin on α-adrenergic responsiveness 
First, after 30-min equilibration, baseline measurements were performed during 
concomitant intraarterial infusion of placebo (NaCI 0.9%, 50 ^L-dL'-min')• In 12 
subjects, NE (Centrapharm) was infused in six sequential ascending doses into the 
brachial artery. Each concentration was prepared separately so that infusion 
volume did not change. The doses were 1.25, 5, 20, 80, 160 and 240 ngdL'-min-1 
(17). Each infusion lasted 4 min; in the third and fourth minute, MAP and FBF 
were measured. Between the first and second series of three dosage levels, 15 
min of rest were included to restrict the occlusion time of the hand circulation. To 
avoid eventual ß-adrenoceptor-mediated effects of the intravascular NE infusion 
(32), the nonselective ß-blocking drug propranolol was infused concomitantly in a 
dose of Ι.Ομς-αΙΛπηίη1 from 2 min before until discontinuation of the NE 
infusion. After the final dose of NE, baseline measurements were repeated after 
30-min equilibration. Subsequently, instead of NaCI 0.9%, insulin (Actrapid, Novo-
Nordisk, Denmark) dissolved in an equal volume was infused intraarterial^ in a 
dose of 0.3 mll-dL'-min '. After 30 min of insulin infusion, measurements were 
repeated, during ongoing insulin infusion. Insulin was diluted twice by addition 
of human albumin 20% (CBR Amsterdam) or autologeous plasma. Subsequently, 
six increasing dosages of NE were infused, with addition of propranolol, exactly as 
before the insulin administration. 
Second, after an interval of at least one month, the protocol was repeated in 9 of 
the 12 subjects, but without the concomitant infusion of propranolol, to study the 
effects of NE alone. Unfortunately, 3 subjects were not measured for a second 
time: 1 refused a second measurement, 1 could not be cannulated again, and 1 
could not be measured again due to lack of time. Because of these 3 drop-outs, 3 
other subjects were included in the second protocol to obtain a similar statistical 
power as in the first series. 
Third, time control studies were made of α-adrenergic responsiveness. To exclude 
the possibility of down regulation of α-adrenoceptor induced by the first infusion 
of multiple doses of NE, to correct for eventual systemic effects, and to exclude 
an effect of the time course and vehicle, control experiments were performed in 6 
subjects: NE was administered in six doses (similar to the first and second series), 
first with placebo (NaCI 0.9%) and followed by a time period of saline + addition 
of autologeous plasma (but not insulin); NE dose-response measurements were 
then repeated. 
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Effect of insulin on ß-adrenergic responsiveness 
In 12 other subjects, an identical protocol was performed, but instead of NE, ISO 
(isoproterenolsulfaat, 1 mL=1mg, RVG 51722 UR, Fresenius BV, 's-Hertogenbosch, 
The Netherlands), a pure ß-adrenoceptor agonist, was infused in six increasing 
dosages of 0.03, 0.1, 0.3, 1.0, 3.0 and 10 ng.dL'.min', each dose lasting 5 min. 
After completion of the last dose, at least 45 min equilibration was allowed 
before repeated baseline measurements were performed. Insulin was then again 
infused into the brachial artery in exactly the same way and dose as in the first 
two studies, but for 60 min before readministration of the six ISO dosages. 
Calculations and Statistical analysis 
All descriptive data are expressed as mean ± SD. FBF is expressed as mLdL'-min1. 
Furthermore, the ratio of blood flow in the infused arm as compared with that in 
the control arm was calculated for each FBF measurement. According to the 
literature, presentation of the data as the ratio of the left and right FBF is the 
best way to correct for eventual systemic changes due to arousal or to systemic 
effects of drugs (28,33). Therefore the FBF ratio was chosen as the preferential 
parameter and calculated percentage change was used for comparison. Often, FBF 
at the experimental side is also indicated to illustrate obtained flows. 
Differences between baseline flow parameters and flows during local 
hyperinsulinemia were calculated by Student's paired ttest. 
The NE (± propranoloiyiSO dose-response curves expressed in percentage change 
in FBF ratio from baseline, before and during hyperinsulinemia, were evaluated 
by a two-factor repeated-measures analysis of variance (ANOVA) to assess the 
effects of insulin, NE (± propranolol)/ISO and the interaction of these agents. In 
the 9 subjects in whom two experiments were performed (once with and once 
without propranolol), the differences in the individual responses were used to 
calculate a ß-adrenoceptor-mediated vasodilator component of NE infusion. When 
data were pooled (effect of insulin/time), only the first obtained data set of 
subjects who were studied twice was used for evaluation. 
A P-va lue of <0.05 was considered statistically significant. All statistical analyses 
were performed with the SPSS personal computer package. All results are given as 
mean±SEM unless otherwise indicated. 
Results 
Insulin and glucose concentrations during the study 
During intraarterial infusion of insulin, deep venous forearm insulin concentration 
increased from 65±22 to 498±48 pmolL', indicating regional physiological 
hyperinsulinemia. In contrast, arterial insulin levels did not change. After 30 min 
of local insulin administration, venous plasma glucose concentration was 
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decreased from 4.6±0.3 to 3.8±0.6 mmol-L1, whereas arterial levels did not change 
(from 4.8±0.3 to 4.7±0.3 mmolL·'). 
Effects of adrenergic stimulation on skeletal muscle blood flow 
Regional infusion of propranolol in itself did not affect baseline f low (FBF ratio 
1.08±0.08 vs. 1.07±0.09, P=NS). NE in combination with propranolol caused a dose-
dependent decrease in f low (FBF-ratio from 1.07±0.09 to 0.22±0.04, FBF from 
1.7±0.2 to 0.4±0.1 mLdL'-min Λ P<0.001) (Fig. 1). NE alone again induced a 
forearm vasoconstrictor respons (FBF ratio from 1.12±0.0.07 to 0.45±0.07, FBF 
from 1.8±0.2 to 0.8±0.2 m L d L ' m i n ', /40.001 for both) that was initially dose 
dependent, but the response to the highest NE dose (FBF ratio 0.52±0.11, FBF 
1.0±0.3 m L d L ' m i n ' ) appeared to be less pronounced than that to the preceding 
dose. Moreover, the overall responses were smaller than those to NE in 
combination with propranolol (Fig. 1). 
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Fig. 1: Effect of six increasing doses of norepinephrine (1.25, 5, 20, 80, 160 and 240 
ngdL'-min') with and without propranolol (1.0 jugdL'min '), or isoproterenol 
(0.03, 0.1, 0.3, 1.0, 3.0 and 10 ngdL'min1) on forearm blood flow (FBF) ratio. B, 
Baseline, D, Dose; norepi, norepinephrine; prop, propranolol. 
In the 9 subjects who underwent both experiments, the responses to NE alone 
were significantly different from those to NE + propranolol (P<0.001). Subtraction 
of the vasoconstrictor response to NE + propranolol and the response to NE alone, 
showed a dose-dependent vasodilatory component in the effect of NE, presumed 
t o be ß-adrenoceptor-mediated (it can be inhibited by propranolol) (34) (Fig. 2). 
ISO induced a dose-dependent vasodilation (FBF-ratio from 0.90±0.08 to 
5.16±0.65, FBF from 1.7±0.3 to 8.1±0.8 mLdL 'm in ', P<0.001) (Fig. 1). After this 
first series of vaso-active drugs, f low parameters returned toward baseline values: 
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all data pooled (n=33) — FBF ratio 1.03±0.04 and 1.11±0.10 (P=0.45), FBF 1.7±0.1 
and 1.9±0.1 mLdL'min ' (P=0.18), before and after vaso-active drugs, respectively. 
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Fig. 2: Difference between the decrease in forearm blood flow (FBF) during six increasing 
doses of norepinephrine (NE) alone and decrease in FBF during identical dosages 
of NE in combination with propranolol (prop). The decrease was in FBF was larger 
when propranolol was added, presumably because of an intrinsic ß-adrenergic 
vasodilatory effect of NE. This effect appeared to show a dose-dependent 
relation. 
Effects of insulin on skeletal muscle blood flow 
In 27 subjects, insulin was locally infused as part of the protocol. After 30 min of 
regional hyperinsulinemia, an obvious increase in the FBF ratio (infused/control 
arm) was observed from 1.16±0.12 to 1.56±0.15 (P=0.009). FBF increased from 
2.2±0.3 to 2.8±0.4 mLdL'min ' (P=0.002). Mean percentage increase in blood flow 
was 38±11%, P=0.001, with a wide range (-23 to +158%). In the subgroup of 9 
subjects who had participated in both the NE alone and the NE in combination 
with propranolol experiments, there was no difference in the increase in FBF with 
insulin alone, vs. increase in FBF after previous propranolol administration 
(percentage increase 43±17 vs. 50±12%, without and with propranolol, 
respectively, P=0.68). 
Effects of insulin on adrenergic responsiveness 
Due to the previous insulin-induced vasodilator response, baseline parameters 
before the two sets of experiments were not equal. To correct for these 
differences and for possible nonspecific systemic changes, we calculated 
percentage changes of FBF ratios, according to the literature (28) (described in 
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the Materials and Methods section). 
Percentage changes in FBF ratio during NE + propranolol were similar and not 
significantly different before and during hyperinsulinemia (maximum percentage 
decrease 79.5±3.0% before insuline, vs. 75.5±4.0% during hyperinsulinemia, 
P=0.25) (Fig. 3). 
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Fig. 3: Effect of six increasing doses of norepinephrine (+ propranolol) on percentage 
decrease in forearm blood flow (FBF) ratio before and during hyperinsulinemia. 
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Fig. 4: Effect of repeated administration of six increasing doses of norepinephrine 
(+ propranolol) on forearm blood flow (FBF) ratio. 
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Similar results were observed for the percentage changes of the FBF ratios during 
insulin and NE administration alone (maximum percentage decrease 55.7±8.7% 
before insulin vs. 57.4±3.8% during insulin, P=0.81). In time control studies, as 
shown in Fig 4, repeated infusion of NE induced a reproducible degree of 
vasoconstriction. 
In 9 subjects, experiments with both NE alone and with NE + propranolol were 
performed. Vasoconstriction with NE + propranolol was more intense than 
vasoconstriction with NE alone. Subtraction of the individual vasoconstrictor 
responses to NE from the first and the second study showed a vasodilator 
component of the NE administration (described in the Materials and Methods 
section). The results of this subtraction procedure for all six NE dosages showed a 
dose relation before as well as during hyperinsulinemia. The difference in 
percentage change in FBF ratio between NE + propranolol and NE alone was 
maximal 27±9% before insulin vs. maximal 18±3% during insulin, P=0.41. Again 
therefore, this ß-adrenoceptor-mediated vasodilator component was not 
significantly altered by regional hyperinsulinemia. Finally, the responses of FBF 
ratio during ISO infusion were identical before and during hyperinsulinemia 
(maximum percentage increase 524±88% before insulin vs. 441 ±63% during 
insulin, P=0.19) (Fig. 5). 
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Fig. 5: Effect of six increasing doses isoproterenol on percentage increase in forearm 
blood flow (FBF) ratio before and during hyperinsulinemia. 
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Discussion 
We confirm that insulin administered locally in physiological concentrations 
induces vasodilation in forearm skeletal muscle. Our results also show that 
hyperinsulinemia in the physiological range does not attenuate the forearm 
vasoconstrictor response to NE, nor the vasodilatory response to ISO. This 
conclusion is based on the comparable percentage responses of FBF ratio before 
as compared with during insulin administration. Indeed, evaluation of the 
absolute changes after drug infusion would have shown a more pronounced 
response during hyperinsulinemia. However, as reported previously (28), the 
absolute decrease in FBF during administration of a vasoconstrictor is significantly 
correlated to the level of the baseline FBF (correlations in our study between 
mean decrease in FBF during combined NE/propranolol and baseline flow: r=0.76 
before insulin and r=0.93 during insulin). Because insulin increased the baseline 
FBF significantly, the subsequent absolute NE-induced decrease in FBF was also 
increased, but nonspecifically. This view is further supported by the study of 
Neahring and colleagues (20), who showed that the absolute but not the relative 
response to intrabrachial NE infusion was increased by regional infusion of the 
vasodilator drug sodium nitroprusside. 
Neither were the responses to the ß-adrenoceptor-mediated vasodilator ISO 
affected by local hyperinsulinemia. With all these considerations taken into 
account, our data suggest that insulin in physiological concentrations shows no 
specific interaction with a- or ß-adrenergic-stimulating agents at the level of the 
forearm vascular bed. 
Vasodilatory effect of insulin 
In acute experiments in humans, systemic insulin infusion with maintenance of 
euglycemia exerted a vasodilator effect in skeletal muscle (9,12,35). Although 
controversial results have been reported after local insulin administration, recent 
reports mostly show a local vasodilatory effect as well (10,36). Two important 
aspects could explain part of the controversial findings. First, insulin-induced 
vasodilation apparently is not an acute effect, but instead is one of slow-onset. 
Steinberg and associates infused insulin into the femoral artery and reported a 
significant increase in femoral blood flow after 20 min but not after 10 min of 
infusion (37). We noted a clear increase in FBF after 30 min. In the group 
receiving ISO, insulin was infused for 60 minutes, but FBF did not increase from 30 
to 60 min. Second, the individual vasodilator response to insulin shows a high 
variability, in our study ranging from -23 to +158%, as has has been reported by 
other investigators (10). This indicates that in studies with small sample sizes the 
effect could be missed due to a type 2 statistical error. Because of the many 
participants, the insulin-induced vasodilation was highly significant in the current 
study. 
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Effect of insulin on a-adrenoceptor-mediated vasoconstriction 
Several reports have shown very controversial findings with regard to the effect 
of insulin on a-adrenoceptor-mediated vasoconstriction. Results of several recent 
studies in vivo in humans, comparable to ours, appear to be in contrast to our 
findings. Sakai and co-workers (18) did not observe a significant vasodilator effect 
of insulin infusion but reported an attenuated α-adrenoceptor stimulation by PE. 
We believe that the contrasting results may be explained by slight but relevant 
differences in the design of the studies. Sakai and co-workers started the infusion 
of PE after 20 min insulin infusion and evaluated the effect of insulin alone after 
10 min. Therefore, because the insulin-induced vasodilation can be slow in onset, 
Sakai and co-workers may have missed this effect. Assuming that the vasodilator 
effect occurred later, the attenuated response to PE could be explained simply by 
the additive effects of vasodilation by insulin and vasoconstriction by PE. The 
same is true of the results of Lembo (30). On the contrary, results of other 
investigators, although in studies with a slightly different design, are in complete 
accord with our results (14,20) 
Effect of insulin on ß-adrenoceptor-mediated vasodilation 
Recent in vitro experiments have shown an insulin-mediated enhancement of 
vascular ß-adrenergic responsiveness to ISO (24). On the other hand, impaired 
forearm ß-adrenoceptor-mediated vasodilation to ISO has been described in 
patients with hypertension (25). Our experiments quite convincingly show that 
acute local physiological hyperinsulinemia in the human forearm vascular bed 
does not influence the sensitivity to the ß-receptor agonist ISO. In addition, we 
provide further indirect evidence for these findings: Our experiments were 
performed with the endogenous neurotransmitter NE in stead of PE or related a-
adrenoceptor agonists, especially because it is the most physiological method of 
investigating the effect of insulin on α-adrenoceptor sensitivity. However NE can 
induce ß-adrenoceptor-mediated vasodilation and has also vasoconstrictor 
properties (34,38). To study the pure α-effect, we performed the study twice, once 
with and once without a ß-adrenoceptor blocking agent. The last study was also 
performed to exclude an effect of insulin which could have been ß-adrenoceptor 
mediated, an effect that has been reported previously (39). By comparing the 
paired studies with and without propranolol, we were able to confirm the dose-
dependent (ß-adrenoceptor-mediated) vasodilator component of NE and were 
also able to confirm that this vasodilator component was not influenced by 
regional hyperinsulinemia. 
This further supports our conclusion that the vascular effects of the endogenous 
neurotransmitter NE are not altered by increased insulin concentrations. 
Moreover, our results further show that the addition of a ß-adrenoceptor 
blocking agent is essential when NE is used to study pure a-adrenoceptor-
mediated effects. Therefore, our results appear to be significant because most 
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studies of the interaction between insulin and NE did not correct for eventual 3-
adrenoceptor-mediated effects of NE (14-17,20,21). 
We confirmed that regional infusion of insulin induced a unilateral increase in 
FBF, indicating a local mechanism. The mechanism of action of this direct 
vasodilator effect of insulin is not completely clear (40), but our results indicate 
that it is not related to modulation of a- or ß-adrenergic responsiveness. Other 
mechanisms probably are involved; recent reports indicate a nitric oxide-
dependent pathway (37,41). 
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Abstract 
Systemic hyperinsulìnemia induces vasodilation in human skeletal muscle. This 
vasodilation contributes to insulin-stimulated glucose uptake and has been found 
to be reduced in various insulin-resistant states. The mechanism of the effect of 
insulin on vascular tone is not completely understood. We hypothesized that 
activation of the sodium-potassium pump (Na*-K+-ATPase) located in endothelial 
or smooth muscle cells would be involved in the insulin-mediated vasodilation. 
Therefore, in 24 healthy, nonsmoking, nonobese, normotensive volunteers, we 
infused ouabain, a specific inhibitor of Na*-K*-ATPase, into the brachial artery 
before and during euglycemic hyperinsulìnemia. As expected, insulin (systemic 
concentrations approximately 700 [low] and 1400 [high] pmol-L·1) induced 
vasodilation in the control arm (forearm blood flow [FBF, plethysmography] from 
1.6±0.2 to 2.1±0.4 mLdL'min' [low insulin] and from 1.6±0.2 to 2.1±0.2 [high 
insulin], P<0.05 for both), but the increase in FBF was abolished in the ouabain-
infused forearm (from 1.3±0.1 to 1.4±0.2 mLdL'min1 [low], and from 1.3±0.1 to 
1.3±0.1 [high insulin], P=NS). Ouabain-induced increases in forearm potassium 
release was partly reversed by insulin. To investigate whether the mechanism of 
action could be at the endothelial level, we infused /Vö-monomethyl-L-arginine 
(L-NMMA), an inhibitor of endothelial nitric oxide synthase (0.05, 0.1 and 0.2 
mgdL'min') intra-arterially in 12 subjects, and induced a clear, dose-dependent, 
decrease of FBF from 1.7±0.2 to 1.2±0.1 mLdL-1min-1 (P<0.01). In contrast, after 
ouabain (and continued insulin) infusion, L-NMMA had no effect on FBF (from 
1.6±0.4to 1.5±0.3 mLdL-1min-1, n=6, P=0.66). These results demonstrate that 
insulin induces vasodilation by stimulation of Na*-K*-ATPase. This activation of 
Na*-K>ATPase could occur at the level of the endothelium, rather than that of 
vascular smooth muscle and contributes to the endothelium-dependent 
vasodilator response to insulin. 
Introduction 
Various investigators, including ourselves, have shown that in acute experiments 
in humans, systemic insulin infusion with maintenance of euglycemia has a 
vasodilator effect in skeletal muscle (1-3). This insulin-induced vasodilation has 
been found to be reduced in disorders characterized by insulin resistance such as 
obesity (1), hypertension (4), and non-insulin-dependent diabetes mellitus 
(NIDDM) (5,6). Since insulin-mediated skeletal muscle vasodilation significantly 
contributes to glucose disposal, a diminished vasodilator capacity in itself explains 
part of the decreased insulin sensitivity in insulin-resistant states (1,4). Therefore, 
further research on the mechanism of action of insulin-induced vasodilation may 
be of clinical importance with respect to the issue of insulin resistance. 
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One of the well-described cellular actions of insulin is an effect on ion transport 
in general, and on stimulation of the Na*-K*-ATPase activity in particular (7,8). 
Based on the exchange of three intracellular potassium ions with two 
extracellular sodium ions, stimulation of the Na'-IC-ATPase will result in 
hyperpolarization of the cell membrane. In vascular smooth muscle cells, this 
hyperpolarization will trigger closure of voltage-dependent calcium channels, 
resulting in decrease of intracellular Ca2* concentration (9). This will lead to 
relaxation of the smooth muscle cell and hence in the vascular bed to vasodilation 
(10). This means that insulin-induced vasodilation may in theory be explained by 
stimulation of the Na*-K>ATPase in vascular smooth muscle cells. However, Na*-K> 
ATPase is also located in endothelial cells (11), in which hyperpolarization will 
lead to an influx of calcium into the cell because of the increased electrogenic 
driving force (calcium channels in endothelial cells are voltage independent (12)). 
The increase in cytosolic Ca2+ concentration will stimulate endothelial synthesis 
and release of nitric oxide (NO) (13). Therefore, an alternative explanation for the 
mechanism of insulin-induced vasodilation could be insulin-mediated stimulation 
of endothelial Na*-K*-ATPase, giving rise to NO-dependent vasodilation. Recent 
observations that insulin-induced vasodilation can be blocked by inhibition of NO 
synthase (14,15), are in accord with this latter theory. Furthermore, stimulation of 
Na*-K>ATPase probably occurs by translocation of intracellular Na*-K*-ATPase 
molecules to the cellular membrane (8,16). This process needs some time for its 
full effect, which fits with the observation that insulin-mediated vasodilation is 
slow in onset (1,2,17-19). 
Therefore, in the present human in-vivo study, we investigated the role of Na*-K*-
ATPase activation in the vascular response to insulin by evaluating the effects of 
ouabain, a specific inhibitor of the sodium-potassium pump. Moreover, we tried 
to establish whether the putative mechanism of action could be at the level of 
the vascular endothelium by use of the specific NO synthase inhibitor L-NMMA. 
Methods 
Subjects 
The study group consisted of 36 healthy volunteers. All met the following 
inclusion criteria: age between 18 and 35 years, nonsmoking, normotensive (office 
blood pressure <140/90 mmHg measured after 5 minutes rest in the supine 
position), and body mass index less than 25 kgm2. Participants used no 
medication, with the exception of oral contraceptives. The subjects were selected 
by advertisement and received payment. All subjects had a negative family history 
of diabetes and hypertension. They all gave written informed consent before 
participation. The experimental protocol was approved by the hospital ethics 
committee. 
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Procedures 
The experiments were performed with the subjects in a supine position after an 
overnight fast and in a quiet, temperature-controlled room (23eC to 24°C). Under 
local anaesthesia (0.3 to 0.4 mL lidocaine HCl, 20 mg-mi1), a 20-gauge catheter 
(Angiocath, Becton Dickinson) was inserted into the left brachial artery and 
connected with an arterial pressure monitoring line (Viggo Spectramed, 5269-129) 
to a monitor (Hewlett-Packard 78353B). Mean arterial pressure (MAP) was 
determined by the electronically integrated area under the brachial arterial pulse-
wave curve. The arterial line was kept patent with saline infusion (3 mLlr' with 2 
U heparinmL' added). In the same arm, a catheter (Venflon, 20-gauge, 32 mm) 
was inserted retrogradely into a deep forearm vein so venous blood samples 
could be obtained. On the contralateral side, an identical catheter was inserted 
into a large forearm vein for infusion. 
Forearm volume was measured with the water displacement method, and all 
drugs were dosed per 100 mL forearm tissue. FBF was measured using mercury-in-
silastic strain-gauge venous occlusion plethysmography as previously described 
(20). One minute before the start of measurements, a wrist cuff was inflated to 
100 mmHg above systolic pressure. The collecting cuff around the upper arm was 
inflated to 40 mmHg during eight heart cycles with a rapid cuff inflator (DE 
Hokanson E20). The strain gauges were connected to the Plethysmographs 
(Hokanson EC4). 
For the calculation of net uptake or release of glucose and potassium, arterial and 
venous blood was sampled simultaneously at relevant time (see Fig. 1 and 
calculations). Venous blood was sampled with inflated wrist cuffs. 
G 
FBF φ I \ \ i l i 
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ouabain 
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Minutes 
Fig 1. Time schedule of the protocol. Ouabain was infused in three 20-minute periods. 
Insulin (plus glucose[G]) was infused during 90 min. In six individuals, this protocol 
was extended: After the last ouabain infusion, L-NMMA was given in three 
increasing doses, while systemic insulin and glucose infusions were continued. See 
text (protocol 3), for further explanation. 
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Protocols 
Effect of Ouabain Alone 
After complete instrumentation, at least 30 min of rest were allowed for subjects 
(n=6) to obtain a steady state, after which baseline measurements were 
performed and repeated after 15 min. When FBF was stable, ouabain was infused 
into the brachial artery, in a dose of 0.2 /ig-dL'-min1 (approximately 0.3 
nmoldL 'min '; volume rate, 50 /iL-dL 'min ') for 20 min. It was calculated that 
with this dose, local ouabain concentrations of 107 to 10s mol-L1 would be 
reached, a concentration shown to inhibit Na*-K*-ATPase activity in vitro (21). 
Earlier studies in which ouabain was infused indicated that the vascular effect of 
ouabain was maximal after 10 to 15 min (22-26), and lasted for at least 30 min 
after administration was interrupted (23,24). Pilot studies in our laboratory in 
which ouabain was infused for more than 60 min confirmed that vasoconstriction 
was maximal after 15 min and did not increase over time. To obtain effective 
Na'-IO-ATPase inhibition throughout the study, we repeated the 20-min ouabain 
infusion twice at 45 and 90 min after the first administration was started. With 
this intermittent dosage schedule, the cumulative dose of ouabain was only 
128±25 μg, minimizing the risk of systemic effects (27). 
Effects of Ouabain on Insulin-Induced Vasodilation 
In these protocols, we used the hyperinsulinemic, euglycemic clamp technique. In 
six individuals, insulin (Actrapid, Novo-Nordisk) was systemically infused in a dose 
of 430 pmolm^min' IV (60 mU-dL'-min') during 90 min. Insulin (50 ll-mL') was 
diluted in 47.5 mL of 0.9% NaCI with the addition of 2 mL of 20% human albumin 
(Central Laboratory of Blood Transfusion, Amsterdam, Netherlands) to a 
concentration of 1 UmL'. Euglycemia was maintained by a variable infusion of 
glucose (20% solution) adjusted by arterial glucose measurements at 5-min 
intervals (28). Before and during systemic hyperinsulinemia, ouabain was infused 
into the left brachial artery (see Fig. 1 for a protocol schedule). With the use of 
this experimental set-up, it was possible for us to study the vasodilator effect of 
insulin alone (control arm) and insulin plus ouabain (experimental arm) 
simultaneously within each subject. 
In another six individuals, exactly the same study was performed, but insulin was 
infused at a higher dose (860 pmol-m'-min1 [120 mU-m'-min1]). 
Effects of L-NMMA Alone and With Ouabain Plus Insulin 
To quantify the baseline endothelial production of NO in the forearm vascular 
bed, we first measured the vasoconstrictor response to three sequential intra­
arterial infusions of L-NMMA (0.05, 0.1 and 0.2 mgdL'min', 5 min per dose, 
n=12). 
Using the same technique, two independent investigators have recently shown 
that the vasoconstrictor response to L-NMMA was augmented during insulin 
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administration (14,15), suggesting an increased endothelial NO-release. Since 
these experiments showed convincing results, we decided not to repeat these 
particular tests. However, to elucidate the role of Na*-K*-ATPase activation on this 
insulin-mediated stimulation of baseline NO release, we recorded the 
vasoconstrictor response to L-NMMA during insulin infusion after previous 
ouabain administration. Therefore, again in six subjects, insulin was systemically 
infused at a dose of 430 pmolm 2min ' (60 mUnr2min1) during 90 minutes with 
intra-arterial ouabain infusion before and during systemic hyperinsulinemia, 
identical to the second protocol. Now the three doses of L-NMMA were infused 
after the last ouabain infusion, with continuation of insulin (and glucose) 
infusion. 
During the low-dose insulin experiments, no potassium supplementation was 
given; during high-dose insulin, 8 mmol KCl was infused during the last 60 min of 
the clamp. In women, experiments were planned during the luteal phase of the 
menstrual cycle. 
Drugs 
L-NMMA was obtained from Sigma Chemical Co and stored as a dry powder after 
manufacturing. The solution was freshly diluted with 0.9% NaCI to its final 
concentration just before the experiment. Ouabain (0.025%) was obtained from 
Pharmachemie BV. 
Analytical Methods 
Plasma glucose was measured in duplicate with the glucose oxidation method 
(Glucose Analyzer 2, Beekman Instruments Ine). Plasma insulin was measured with 
a conventional double-antibody radioimmunoassay (interassay coefficient of 
variation 6.2%). Potassium was measured by a standard procedure using а Ю ion-
selective electrode and Hitachi 747 Auto-analyzer (Boehringer Mannheim). 
Calculations and Data Analysis 
Forearm Vascular Resistance (FVR) was calculated by dividing mean arterial 
pressure and FBF and is expressed as AU. Assuming that Whole Blood Glucose=(1-
0.3xHematocrit)xPlasma blood glucose (29), glucose uptake was calculated as: 
AGIucoseArt«¡aivenouSx(1-0.3xHematocr¡t)xFBF. 
Potassium uptake was calculated as AK4Arun.i.v<no,«xForearm Plasma Flow (=FBFx 
[1-Hematocrit]). 
During euglycemic clamp, one coefficient of plasma glucose variation was 
calculated. Whole-body glucose uptake was defined as the glucose infusion rate 
during the last 30 minutes of the the clamp and expressed as micromoles per 
kilogram per minute. Effects of insulin on hemodynamic parameters were 
analyzed by one-way repeated measures ANOVA, with insulin as independent 
factor. Percent changes in flow did not meet the criteria for a gaussian 
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distribution and were analyzed by a nonparametric test (Wilcoxon). All other data 
were statistically analyzed with the use of Student's ί test. All statistical analyses 
were performed with the SPSS personal computer software package. 
Results in the tables and figures are expressed as mean±SE, unless otherwise 
indicated. Statistical significance was set at a value less than 0.05 (two-sided). 
Results 
Baseline Characteristics: 
Baseline characteristics of the three study groups are given in Table 1. Participants 
were lean, young, and normotensive and had a strictly normal fasting glucose 
level. 
Table 1. Clinical Characteristics of Study Participants 
η (M/F) 
Age, y 
BMI, kgm1 
SBP mmHg 
DBP mmHg 
Ouabain 
Alone 
6 (2/4) 
24.5±2.3 
21.8±1.3 
125±12 
74±5 
Fasting glucose, 
mmol-L' 4.96±0.29 
Low Insulin 
+Ouabain 
6(4/2) 
23.7±2.3 
21.8±1.2 
126±6 
72*5 
5.03*0.20 
High Insulin 
•(Ouabain 
6 (4/2) 
21.8*2.1 
22.9*1.7 
132±8 
76±9 
5.22*0.30 
L-NMMA 
Alone 
12 (7/5) 
25.7*5.7 
21.3*1.8 
123*9 
71*6 
5.12*0.32 
Low Insulin* 
Ouabain+L-NMMA 
6(4/2) 
22.7*1.7 
22.6*2.6 
126*11 
77*7 
5.01*0.27 
BMI indicates body mass index; SBP, systolic blood pressure; and DBP, diastolic blood 
pressure. Values are mean±SD. 
Responses to Ouabain infusion Alone: 
Initial administration of ouabain alone was part of the protocol in a total of 24 
subjects. Ouabain infusion induced vasoconstriction in the infused arm (FBF from 
1.6±0.1 to 1.2±0.1 mLdL'min·1, P<0.001, with an increase in FVR from 56±4 to 
73±5 AU, /><0.001). FBF in the control arm did not change (from 1.6±0.1 to 1.6±0.1 
mLdL 'min ', P=0.67, FVR from 60±5 to 60±5 AU, P=0.93). Mean arterial pressure 
remained stable (from 81 ±1 to 82±1 mmHg, />=0.36). 
Ouabain induced a clear increase of venous potassium levels (from 4.2±0.1 to 
4.8±0.1 mmol-L', P<0.001), whereas arterial levels changed slightly (4.0±0.0 to 
4.2±0.1, P<0.01), indicating an obvious increase of net forearm potassium release 
(from 0.18±0.06 to 0.36±0.08 /mtol-dL/'-min ', P<0.01). 
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Fig. 2. Time course of FBF in control arm and experimental (ouabain-infused) arm during 
three sequential 20-min periods of ouabain (oua) infusion. 
Response to Repeated Ouabain Administration: 
During prolonged intermittent ouabain infusion alone (three periods of 20-min 
infusions, n=6), FBF in the infused and control arms remained stable throughout 
the study (ouabain-infused arm: from 1.1±0.1 mL-dL'min ' at the end of first 
ouabain infusion to 1.2±0.2at the end of third ouabain infusion 90 minutes later, 
P=0.78; control arm: from 1.5±0.2 mLdL'min"1 at the end of the first ouabain 
infusion to 1.7±0.2 at the end of the third ouabain infusion, P=0.13) (see Fig. 2). 
During prolonged intermittent ouabain infusion alone, arterial potassium 
concentration did not change (from 4.0±0.1 mmolL-1 before to 4.0±0.1 at the end 
of the third ouabain infusion); venous potassium increased after the first infusion 
but remained stable thereafter (from 4.1±0.2 mmol-L-1 to 4.6±0.3, 4.7±0.3 and 
4.6±0.2, before and at the end of the first, second and third ouabain infusions, 
respectively). The net potassium release (see response to ouabain infusion alone) 
remained stable (Table 2). Ouabain did not affect baseline forearm glucose 
uptake (from 0.41±0.09 /imoldL'-min1 before to 0.41±0.15 during ouabain). 
Table 2. Forearm Potassium Release During Baseline, Ouabain and Ouabain Plus Insulin 
Ouabain 
Alone (n=6) 
Low Insulin 
(n=6) 
High Insulin 
(n=6) 
Low Insulin 
(n=6)* 
Baseline 
Ouabain 
Insulin (45 min)+ouabain 
Insulin (90 min)+ouabain 
0.09±0.07 
0.27±0.09 
0.36±0.13 
0.36±0.09 
0.25±0.13 
0.39±0.20 
0.24±0.10 
0.03±0.09 
0.16±0.14 
0.44±0.11 
0.19±0.04 
-0.03±0.06 
0.17*0.11 
0.33±0.15 
0.12±0.15 
0.18*0.05 
Values are expressed as//moldL-1min-1. Note that ouabain induced an increase in net potassium 
release, which remained stable during continued ouabain administration (ouabain alone), but was 
partly reversed by additional insulin administration. For Ρ values, see text. 
* These individuals were subsequently given L-NMMA, see "Methods", third protocol. 
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Vascular Response to Insulin Plus Ouabain 
Low-dose insulin infusion (n=6) increased arterial (systemic) insulin concentrations 
from 43±7 to 695±7 and 688±29 pmol-L' after 60 and 90 minutes, respectively. As 
can be seen in Fig. 3 (top), insulin induced a gradual vasodilation in the control 
arm (FBF from 1.2±0.2 to 1.8±0.2 mLdL'min' after 90 minutes, P<0.05; FVR from 
78±12 to 54±7 AU, P<0.01), but FBF in the ouabain-infused arm did not change 
(from 1.1±0.1 to 1.1±0.2 mLdL'min', />=0.70; FVR from 91±16 to 90±13 AU, 
Р=0.9б). After 90 minutes of insulin infusion, FBF had not reached a steady state 
but still seemed to increase. Mean arterial pressure did not change significantly 
(from 86±2 to 88±3 mmHg, P=0.46). 
- П - low insulin 
— · - ouabain+insuhn 
| Insulin (high dose) 
(oua [ ι qua ι ι Sua" 
90 105 
minutes 
Fig. 3. Time course of FBF in both control arm (insulin) and experimental arm 
(ouabain+insulin) during low-dose (430 pmolm2-min', top), and high-dose (860 
pmol-m^min', bottom) insulin infusions. Oua indicates ouabain. 
High-dose insulin infusion (n=6) increased arterial (systemic) insulin 
concentrations from 57±7 to 1477±165 and 1506±86 pmol-L' after 60 and 90 
minutes, respectively. Again, insulin induced a gradual vasodilation in the control 
arm (FBF from 1.6±0.2 to 2.1±0.2 mLdL'min' after 90 minutes, P<0.05; FVR from 
57±9 to 44±4 AU, P=0.15), but FBF in the ouabain-infused arm remained 
unchanged (from 1.3±0.1 to 1.3±0.1 mLdL'min', P=0.69; FVR from 62±5 to 67±3 
AU, P=0.64) (Fig 3., bottom). Percent flow changes were not different (P=0.S3) 
between the insulin experiments (see Fig. 4.). 
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Fig 4. Percent change in FBF after 90 minutes of low-dose (430 pmol-m'-min ') and high-
dose (860 pmolnVmin') insulin infusions in control arm (insulin) and 
experimental arm (ouabain+insulin). 
Metabolic Responses to Insulin Plus Ouabain 
Arterial forearm glucose values were clamped at fasting levels (coefficient of 
variation, 5.1 ±0.4%; n=18); forearm deep venous glucose levels decreased to 
trough levels at 45 minutes and remained at this level throughout the study. 
Therefore, despite ouabain infusion, insulin thus induced a clear increase in 
forearm skeletal muscle glucose uptake from 0.35±0.06 to 2.35±0.52 μгr\o\•dL·ì•m\n, 
(P=0.01) (low insulin) and from 0.23±0.08 to 2.48±0.48 μ ί τ ι ο ί ^ ' · ! ™ ' (P=0.003) 
(high insulin). As can be seen in Fig 5., forearm glucose uptake was already near 
maximal after 45 minutes. Maximum forearm glucose uptake did not differ 
significantly between the low- and high-dose insulin experiments (P=0.86). Also, 
whole body glucose uptake during the last 30 minutes of the clamp was not 
different (51±7 [low insulin] and 42±4μιτιοΙ^ ,·Γτυη"' [high insulin]) (/>=0.31). 
Insulin decreased ouabain-induced forearm potassium release from 0.39±0.20 to 
0.03±0.09 ¿tmol-dL-'-min-1 (P=0.18) (low insulin) and from 0.44±0.11 to -0.03±0.06 
(P<0.01) (high insulin) (see also Table 2). 
Response to L-NMMA 
The single infusion of three doses of L-NMMA into the brachial artery induced a 
dose-dependent decrease in FBF from 1.7±0.2 to 1.2±0.1 mLdL'min' (n=12, 
/><0.01). 
In six individuals, L-NMMA was administered after insulin was infused (systemic 
insulin concentrations from 43±7 to 645±50 pmol-L') during 90 minutes, identical 
to the low-insulin dose protocol. However, after the previous administration of 
ouabain, L-NMMA induced no vasoconstriction (FBF from 1.6±0.4to 1.5±0.3 
mLdL'-min·' at the highest L-NMMA dose) (P=0.66, ANOVA), despite the 
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concomitant continued administration of insulin. A significant difference between 
the percent change of FBF was established between the two groups (P<0.03, see 
Fig. 6). 
Again, the prior administration of insulin induced vasodilation at the control side 
(FBF from 1.9±0.3 to 2.4±0.8 mLdL'min '), but did not change FBF at the ouabain-
infused side (from 1.5±0.2 to 1.6±0.4 mLdL'min1). Furthermore, ouabain induced 
potassium release, which was counteracted by insulin (see Table 2), but ouabain 
did not affect insulin-induced forearm glucose uptake (from 0.42±0.16 to 
г^іО.ЭЗ/лтюІ^и-тіп'). 
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Fig 5. Time course of forearm glucose uptake during low-dose (430 pmol m2-min ') and 
high-dose (860 pmolm2 min1) insulin infusions, oua indicates ouabain. 
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Fig 6. Percent change ¡η FBF from baseline during three subsequent inta-arterial L-
NMMA infusions alone (control) or after ouabain (and continued 
hyperinsulinemia) (ouabain+insulin). 
Discussion: 
The major new observation of the present study is that ouabain largely inhibits 
insulin-induced vasodilation, which indicates that activation of Na*-K*-ATPase is a 
key factor in the mechanism of insulin-mediated vasodilation. 
In recent years, the vasodilator capacity of insulin has again been recognized (1-3) 
and considered to be important with respect to a further increase of glucose 
disposal in target tissues. Interestingly, in various related disorders such as obesity, 
hypertension, and non-insulin-dependent diabetes mellitus, in which resistance to 
the metabolic effect of insulin has been described (30), a decreased insulin-
induced vasodilation has also been reported (1,4,5). Therefore, unraveling the 
mechanism of the effect of insulin on vascular tone could be of great 
pathophysiological importance. In this study, as in many others (1,2,17-19), 
systemic insulin infusion induced a gradual slow-onset vasodilation (control arm) 
that after 90 minutes did not seem to have reached its maximal effect. Forearm 
glucose uptake, being maximal after 45 minutes, precedes vasodilation (1) and 
was similar during the low- and high-dose insulin experiments, confirming that 
arteriovenous glucose difference is already maximal at an insulin concentration of 
approximately 700 pmolL·1 (18). 
Interactions Between Na*-K*-ATPase and Insulin 
It has long been described that insulin induces Na'-K'-ATPase activity (7,8), but the 
underlying signals and mechanisms are not yet fully clear. Possible reported 
mechanisms are an increase in skeletal muscle mRNA levels (31), translocation of 
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Na*-K*-ATPase molecules (especially a2-isoforms) from intracellular stores to the 
plasma membrane (16,8), or activation of protein kinase С (32). Na*-K>ATPase is a 
ubiquitous enzyme located in nearly every cell type, and when involved in insulin-
induced vasodilation, it theoretically could be located at the level of the smooth 
muscle cell, the endothelium, or both. 
Ouabain infusion alone induced vasoconstriction in our study, an effect that was 
maximal after 10-15 minutes, and has been reported before (22,24,25). 
Apparently, baseline activity of Na+-K*-ATPase contributes to resting vascular tone. 
Ouabain induced a clear forearm release of potassium, which was stable 
throughout the study, indicating an effective inhibition of Na+-K*-ATPase-activity. 
The absence of systemic effects (no change in blood pressure or pulse rate, no 
change in arterial potassium levels) and the unchanged FBF at the contralateral 
side make it reasonable to conclude that ouabain had significant effects only at 
the experimental side, of course as a result of the small cumulative dose. Ouabain 
did not affect baseline glucose uptake, and insulin-induced increase in forearm 
glucose uptake appeared normal, confirming that ouabain does not inhibit 
insulin-induced glucose uptake (25). 
Hyperinsulinemia was still capable of reversing (gradually) the ouabain-induced 
forearm potassium release, although this did not result in a net uptake during the 
experiment. This could indicate that the Na*-K*-ATPase inhibition by ouabain was 
not complete or alternatively, that insulin-induced potassium uptake might be 
mediated by mechanisms other than activation of Na*-K*-ATPase. We also noticed 
that opposite to the effect on glucose uptake, the stimulation of potassium 
uptake seemed more pronounced during the high-dose insulin infusion. 
Mechanism of Effect 
Ouabain was clearly capable of preventing the insulin-induced vasodilation. This 
seems to be a specific effect, as it has been demonstrated quite convincingly that 
ouabain does not inhibit the effects of various other vasodilator substances, such 
as verapamil, sodium nitroprusside (24), nifedipine, phentolamine, prazosine (33), 
or histamine (26). 
The exact level at which insulin stimulates an increase in Na*-K+-ATPase activity 
was not determined. Na*-K*-ATPase could be stimulated at the level of the smooth 
muscle cell, as shown by data from in vivo experiments (16,32). This concept, in 
which the inhibition of insulin-induced vasodilation by ouabain is well explained, 
seems to conflict with the fact that insulin-induced vasodilation can also be 
inhibited by L-NMMA (14,15). 
In the current study, we report that compared with subjects not treated with 
ouabain, subjects treated with ouabain showed blunted responses to L-NMMA-
induced vasoconstriction, whereas the responses to LNMMA would be expected to 
be more intense than normal because of the previous 90 minutes of 
hyperinsulinemia (14,15). This may be explained by recent in vitro data providing 
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some evidence that part of endothelium-dependent NO-induced vasodilation is 
mediated through stimulation of Na*-K*-ATPase and thus inhibited by ouabain 
(34,35), but of course, also by L-NMMA. 
Another explanation could be that insulin activates Na*-K*-ATPase also at the level 
of the endothelial cell. It has been shown that endothelial cells contain Na*-K*-
ATPase molecules (11,36). Activation of the sodium-potassium pump and 
subsequent hyperpolarization have different effects on intracellular calcium in 
endothelial cells ([Ca2*], decrease) compared with smooth muscle cells ([Ca2*], 
increase) (12). An increase of intracellular calcium in the endothelial cell would 
induce release of NO (12). In this concept, insulin-induced vasodilation could be 
inhibited by both L-NMMA and ouabain. Some reports, in which acetylcholine-
induced vasodilation and insulin-mediated potentiation of this response were 
partly inhibited in vivo by ouabain (21,31,37), seem to support this concept. 
Further research will be needed to identify the exact mechanism underlying the 
ouabain-related inhibition of insulin-induced vasodilation. 
In conclusion, we report that inhibition of Na+-K*-ATPase by ouabain largely 
inhibited in vivo insulin-induced vasodilation in humans, which suggests that 
activation of this enzyme must be involved in the effects of insulin on vascular 
tone. We hypothesize that insulin could activate Na*-K*-ATPase at the level of the 
endothelial cell, which implies that Na*-K+-ATPase activation will contribute to the 
endothelium-dependent vasodilator response to insulin. Clearly, the interaction 
between insulin and Na*-K*-ATPase should be investigated further at different 
cellular levels. 
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Abstract 
In healthy subjects, acute physiological hyperinsulinemia induces activation of the 
sympathetic nervous system, but in the absence of hypoglycemia, plasma 
epinephrine levels have not been found to increase during insulin administration. 
Venous levels of catecholamines however, reflect the nett result of release, 
clearance and uptake and are therefore not a good measurement of 
adrenomedullary epinephrine secretion. 
The influence of 90 min euglycemic physiological hyperinsulinemia (60 
mUm'-min', plasma insulin concentration approximately 700 pmol-L1) on 
epinephrine kinetics using the [3H]-epinephrine-tracer method was studied in 12 
healthy, normotensive, non-obese subjects. After bolus injection, [3H]-epinephrine 
was continuously infused (0.35 juCuriem 2min '), with arterial and venous blood 
sampling at regular intervals, enabling calculation of total-body (systemic) and 
forearm epinephrine release and clearance. Studies were performed in the basal 
state and during sympathetic stimulation by lower body negative pressure [LBNP] 
of -15 mmHg for 15 minutes. Control experiments ("sham" clamps, but with LBNP) 
were performed in 4 out of the 12 individuals. 
Euglycemic hyperinsulinemia (all arterial glucose samples >4.2 mmolL'), induced 
an increase of arterial epinephrine concentration (relative increase 53±22 %) as 
well as of total-body epinephrine release (54±20%, P<0.05 for both). In contrast, 
total body epinephrine clearance did not change during hyperinsulinemia. The 
insulin-induced increase in forearm blood flow [plethysmography] (from 3.0±0.4 
to 3.8±0.6 mLdL'min ', P=0.01) showed a high correlation with the increase in 
arterial epinephrine (r=0.78, P<0.01). In the control experiments the "sham 
clamp" did not induce changes in epinephrine concentrations (percent increase of 
arterial epinephrine: 3±16%, P=0.86). 
Sympathetic stimulation, induced by LBNP, did not stimulate epinephrine release. 
However the combination of insulin and LBNP significantly raised epinephrine 
release (from 0.37±0.06 to 0.56±0.12 nmolnv'min ', /><0.05). LBNP alone and in 
combination with insulin induced similar forearm vasoconstriction. 
We conclude that acute physiological hyperinsulinemia under euglycemic 
conditions induces epinephrine release and increases epinephrine responses to 
sympathetic stimuli. Due to increased forearm removal however, venous 
epinephrine concentrations hardly change. The epinephrine release could explain 
part of the hemodynamic effects of insulin. 
Introduction 
Besides its key role in the regulation of metabolism (1), it has become clear that 
insulin has also important cardiovascular effects. Acute hyperinsulinemia induces 
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activation of the sympathetic nervous system as measured by plasma 
norepinephrine concentration, by direct measurement of muscle sympathetic 
nerve activity traffic (microneurography) (2,3), and by norepinephrine kinetic 
studies (4,5). The increased sympathetic noradrenergic activity to skeletal muscle, 
inducing vasoconstriction, is overridden by a vasodilator action of insulin (2,6). In 
contrast to the effects of insulin on norepinephrine release, the relationship 
between insulin and adrenomedullary function has received little attention. 
Although plasma norepinephrine concentrations increase during acute insulin 
administration (2,7,8), plasma epinephrine levels are generally reported not to 
change under euglycemic conditions (2). 
The plasma epinephrine concentration is a function of both the rate of 
epinephrine secretion into the plasma from the adrenal medullae and the rate of 
clearance of epinephrine from the circulation (9). The interpretation of venous 
plasma epinephrine concentration as an index of adrenomedullary activity is 
therefore flawed by the rapid removal of epinephrine from the circulation by 
many tissues. For example, there is a ±50% extraction of epinephrine across the 
forearm (10), which will especially affect venous plasma epinephrine levels. Thus, 
the measurement of venous plasma epinephrine levels during physiological and 
pathophysiological states may not be an adequate reflection of adrenomedullary 
function in humans. Moreover, venous plasma epinephrine concentrations in 
healthy individuals are generally low, and hence, in order to be able to measure 
small increments in plasma epinephrine reliably, a very sensitive laboratory 
method has to be used (11). 
Insulin-induced increase in adrenomedullary secretion of epinephrine might be of 
clinical relevance, because it would lead to an increase in systolic and a decrease 
in diastolic blood pressure, as well as to increments in (forearm) blood flow and 
heart rate (12), all factors that cause a hyperdynamic circulation (13). As such the 
effects of epinephrine resemble those that are found during acute 
hyperinsulinemia (2), and could explain part of the reported relationship between 
hyperinsulinemia/insulin resistance and hyperkinetic circulation (13,14). In 
addition, increased circulating epinephrine levels during hyperinsulinemia may 
contribute to the increase in norepinephrine levels, because it has been shown 
that epinephrine facilitates neuronal release of norepinephrine by presynaptic 
stimulation of ß-adrenoceptors (15). 
The aim of the present study was to quantify the responses of epinephrine 
kinetics to hyperinsulinemia in detail, with use of the [3H]epinephrine tracer 
technique (10,11,16). 
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Methods 
Subjects 
The study group consisted of 12 healthy volunteers. All met the inclusion criteria: 
Age between 25 and 60 years, non-smoking, absence of hypertension (office 
blood pressure <160/90 mmHg, measured after 5 min rest in the supine position), 
body mass index <27 kgm J . Participants used no medication. They were selected 
by advertisement and received a payment. All subjects had a normal glucose 
tolerance, and a negative family history of diabetes and hypertension. All 
participants gave written informed consent. The experimental protocol was 
approved by the hospital ethics committee. 
Protocol and procedures 
During the experiments subjects remained in supine position in a quiet, 
temperature-controlled room (25-26° C). Experiments were performed after an 
overnight fast. A 20-gauge catheter (Angiocath", Becton Dickinson, Sandy, Utah) 
was inserted into the left brachial artery [local anesthesia with 0.3-0.4 mL 
lidocaine HCl 20 rngmL1], and connected with an arterial pressure monitoring line 
(Viggo Spectramed, 5269-129) to a Hewlett Packard 78353B Monitor. The arterial 
line was kept patent with NaCI 0.9%/heparin infusion (2 U heparinmL1 NaCI, 3 
mlh '). In the ipsilateral arm a catheter (Venflon", 20 G, 32 mm) was inserted into 
a deep forearm vein to obtain venous blood samples. On the contralateral side an 
identical catheter was inserted into a large forearm vein for the infusion of 
[3H]epinephrine, insulin and glucose 20%. 
At least 30 minutes of rest were included after complete instrumentation. Then, a 
priming dose of 15 дСі-т2, followed by a continuous infusion of 0.35μΟ·πι 2min ' 
[3H]epinephrine was given during the entire experiment. Again 30 min were 
waited to obtain a steady state, after which baseline hemodynamic and endocrine 
measurements were performed. Subsequently, Lower Body Negative Pressure 
(LBNP) at -15 mmHg using a perspex box, was applied for 15 min to stimulate the 
sympathetic nervous system (17). Thereafter 30 min rest were inserted to allow all 
parameters to return towards baseline level. 
After this second baseline, a hyperinsulinemic euglycemic clamp was started in 
which insulin (Actrapid, Novo-Nordisk, Denmark), 430 р т о І т 2 т і п ' (60 
mUm2min') was infused during 90 minutes. Arterial plasma glucose 
concentrations were clamped at fasting levels by a variable glucose 20% infusion 
rate, adjusted by arterial plasma glucose levels, measured at 5 min intervals (18). 
Finally, with the continuation of insulin and glucose infusion, a second LBNP at 
-15 mmHg was applied for 15 minutes. 
Forearm blood flow (FBF) was measured using mercury-in-silastic strain-gauge, 
venous occlusion plethysmography as previously described (19). The collecting cuff 
around the upper arm was inflated to a pressure of 40 mmHg during 8 heart 
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cycles using a Hokanson E20 rapid cuff ¡nflator. The strain gauges were connected 
with the Hokanson EC4 Plethysmographs (D.E. Hokanson Ine, Bellevue, WA 98005, 
US). 
Time control experiments 
In 4 male subjects, randomly selected from the study group, the entire experiment 
was repeated on a separate day, but now without the administration of insulin 
(and glucose), and tritiated epinephrine. Arterial and venous lines were placed as 
in the original protocol, and LBNP was applied similarly, twice for 15 min. During 
the 90-min "sham clamp" period, arterial blood was sampled every 5 min, and 
subjects received a variable saline infusion in amounts exactly identical with the 
infusion rate of glucose 20% during the original experiment. Blood samples for 
determination of epinephrine were taken at the same time intervals, and 
processed identically. 
Analytical methods 
Plasma glucose was measured in duplicate, in arterial blood samples that were 
immediately centrifuged during 20 seconds, by the glucose oxidation method 
(Beekman Glucose Analyzer 2, Beekman Instruments Ine, Fullerton, CA 92634, 
USA). Plasma insulin was measured with a double antibody radioimmunoassay 
(Interassay coefficient of variation (CV) 6.2%). Plasma C-peptide was measured 
with a commercially available double antibody radioimmunoassay (Diagnostic 
Products Corporation, LA, CA 90045 5597, interassay CV 4.3%). Hemoglobin Au 
was measured using a HPLC technique (BIO-RAD Laboratories B.V. Veenendaal, 
the Netherlands; reference values 4.8-6.2 %). 
Tritiated epinephrine (levo-[N-methyl-3H]epinephrine; specific activity 55-85 
Ci-mmol ') was obtained from Du Pont, New England Nuclear ('s Hertogenbosch, 
The Netherlands). It was sterilized using a micropore filter (0.22 μπ\) and diluted 
in NaCI 0.9%, containing glacial acetic (0.2 molL') and ascorbic acid (1 mg-mL'). 
Sterilization, dilution, and batch dividing were carried out under nitrogen. 
Aliquots of approximately 70 μΟ/τηί [3H]Epinephrine were stored at - 80° С until 
the morning of the experiment, which was always within 3 months from 
preparation. The weight of the syringe containing the radiotracer was measured 
just before and after the infusion, to verify the infusion rate. At the end of the 
experiment an aliqout of the radiotracer was frozen and stored at - 80° С for later 
analysis. 
Blood samples for measurement of plasma catecholamines were collected in 
prechilled tubes on melting ice, containing glutathione (0.2 mol-L') and EGTA 
(0.25 molL') and centrifuged at 4"C. Plasma was stored at -20°C; analyses of 
plasma samples and infúsate occurred within 2 months from collection. Plasma 
samples were analyzed for concentrations of unlabelled and tritium-labelled 
epinephrine by high performance liquid chromatography (HPLC) with fluorometric 
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detection after precolumn derivatization with the selective detection agent 1,2 
diphenylethylenediamine. The laboratory procedure is a modification of a 
previously published method, and has been extensively validated in our 
laboratory (11). The detection limit of unlabeled epinephrine was 3.2 pmol-L1, the 
intra-assay coefficients of variation were 3.4% at plasma concentrations of 0.11 
nmol-L', and 7.2% at plasma concentrations of 0.15 nmol-L'. The detection limit 
of [3H]epinephrine was б dpm; the interassay coefficient of variation of 
[3H]epinenephrine was 7% in venous plasma samples. 
Calculations and data analysis 
The following kinetic variables were calculated according to the next formulas: 
Infusion rate (dpm-m ' -min1) 
Total body clearance (TCL, L-m '-min ')= 
PH]E (dpm-L <) 
Total body E spillover (T50, nmohm'-min ')= TCL (L-m'-min ') χ [E]«< (nmol-L ') 
Forearm E spillover (FSO, pmoldLFAV 'min <)= FFF χ ( [E]-. - [E]*, * FE χ IE]art) 
Forearm removal (FRM, pmoldLFAV 'min ')= FPF χ FE χ [E] « 
In which: 
Forearm Plasma Flow (FPF, mLdL FAV 'min ')= (1-Hematocrit) χ FBF 
FAV=Forearm Volume (measured by volume plethysmography) 
pH]E«, - fH/f«. 
Fractional extraction (FE)= 
РН]Е« 
Forearm Vascular Resistance (FVR) was calculated by dividing mean arterial 
pressure (MAP) and FBF, and expressed in arbitrary units (AU). Pulse pressure was 
calculated by subtracting diastolic from systolic blood pressure. 
Data on norepinephrine kinetics from this study group were used as controls in a 
manuscript on non-insulin-dependent diabetes mellitus (NIDDM) (5). 
During the last 30 minutes of the clamp, the glucose infusion rate was calculated 
as /jmolkg 'min ', to obtain whole-body glucose uptake, a measure of insulin 
resistance (20). 
Effects of insulin on hemodynamic parameters were calculated using repeated 
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measures ANOVA, with insulin as independent factor, and hemodynamic data on 
the relevant time points as dependent variables. Changes in epinephrine kinetic 
data in response to insulin were statistically analyzed by use of the Student's t 
test. Comparison of changes in epinephrine kinetics to both LBNP procedures was 
performed by repeated measures ANOVA with insulin and LBNP as independent 
factors. Correlations were calculated using Spearman's rank correlation tests. All 
statistical analyses were performed using the SPSS personal computer software 
package. 
Results in text, tables and figures are expressed as mean ± SEM, unless otherwise 
indicated. Statistical significance was set at a value less than 0.05. NS means not 
significant. 
Results 
Baseline measurements 
The 12 subjects (8 males, 4 females), had a mean (±SD) age of 46.2±6.0 (range 36-
59) years and body mass index (BMI) of 24.3±1.7 kgnr2. They were normotensive 
(systolic blood pressure 126±10, diastolic blood pressure 79±7 mmHg), and had 
normal fasting glucose (5.1±0.4 mmolL') and HbAic levels (5.5±0.5%). Fasting 
insulin concentration was 56±14 pmol-L', fasting plasma C-peptide level was 
0.40±0.07 nmol-L'. Baseline epinephrine-kinetic parameters (arterial and venous 
plasma concentration, total-body and forearm spillover, total-body and forearm 
clearance) are denoted in Table 1 (first column). 
The characteristics of the subjects in which control experiments were performed, 
resembled that of the whole study group (age 44.0±2.6 yr, BMI 25.2±1.6 kgm2). 
Table 1. Epinephrine (E) kinetic data (mean±SE) 
Baseline 1 LBNP Baseline 2 Insulin Insulin + 
LBNP 
ArtE(nmolL') 
VenE(nmolL') 
TSO (nmolm'min') 
TCL (nmolm'min') 
FSOipmoldL'min') 
FRM (pmoldL'min1) 
0.25±0.03 
0.09±0.02 
0.28±0.04 
1.09±0.05 
0.02±0.01 
0.3U0.05 
0.27±0.04 
0.11±0.02 
0.27±0.05 
0.97±0.06' 
0.02±0.02 
0.27±0.06 
0.24*0.04 
0.09±0.02 
0.28±0.06 
1.09±0.06 
0.03±0.02 
0.28±0.04 
0.34±0.05' 
0.13±0.02' 
0.37±0.06' 
1.07±0.05 
-0.02±0.02 
0.50±0.12' 
0.58±0.10s 
0.17*0.03 
0.56±0.12s 
0.95±0.07' 
-0.12±0.07 
0.68±0.22 
0 indicates P<0.05 vs. baseline 1, ' P<0.05 vs. baseline2 ' P=0.06,s P<0.05 vs. insulin, TSO: 
total body E spillover, TCL: total body E clearance, FSO: forearm E spillover, FRM: Forearm E 
removal). 
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Metabolie response to euglycemic hyperinsulinemic damping: 
Blood glucose values during the clamp procedure were stable in all individuals 
(last 30 minutes: mean glucose concentration 4.9±0.1 mmol-L', coefficient of 
variation 4.3±0.5 %). Plasma insulin concentration was 651 ±40 pmolL' after 60 
min and 645±48 pmol-L-1 after 90 min insulin infusion. Whole-body glucose 
uptake, as an index of insulin sensitivity and calculated from the last 30 min 
infusion rates, was 48.9±2.0 (range 34.5-58.4) μπΊοΙ^'-πυη1. During all clamp 
procedures, arterial plasma glucose concentration was never below 4.2 mmolL'. 
Epinephrine kinetics: 
Absolute epinephrine kinetic data of the entire experiment are given in table 1. 
LBNP: During LBNP alone, arterial, venous and total-body epinephrine spillover 
remained unchanged (Fig. 1, left panels), but calculated total-body epinephrine 
clearance decreased significantly. After this first LBNP all parameters returned to 
baseline values (Table 1). 
LBNP in the control experiment, induced no changes in arterial and venous 
epinephrine concentrations (Fig. 1, left panel). 
Insulin: After 90 min of insulin infusion, arterial and venous epinephrine 
concentrations were increased (percent increase: arterial E, 53±22%, venous E 
64±24%, both P<0.05 vs. baseline). Total-body epinephrine spillover increased by 
54±20% (P<0.05). Total-body epinephrine clearance did not change during 
hyperinsulinemia (-0.3±4.4%, P=0.94). Forearm epinephrine removal increased by 
78.6±27.2% (P<Q.QS), but (as expected (11)) forearm epinephrine spillover did not 
change. 
During the sham clamps, no changes in arterial or venous epinephrine 
concentrations were observed (percent change after 90 min: 3±16%, P=0.86, and 
-1±16%, P=0.95 respectively, Fig. 1 vertical middle panels). 
Insulin+LBNP: In contrast to the responses during LBNP alone, arterial and venous 
epinephrine increased significantly during LBNP+hyperinsulinemia, (Table 1 and 
Fig. 1 right panel). Despite the higher baseline levels at the start of this LBNP due 
to the previous insulin effect, the responses of arterial epinephrine and total 
body epinephrine spillover were more pronounced as compared with the 
responses during the first LBNP procedure (ANOVA /»=0.018 and P=0.023 
respectively). When the increments to LBNP on both occasions were calculated as 
absolute or relative increase, the response to LBNP during hyperinsulinemia was 
clearly increased as compared with LBNP alone [percent increase in arterial 
epinephrine 7.7±7.8% during LBNP alone, vs. 76.4±20.7% during LBNP+insulin 
(P=0.019), percent increase in total body epinephrine spillover (-3.0±9.9% during 
LBNP alone, vs. 50.3±14.0% during LBNP+insulin (P=0.02)]. Changes in venous 
epinephrine concentration, total-body epinephrine clearance and forearm 
removal were not different between the two tests. 
In the control experiments, the second LBNP induced a slight increase in arterial 
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Fig. 1: Changes ¡η venous epinephrine (lower panel), arterial epinephrine (middle panel] 
and total-body epinephrine spillover (upper panel), in response to LBNP, insulin 
and the combination of insulin and LBNP. (closed circles: results in experimental 
group, open circles: results of control studies). #P<0.05 vs. baseline 2, *P<0.05 vs. 
insulin alone. 
Note: There was no washout period between the second and the third 
experimental part; the second LBNP was superimposed on continued 
hyperinsulinemic euglycemic clamp. 
epinephrine concentrations which was clearly less pronounced than during 
hyperinsulinemia. Venous epinephrine concentration did not change during the 
second LBNP in the control experiments. 
Hemodynamic changes: 
LBNP: LBNP induced vasoconstriction, but did not change blood pressure or heart 
rate (Table 2), in the experimental group as well as in the control experiments. 
Insulin: As can be derived from Table 2, 90 min of hyperinsulinemia induced 
forearm vasodilation. The absolute increase in arterial epinephrine concentration 
during insulin was highly correlated wi th the increase in FBF (r=0.78, P<0.01, Fig. 
2), as was percent increase in arterial epinephrine (correlation with AFBF: r=0.72, 
/>=0.008, with AFVR: r=-0.76, /»=0.004). 
Systolic blood pressure did not change, diastolic blood pressure decreased during 
insulin. Pulse pressure increased significantly (from 59±2 to 63±2 mmHg, P<0.001). 
Heart rate did not change. In the control group sham clamping did not affect FBF 
or blood pressure (Table 2). 
Insulin+LBNP: Also during hyperinsulinemia, LBNP induced vasoconstriction, but 
did not change blood pressure or heart rate (Table 2). Again, the control group 
showed comparable hemodynamic responses to the second LBNP. 
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Table 2. Hemodynamic changes ¡η experimental and control group (Mean±SE) 
FBFdnL-dL'-min') 
Experimental 
Control 
FVR (AU) 
Experimental 
Control 
SBP (mmHg) 
Experimental 
Control 
DBP (mmHg) 
Experimental 
Control 
Baseline 1 
3.0±0.4 
2.3±0.2 
34±4 
40±3 
125±3 
127±5 
66±2 
66±2 
LBNP 
2.5±0.5' 
1.6±0.3' 
47±7 
59±10* 
125±4 
123±5 
67±2 
66±2 
Baseline 2 
3.0±0.4 
1.9±0.2 
35±5 
49±5 
126±3 
128±5 
67±2 
67±2 
Insulin 
3.8±0.6' 
1.7±0.1 
27±3' 
57±4 
128*3 
135±4 
65±2 
69±2 
Insulin + LBNP 
2.6±0.4S 
1.5±0.Γ 
46±95 
62±5 
126±3 
130±3 
6 6 i 2 
68±3 
(' indicates P<0.05 vs. baseline 1, ' P<0.05 vs. baseline 2, s P<0.05 vs. insulin, * P=0.06. 
FBF: Forearm blood flow, FVR: forearm vascular resistance, SBP: systolic blood pressure, 
DBP: diastolic blood pressure. 
•a 
с 
'ε 
Li. 
CD 
LL 
< 
3 
2 
1 
0 
-1 
-
• 
f 
* 
I 
r-0.78, p<0.01 
• 
• 
• · 
> 
1 . 1 
• 
• 
1 
-0.20 -0.10 0.00 0.10 0.20 0.30 0.40 
Δ arterial ep¡nephrine(nmol-l ) 
Fig. 2: Correlation between absolute change in FBF and absolute change in arterial 
plasma epinephrine level in response to 90 min hyperinsulinemia. 
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Discussion 
The major new observation of the present study is that short term physiological 
hyperinsulinemia causes systemic release of epinephrine, even under strict 
euglycemic conditions. The increased plasma levels of epinephrine correlate 
strongly with the observed increase in skeletal muscle blood flow, suggesting that 
a relevant part of the vascular and hemodynamic effects of insulin may be 
mediated by epinephrine. 
Sympathetic stimulant effects of insulin 
One of the first studies showing a direct relationship between insulin and the SNS 
were the studies of Rowe et al, demonstrating an increase in plasma 
norepinephrine concentrations in response to insulin infusions (clamp conditions) 
during 150 min. The increase was most prominent at fairly high doses of insulin 
(21). The group of Anderson has extended and repeated these experiments with 
the use of microneurography. Physiological and supra-physiological plasma insulin 
concentrations, gradually increased muscle sympathetic nerve activity, expressed 
as bursts per minute (2). Plasma norepinephrine concentrations rose too (2). These 
results were confirmed by Berne et al (3). There are no studies specifically 
addressing time-relationships. In those studies with constant insulin-infusion, most 
changes take place during the first hour (22-24). The increase in norepinephrine 
concentration is due to increased systemic spillover (and hence probably increased 
neural release), as can be derived from norepinephrine kinetic studies (25). In 
summary, it now seems generally accepted that acute insulin administration 
activates the sympathetic nervous system in healthy humans (2,3) and leads to an 
increase in arterial and venous plasma norepinephrine concentrations (5,8,21-25), 
along with an increase in muscle sympathetic nerve activity (MSNA) (2,3,8,22,23). 
It is generally assumed that plasma epinephrine concentrations do not increase 
during euglycemia, despite high insulin concentrations. However, looking at 
previous studies in more detail, several suggest a small, non-significant increase. 
For example in the study of Anderson et al, venous epinephrine concentration 
rose from 28±5 to 35±7 pg.mL' after 60 min of euglycemic hyperinsulinemia (2). 
In another study of Scherrer et al, venous epinephrine concentration increased 
during a 1 h euglycemic hyperinsulinemic clamp procedure from 0.30±0.05 to 
0.36±0.05 nmolL' (22), and in Vollenweider et al from 0.45±0.07 to 0.52±0.08 
nmolL' (8). A very recent study reported even a reproducible significant 
epinephrine increase in NIDDM subjects during hyperinsulinemic clamping (26). In 
general, most studies report at least a tendency to increase. 
The results in our study have been obtained with the use of the tritium labelled 
epinephrine kinetic technique (10). Although venous epinephrine concentrations 
increased slightly in the present study, the absolute changes were small, and 
could easily have been missed by less sensitive laboratory assays. Most studies 
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mentioned above have measured epinephrine concentrations in venous or 
arterialized blood, but this is not equal to arterial epinephrine concentrations 
(27,28). In addition, arterialisation often has been achieved by a hand warming 
device, which might be a confounding factor. 
The adrenomedullary system is an important part of the autonomic nervous 
system (29). Sympathetic activation may also induce epinephrine release from the 
adrenal medulla. Epinephrine in turn facilitates the release of norepinephrine 
from sympathetic nerve endings (15). Despite the activation of the sympathetic 
nervous system, hyperinsulinemia induces vasodilation (2). Therefore, the 
vasoconstrictive effects of norepinephrine may be counterbalanced by a ßj-
adrenoceptor mediated vasodilator effect of epinephrine. Previous studies have 
indeed suggested that the effects of insulin on the cardiovascular system can be 
inhibited by the ß-adrenoceptor blocker propranolol (30,31). As such, the 
literature provides indirect evidence to hypothesize that insulin might induce 
release of epinephrine. 
Mechanism of adrenomedullary activation 
While we have found that insulin induces systemic epinephrine release, the study 
was not designed to explain the mechanism of these effects. Several possible 
mechanisms have to be considered. 
The experimental procedure itself can be regarded as a sympathetic stimulus, and 
might lead to an increase in norepinephrine and/or epinephrine levels. One recent 
reports has suggested this possibility (32). It is however of importance to stress 
that at least two groups (3,33) have performed control studies and reported that 
the observed changes during insulin, were not found during placebo. In addition, 
in the present study arterial and venous epinephrine concentrations were 
completely stable during sham clamp experiments. We show in our study with the 
use of epinephrine tracer kinetics that insulin induces an increase in arterial 
plasma epinephrine concentration, and that this is due to increased epinephrine 
release, since epinephrine clearance did not change. This indicates that under 
these conditions, the change in arterial epinephrine concentration reflects only 
the change in epinephrine release. Hence, for control experiments, measurement 
of arterial epinephrine concentration is sufficient, and tracer kinetic studies not 
indicated. Based on these results, it seems unlikely that the present findings can 
be explained as a consequence of the experimental procedure itself. 
It is well known that hyperinsulinemia in combination with hypoglycemia is able 
to stimulate adrenomedullary epinephrine secretion. In our study hypoglycemia 
was carefully avoided. Moreover, fairly all subjects showed a small increase in 
arterial epinephrine concentrations whereas no extreme outlayers were observed, 
further arguing against this possible mechanism. Furthermore it has to be 
emphasized that in most studies on hypoglycemia, the hyperinsulinemic clamp 
procedure is used, and therefore, the increase in epinephrine concentration may 
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have been the result of both hypoglycemia as well as hyperinsulinemia. Indeed 
several studies have now identified increased epinephrine release in response to 
hypoglycemia during high insulin concentrations, as compared with low insulin 
concentrations (34-36). These findings support our conclusions. 
It is unlikely that the first LBNP procedure has influenced the responses of 
epinephrine kinetics to insulin. Firstly the LBNP procedure in itself did actually not 
induce an increase in epinephrine secretion. Secondly, all parameters were back to 
baseline before the insulin infusion was started (table 1). 
As mentioned above, it is now generally accepted that insulin acts as an activator 
of the sympathetic nervous system, at least in acute experiments. Therefore 
insulin infusion can be regarded as a sympathetic stimulus. In general, 
sympathetic stimuli may induce predominantly norepinephrine or epinephrine 
release depending on the type of stimulus, a concept known as differentiated 
sympathetic outflow. Furthermore, sympathetic efferent traffic may vary in 
different organ systems. Therefore, along this line of evidence and based on our 
results, it may be possible that hyperinsulinemia, even under euglycemic 
conditions, induces epinephrine secretion, in addition to norepinephrine release. 
Since hyperinsulinemia did not change epinephrine clearance, the increments in 
arterial plasma epinephrine levels are the consequence of an increased 
adrenomedullary release. This production of epinephrine may occur 
predominantly in the adrenal medullae, although we can not exclude extra-
adrenal production, as has been described previously (37). Activation of the 
adrenal medulla could be postulated to occur by central activation of 
preganglionic sympathetic nerve endings. One of the major determinants of 
sympathetic or adrenomedullary responses to insulin may be the direct vasodilator 
response of insulin itself. Several authors have shown that systemic 
hyperinsulinemia induces an increase in leg blood flow (38-44), as well as in 
forearm blood flow (2,45-47). 
The mechanism of insulin's vasodilator action is not completely understood. An 
interaction with the autonomic nervous system has been proposed; theoretically, 
both a decreased vascular sensitivity to α-adrenergic stimuli, or an augmented 
response to ß-adrenoceptor agonists, might explain insulin-induced vasodilation. 
Indeed, earlier reports seemed to point to a ß-adrenergic mediated vasodilation 
(30,31), which might fit with our findings. These results were not confirmed by 
others (41). More recent reports have indicated that insulin-induced vasodilator 
action seems to be nitric oxide (NO) related (48,49). Novel in vitro experiments 
seem to disagree with these findings, and suggest involvement of potassium 
channels (50). Furthermore, interactions between insulin and Na+-K*-ATPase might 
induce hyperpolarization and subsequent vasodilation (51,52,45). In summary, 
insulin in itself induces vasodilation, and the observed hormonal changes 
might be related to homeostatic responses to these hemodynamic changes. 
The increments in arterial plasma epinephrine concentration are small, and may 
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appear unlikely to produce direct significant hemodynamic effects. However 
plasma concentrations are not necessarily representative for the effects of 
epinephrine at the level of the vascular adrenoceptor site. Although it is possible 
that epinephrine facilitates neuronal norepinephrine release by presynaptic ß-
adrenergic stimulation, it is not known whether the changes in plasma 
epinephrine are sufficiently large for this effect. Others also have described 
interactions between insulin and the ß-adrenergic signal pathway (53,54). 
Effects of hyperinsulinemia on sympathetic responsiveness 
The epinephrine response to the sympathetic stimulus of LBNP, was affected by 
acute hyperinsulinemia; although baseline values just before the second test were 
higher, both absolute and relative changes were more pronounced. This 
augmented response of epinephrine release was also observed in the control 
experiments, but to a lesser extent. It may be possible that the insulin-induced 
vasodilation leads to a more pronounced reduction of venous return in response 
to LBNP, with subsequently a more intense sympatho-adrenal response. Although 
the two LBNP procedures may therefore differ, at least three arguments oppose 
to this possibility: 1. The vasoconstrictive responses (percent increases in FVR), we 
observed in this study were similar during both procedures, thus arguing against 
a more intense stimulus. 2. We have performed a similar study on norepinephrine 
kinetics in both diabetic patients and in healthy subjects, and found no 
differences in absolute or percentage changes of total-body and forearm 
norepinephrine spillover in response to LBNP alone or or in combination with 
hyperinsulinemia (5). 3. The abscence of blood pressure changes during either 
LBNP procedure argues against a more intense stimulus, because a decrease in 
blood pressure would be expected in response to a more intense stimulus, leading 
to a deactivation of the arterial baroreceptor [as for example during LBNP 
exceeding -20 mmHg] (55). 
In conclusion, we report that in healthy, non-obese, normotensive individuals, 
acute physiological euglycemic hyperinsulinemia induces epinephrine secretion 
and amplifies epinephrine responses to sympathetic stimuli. Due to increased 
forearm epinephrine removal however, venous concentrations hardly change. The 
epinephrine release could explain part of the hemodynamic effects of insulin. The 
role of epinephrine in the vascular actions of insulin warrants further research. 
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Chapter 6 
Effects of insulin on vascular tone and 
sympathetic nervous system in non-
insulin-dependent diabetes. 
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Abstract 
Chronic activation of the sympathetic nervous system may be a pathogenetic 
mechanism by which hyperinsulinemia induces cardiovascular damage in insulin-
resistant NIDDM patients. The influence of physiologic hyperinsulinemia 
(approximately 700 pmol-L') on basal and stimulated sympathetic outflow was 
studied in 12 lean normotensive subjects with well-controlled NIDDM without 
complications and in 13 matched control subjects. Forearm blood flow (FBF) was 
measured with forearm plethysmography; sympathetic nervous system activity was 
assessed by the [3H]norepinephrine (NE) tracer method. NIDDM patients were 
insulin resistant (glucose infusion rates 31.8±3.8 vs. 48.7±2.0 дтоікд^тіп' in 
control subjects, P<0.01). After a mixed meal, NIDDM patients showed a 
hyperinsulinemic response (2-h insulin levels: NIDDM patients 324±34 pmol-L', 
control subjects 165±19 pmol-L-1, P<0.001). Insulin infusion induced a vasodilator 
response (not significantly different between the groups). Arterial plasma NE 
levels and total-body NE spillover increased significantly (total spillover in NIDDM 
patients from 0.77±0.09 to 1.18±0.16 nmol-m^min1, in control subjects from 
0.98±0.14 to 1.23±0.18 nmolm^min', P<0.01 for all, not different between 
groups). Total-body NE clearance did not change. Sympathetic stimulation (lower-
body negative pressure [LBNP] 15 mmHg), induced forearm vasoconstriction and 
increased arterial and venous plasma NE and total NE spillover. Responses of FBF 
and NE kinetics to LBNP were not significantly different between groups and 
were not altered by hyperinsulinemia. Although these nonobese subjects with 
uncomplicated NIDDM showed postprandial hyperinsulinemia, and resistance to 
the effect of insulin on glucose metabolism, this group was not resistant to the 
vasodilator and sympathetic stimulant effects of insulin. Responses to sympathetic 
stimuli (LBNP) were normal and unaffected by physiological hyperinsulinemia. 
Therefore, because of daily life hyperinsulinemia, chronic sympathetic stimulation 
could be operative in these patients and may explain the increased incidence of 
hypertension and/or cardiovascular complications. 
Introduction 
As a consequence of insulin resistance, hyperinsulinemia has been related to 
disorders such as hypertension, obesity, dyslipidemia and NIDDM (1-3). 
Furthermore, hyperinsulinemia has been directly associated with atherosclerosis 
and cardiovascular events (4-6). The cause of this relationship between 
hyperinsulinemia and cardiovascular morbidity is not clear, but it may be 
mediated by some cardiovascular effect of insulin. Besides insulin's key role in the 
regulation of carbohydrate metabolism (7), it has become clear that it also has 
important effects on the cardiovascular system (8,9). In acute experiments in 
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humans, insulin infusion exerts a vasodilatory effect (10,11). In addition, acute 
hyperinsulinemia induces systemic sympathetic activation as measured by direct 
muscle sympathetic nerve activity (MSNA) recordings (11,12). Together, insulin-
induced vasodilation and sympathetic stimulation will induce a state of 
hyperdynamic circulation, characterized by a high heart rate, wide pulse pressure, 
and increased cardiac output. Recent epidemiological studies, indeed found a 
relationship between a hyperdynamic circulation and insulin resistance (13,14). 
Continuous sympathetic stimulation has been related to increased cardiovascular 
morbidity (15). Chronic stimulation of the sympathetic nervous system due to 
chronic hyperinsulinemia could therefore be an important factor explaining the 
well-known increased incidence of cardiovascular disease that can be observed in 
NIDDM patient (16). Therefore it seems a valid question whether individuals with 
chronic hyperinsulinemia, which holds true for the initial phase of NIDDM, are 
exposed to normal insulin-induced sympathetic stimulation. In patients with long­
standing established NIDDM, resistance to the vasodilatory effects of insulin has 
been reported (17,18). Data on the early phase of NIDDM are lacking, while 
endogenous hyperinsulinemia is most prominent at this early stage (19,20). 
Moreover, the ability of insulin to stimulate sympathetic neural outflow in NIDDM 
has not been examined before. 
In the present study, we hypothesized that NIDDM patients in the early phase of 
their disease are still sensitive to the sympathetic stimulant effects of insulin. To 
address our hypothesis, sympathetic nervous activity was investigated at baseline 
and during stimulation, both before and during acute hyperinsulinemia, in 
patients with an early mild uncomplicated NIDDM and well-matched healthy 
control subjects. To quantify the response of the sympathetic nervous system in 
detail, the [3H]norepinephrine (NE) tracer technique was used (21). 
Methods 
Subjects 
The study group consisted of 13 patients with NIDDM. All met the inclusion 
criteria: age between 25 and 60 years, nonsmoking, absence of hypertension 
(office blood pressure <160/90 mmHg, measured after 5-min rest in the supine 
position), absence of macrovascular and microvascular complications, as assessed 
by physical examination (normal tendon reflexes and normal vibration sense), 
normal ophthalmoscopic examination, normal renal function and normal albumin 
excretion rate (<20 дд/тіп), body mass index <27 kgm 2 , and good metabolic 
control (HbAic<7.5%) with diet alone or low doses of the first-generation 
sulfonylurea derivative tolbutamide (<1000 mg/day). Participants used no other 
medication. Patients were recruited from our outpatient department (of 
approximately 700 NIDDM patients, 11 met the inclusion criteria, of whome 6 
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participated) and through calls for patients treated by general practitioners 
(approximately 50 candidates of whome 7 were included). Of the 13 patients, 10 
had a family history positive for diabetes. One of these, who had NIDDM 
diagnosed before the age of 25 year, could be classified as having maturity-onset 
diabetes of the young and was excluded from further analysis because the 
etiology of this disease is different (22). Mean diabetes duration was 4.5 ± 6.0 
years (mean ± SD). 
A control group consisted of 13 healthy, lean, normotensive , and nonsmoking 
(meeting the above mentioned criteria) age-, and sex-matched subjects. These 
participants were selected by advertisement and received a payment. All these 
subjects had normal glucose tolerance, and a family history negative for diabetes 
and hypertension. All participants gave written informed consent. The 
experimental protocol was approved by the hospital ethics committee. 
Experimental procedures and protocol 
Before the experiment all participants underwent a mixed-meal test. After an 
overnight fast, they ingested a liquid meal containing 25 g proteins, 18 g lipids 
and 72 g carbohydrates, partly disaccharides, including gelatin and fibres (total 
energy content 548 calories).Before and after 30, 60, 120 and 180 min, blood 
samples were taken for plasma insulin and glucose determinations. 
Within 7 days after the mixed-meal test, the main experiment was performed 
after an overnight fast with the subjects in supine position in a quiet 
temperature-controlled room (25-260C). Under local anesthesia (0.3-0.4 mL 
lidocaine HCl 20 mg-mL'), a 20-gauge catheter (Angiocath, Becton Dickinson, 
Sandy, Utah) was inserted into the left brachial artery and connected with an 
arterial pressure monitoring line (Viggo Spectramed, 5269-129) to a Hewlett 
Packard 78353B Monitor. In the same arm, a catheter (Venflon, 20 gauge, 32 mm) 
was inserted into a deep forearm vein to obtain venous blood samples. On the 
contralateral side an identical catheter was inserted into a large forearm vein for 
the infusion of [3H]NE, insulin and 20% glucose. After complete instrumentation, 
at least 30 min of rest were included. 
Previously prepared aliquots of [3H]NE were thawed and diluted with 0.9% saline 
to an activity of 4 μΟιπβ-ιηΙ. '. The weight of the syringe containing the 
radiotracer was measured just before and just after the infusion to verify the 
infusion rate. At the end of the experiment, a portion of the radiotracer was 
frozen and stored at -80е С for analysis at the time the plasma determination was 
performed. After a priming dose of 15 μΟ·πι2, a continuous infusion of 0.35 
μΰ·ιτί2·ιτΗη ' [3H]NE was given during the entire experiment. Again, 30 min were 
allowed to obtain a steady state, after which baseline hemodynamic and humoral 
measurements were performed. Then, lower-body negative pressure (LBNP) at -15 
mmHg, using a Perspex box, was applied for 15 min to stimulate the sympathetic 
nervous system (23). Subsequently, 30 min were again taken to allow all 
INSUUN-INDUCCD VASODILATION AND SYMPATHETIC STIMULATION IN NIDDM 103 
parameters to return towards baseline level. The hyperinsullnemic euglycemic 
clamp was then started en continued for 90 min. During insulin infusion, 
hemodynamic data were obtained at 20-min intervals and NE kinetic 
measurements were obtained at 45 and 90 min. Plasma insulin concentrations 
were measured after 60 and 90 min. Finally, with the continuation of insulin and 
glucose infusion, a second application of LBNP at -15 mmHg was performed for 15 
min. A schedule of the study protocol is shown in Fig. 1. 
Time Schedule 
FBF / • / / / / / / 
Blood sample * * » « * * 
Time 0 30 45 75 165 180 min 
l i l i I I I I I 
Insulin 60 mil.m'.min1 
1 U 
LBNP 
3H-Norcplnephrlne ^-Norepinephrine | 
Fig.1. Time schedule of the experiments performed. 
Forearm blood flow (FBF) was measured using mercury-in-silastic strain-gauge 
venous occlusion plethysmography as previously described (24). One minute 
before the start of the measurements, a wrist cuff was inflated to 100 mmHg 
above systolic blood pressure. The collecting cuff around the upper arm was 
inflated to a pressure of 40 mmHg during eight heart cycles using a Hokanson E20 
rapid cuff inflator. The strain gauges were connected with the Hokanson EC4 
Plethysmographs. 
Insulin (Actrapid, Novo-Nordisk, Bagsvaerd, Denmark; 430 pmolnv2min ' [60 
mUm2min ']), was diluted in 50 mL 0.9% NaCI with the addition of 2 mL of the 
patient's plasma to a concentration of 1 U-mL·1. Plasma glucose levels were kept at 
euglycemic levels by a variable infusion of 20% glucose solution, adjusted by 
arterial plasma glucose levels measured at 5-min intervals (25). During the last 30 
min of the clamp, the glucose infusion rate was calculated in micromoles per 
kilogram per minute to obtain the whole-body glucose uptake, a measure of 
insulin sensitivity (26). Healthy subjects were clamped at the fasting level; in 
diabetic patients, blood glucose was allowed to fall to a level of 5 mmol-L' and 
kept there. In 3 patients, in whome no steady-state plasma glucose concentration 
was reached after 60 min, the clamp was continued until 30 min of steady-state 
and lasted for a maximum of 120 min. 
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All studies were performed off medication. Of the diabetic patients, five used 
(low-dose) tolbutamide. This medication was stopped 7 days before the meal test, 
and at least 10 days before the experiment. The chance that gross hyperglycemia 
would develop was therefore minimal. 
Analytical methods 
Plasma glucose was measured in duplicate by the glucose oxidation method 
(Beekman Glucose Analyzer 2, Beekman, Fullerton, CA). Plasma insulin was 
measured with a double-antibody radioimmunoassay (interassay coefficient of 
variation [CV] 6.2%). It may be expected that this conventional insulin assay cross-
reacts with proinsulin and proinsulin-insulin split products (27). Therefore, the 
insulin samples before and after 120 minutes of the mixed meal test were 
reanalyzed using the commercially available immunoradinetric insulin assay from 
Medgenix (Fleurus, Belgium). This assay shows no cross-reactivity with proinsulin 
or des 31,32 proinsulin (being the most important insulin split product). Plasma C-
peptide was measured with a commercially available double-antibody 
radioimmunoassay (Diagnostic, Los Angelos) (interassay CV 4.3%). HbAu was 
measured using a high-performance liquid chromatography (HPLC) technique 
(Bio-Rad, The Netherlands) with reference values of 4.8-6.2 %. 
Tritiated norepinephrine (levo-[ring-2,5,6-3H]norepinephrine; specific activity 30-60 
Ci-mmol') was obtained from Du Pont-NEN ('s Hertogenbosch, The Netherlands). 
It was sterilized using a micropore filter (0.22 μιτι) and diluted in 0.9% NaCI 
containing glacial acetic acid (0.2 mol-L') and ascorbic acid (1 mg-mL'). Aliquots 
of approximately 70 μϋ-Γηί' [3H]NE were stored at -80eC until use, which was 
always within 3 months of preparation. Sterilization, dilution, and batch dividing 
were carried out under nitrogen. 
Blood samples for measurement of plasma catecholamines were collected in 
prechilled tubes containing glutathione (0.2 mol-L·') and EGTA (0.25 mol-L·') on 
melting ice. The tubes were centrifuged at 4°C, and plasma was stored at -80° C; 
analyses of plasma samples and infúsate occurred within 2 months of collection. 
Plasma samples were analyzed for concentrations of unlabelled and tritium-
labelled NE by HPLC with fluorometric detection after precolumn derivatization 
with the selective detection agent 1,2-diphenylethylenediamine. The laboratory 
procedure is a modification of an earlier described method (28). 
The instrumentation for the chromatography consisted of a model 610 pump, a 
model 600E system controller, a model 470 scanning fluorescence detector (16 μΐ 
flow cell) and an automated sample processor WISP 710B (all from Waters, 
Millfort, MA). The separations were performed on a silica analytical Nova-Pak Ga 
(150x3.9 mm) column coupled to a Nova-Рак Cíe guard column. The [3H]NE activity 
was measured in the eluate collected for one minute by a Gilson fraction collector 
(model 201-202) connected to the WISP 710B, and programmed to start at the 
begin of the NE peak position in the chromatogram of the standard solution, 
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which was run before the plasma samples and [3H]NE infúsate in each assay. The 
[3H]NE activity of all 1-mL fractionated samples with 8 mL scintillation solution 
(Aqualuma) added was counted for 20 minutes in a Packard Tri-Carb 460 С 
Calculations and data analysis 
The following kinetic variables were calculated according to these formulas (21): 
Infusion rate (dpm-m'min') 
Total clearance (Lm'min')= 
PH]NE (dpm-L') 
Total NE spillover (nmolm2min1)= Total clearance (Lm'-min')χ [NE]«* (nrnohL') 
Forearm Plasma Flow (FPF, mLdLFAV 'min ')= (1-Hematocrit) χ FBF 
PHJNE.« - [3H]NE™ 
Fractional extraction (FE)= 
PHJNE* 
Forearm spillover (pmoldLFAV 'min')= FPF χ ( INE]«« - [NEU + FE χ [NEJart) 
Forearm removal (FRM, pmoldLFAV 'min')= FPF χ FE χ [NE] « 
Forearm Vascular Resistance (FVR) was calculated by dividing mean arterial 
pressure by FBF and expressed in arbitrary units (AU). Pulse pressure was 
calculated by subtracting diastolic from systolic blood pressure. 
Since some parameters of NE kinetics showed a non-Gaussian distribution, 
statistical analysis of these data was performed using a nonparametric paired 
analysis (Wilcoxon). The Mann-Whitney U test was used to compare the NE kinetic 
responses of diabetic patients with those of healthy individuals. Effects of insulin 
on hemodynamic parameters were calculated using repeated-measures analysis of 
variance (ANOVA) with insulin as the independent factor. All other (mainly 
metabolic) data met requirements of normality and were statistically analyzed 
with the Student's ttest. Correlations were calculated using Spearman's rank 
correlation tests. All statistical analyses were performed using the SPSS personal 
computer software package. 
Results in tables and figures are expressed as mean ± SEM, unless otherwise 
indicated. Statistical significance was set at P<0.05. 
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Table 1. Baseline characteristics of the two groups (meanstSD) 
Diabetes «.» Normal »» p-value 
Female:male 
Age (years) 
Quetelet Index (kgmJ) 
Systolic BP (mmHg) 
Diastolic BP (mmHg) 
Basal Flow (ml-dl'min') 
FVR (arbitary units) 
Fasting glucose (mmol·!1) 
HemoglobinAic (%) 
Glucose Infusion Rate, 
60-90 minutes (jumolkg 'min ') 
Results 
Baseline measurements 
Baseline characteristics of the two groups are given in Table 1. Baseline 
hemodynamic variables were not different between NIDDM patients and control 
subjects. NIDDM patients had higher fasting glucose levels and Hb Au values than 
control subjects. The fasting insulin concentration was higher in NIDDM patients 
(106±17 vs. 63±6 pmol-L' in control subjects, P=0.02), as was fasting plasma C-
peptide level (0.59±0.07 vs. 0.40±0.02 nmol.L' in control subjects, P<0.02). 
Baseline NE kinetic parameters (arterial and venous plasma concentration, total-
body and forearm spillover, total-body clearance, and forearm removal) were not 
different between NIDDM patients and control subjects (Table 2). 
Responses to a mixed meal 
In control subjects, the standardized mixed meal induced a slight increase in 
plasma glucose values, from 5.0±0.1 to maximal 6.0±0.2 mmol-L'. NIDDM patients 
showed a more pronounced and prolonged increase of glucose levels, from 
8.8±0.6 to maximal 13.4±1.2 after 60 min and to 9.4±1.1 mmol-L' after 180 min. 
The insulin response to a mixed meal was delayed in NIDDM patients, and on 
every time point it was larger than in control subjects (Fig. 2, lines). When 
expressed as area under the insulin curve, the responses in NIDDM patients were 
significantly increased compared with those in control subjects (58.0±7.3 vs. 
37.0±3.7 nmol-L'-min, P<0.02). Also when measured with a more specific insulin 
assay, NIDDM patients had higher insulin levels than control subjects (baseline: 
80±15 [NIDDM] vs. 51±5 pmol-L' [control], P=0.08; 120 min: 269±33 [NIDDM] vs. 
133±19 pmol-L' [control], />=0.001) (Fig. 2, bars). 
5:7 
46.5 ±11.8 
24.2 ± 2.5 
130 ± 19 
67 ± 10 
2.80 ± 0.88 
35.7 ± 12.1 
8.8 ± 2.0 
6.8 ± 0.8 
5:8 
45.7 ± 6.0 
24.2 ± 1.7 
122.8 ±10.7 
65 ±7 
2.99 ±1.25 
35.2 ± 17.6 
5.0 ± 0.4 
5.5 ±0.5 
NS 
NS 
NS 
NS 
NS 
NS 
<0.001 
<0.001 
31.8 ±13.2 48.7 ±6.9 <0.001 
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Insulin after Mixed Meal Test (rnU.L ) "true" insulin (mU.L ) 
0 30 Θ0 90 120 150 180 0 120 
minutes minutes 
Fig. 2. Response of plasma insulin concentrations during 180 min after a mixed meal as 
measured with the use of a conventional insulin assay (lines) and with a specific 
insulin assay (bars). * P<0.005. 
Metabolic response to euglycemic clamp 
Blood glucose values during the last 30 min of the clamp were stable in all 
individuals (mean glucose concentration 4.9±0.1 [NIDDM] vs. 4.9±0.1 mmol-L' 
[control]; CV 4.8±0.5 [NIDDM] and 4.3±0.5 % [control]). After 60 min plasma 
insulin concentration was 746±65 pmol-L' in NIDDM patients and 645±36 pmol-L·' 
in control subjects (P=0.18). After 90 min, it was 810±50 pmol-L·' in NIDDM 
patients and 645±50 pmol-L' in control subjects (P<0.05). Whole-body glucose 
uptake was significantly different between NIDDM patients and control subjects 
(31.8±3.8 vs. 48.7±2.0 pmol-kg-'-mirr', /Ч0.01). 
Effects of insulin on hemodynamic parameters 
As indicated in Fig. 3, 90 min of hyperinsulinemia induced a forearm vasodilation 
(FBF: 2.75±0.23 to 3.90±0.40 mL-min 'dL·' [NIDDM] vs. 2.98±0.36 to 3.82±0.56 
mL-min'dL ' [control], both /><0.05 by ANOVA), accompanied by a clear decrease 
of peripheral resistance (FVR: 36.9±3.1 to 26.9±3.2 [NIDDM] vs. 35.1±4.6 to 
27.2±3.1 AU [control], both P<0.01). Systolic blood pressure did not change 
significantly and diastolic blood pressure decreased significantly in control 
subjects (from 66.3±2.0 to 65.1±2.1 mmHg, P<0.01), but not in NIDDM patients 
(from 68.6±2.4 to 66.7±3.0 mmHg, P=0.09). Pulse pressure increased in both 
groups (64.6±2.9 to бб.б±2.9 [NIDDM] vs. 58.1±1.9 to 63.1±1.8 mmHg [control], 
both P<0.05). Heart rate tended to increase significantly only in NIDDM patients 
(63.3±1.8 to 69.0±2.3 bpm, /><0.01) and not in control subjects (60.7±2.4 to 
61.5±2.5 bpm, P=0.14). Responses of heart rate, pulse pressure and FVR to the 
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hyperinsulinemic clamp are depicted in Fig. 3. 
There were no significant differences of hemodynamic parameters between 
NIDDM patients and control subjects at different time points; nor were there 
significant differences in hemodynamic responses to insulin. 
Heart rate (bpm) 
ее· 
во-
I—I 
Ϊ — Ϊ 
Pulse pressure (mmHg) 
02 
вО-
N P 
NIDDM 
'Π 
insulin 60 mU m mm 
Fig. 3. Time course of PVR, pulse pressure, and heart frequency during the entire 
experiment. *P<0.05 compared with baseline 1, t P<0.05 during insulin 
(ANOVA), H P<0.05 compared with end of insulin infusion. 
Effect of insulin on NE kinetics 
Absolute NE kinetic data for the entire experiment are given in Table 2. During 
insulin infusion, arterial and venous NE concentrations increased (percentage 
increases after 45 and 90 min: arterial NE in NIDDM patients 62.8±14.0% and 
49.8±10.4%, in control subjects 41.3±9.1% and 33.5±6.1%, P<0.01 vs. baseline for 
all; venous NE in NIDDM patients 17.0±4.8% and 22.4±6.7%, in control subjects 
26.8±8.3%, all P<0.01, and 21.3±7.7%, P<0.05 vs. baseline). 
Calculated total-body NE spillover increased (percentage changes after 90 min: 
51.8±9.4% [NIDDM] vs. 26.5±7.0% [control], P<0.01 for both). Total-body NE 
clearance did not change during hyperinsulinemia (percentage changes after 90 
minutes: 3.7±6.5% [NIDDM], P=0.51 vs. -5.1 ±5.5% [control], N5 for both). 
Forearm NE spillover increased (percentage changes after 90 min: 47.9±21.2% 
[NIDDM], P<0.05 vs. 32.4±18.0 [control] P=0.06), as did forearm NE removal 
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Arterial norepinephrine (nmol L ) 
ο β ο
Μ J_* 
:::fi Ü fi 
η nn — ^ И — I ^ И — ' ^ Н — I — 
Total body NE spillover (nmol m!mm') 
* * 
OSO 
0 25 
0 00 _fc ÈS J^ 
Total body NE clearance (ml m min') 
OSO 
0 25 
0 00 1 U 
LBNP Insulin LBNP 
during 
Insulin 
Fig. 4. Absolute changes of arterial NE, total-body NE spillover, and total-body NE 
clearance during LBNP, insulin alone and application of LBNP during insulin. • , 
NIDDM patients; • , control subjects. * P<0.05 for LBNP compared with baseline 1, 
for insulin alone with baseline 2 and for the combination with the end of the 
insulin infusion (Table 2). 
Venous norepinephrine (nmol L ) 
0 60 
* * 
0 60 
0 40 
0 20 
0 00 
Forearm NE spillover (pmol dL1 mm ) 
1 00 
0 50 
0 00 J±- jtb. 
Forearm NE removal (pmol dL' mm) 
0 75 
0 50 • 
0 25 
0 00 h^ 
LBNP 
Й 
Insulin 
JL 
il a il 
A 
V 
LBNP 
during 
Insulin 
Fig. 5. Absolute changes of venous NE, forearm NE spillover, and forearm NE removal 
during LBNP, insulin alone and application of LBNP during insulin. •, NIDDM 
patients; •, control subjects. * P<0.05 for LBNP compared with baseline 1, for 
insulin alone with baseline 2 and for the combination with the end of the insulin 
infusion (Table 2). 
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(percentage changes after 90 min: 117.1±35.8% [NIDDM] vs. 57.9±25.0% [control], 
/><0.01 for both). 
The quantitative responses to insulin were not significantly different between 
NIDDM patients and control subjects (Figs. 4 and 5). 
Effect of LBNP 
LBNP induced vasoconstriction (FVR: 36.9±4.5 to 48.7±8.5 AU [NIDDM] vs. 34.7±4.0 
to 46.0±6.5 AU [control], P<0.05 for both) without affecting blood pressure and 
heart rate (Fig. 3). Responses of NE kinetics to LBNP are denoted in Table 2. 
Arterial and venous NE as well as total-body NE spillover increased significantly, 
and forearm NE spillover remained unchanged (Figs. 4 and 5). Responses in 
NIDDM patients were not different from those in control subjects. After this first 
LBNP, all parameters returned to baseline values, as can also be seen in Table 2. 
Effect of hyperinsulinemia on LBNP responses 
Three NIDDM patients developed presyncopal symptômes of dizzyness and nausea 
during the second LBNP, which was then interrupted. Hypoglycemia was excluded. 
Blood samples of these subjects taken just before the interruption were not used 
in the analysis. If they were used, however, the conclusions would be the same. 
In addition, during hyperinsulinemia, LBNP induced vasoconstriction (FVR in 
NIDDM patients [n=9] 24.1±3.0 to 34.0±6.1 AU and in control subjects 27.2±3.0 to 
45.7±9.5 AU, P<0.05 for both), without changes in blood pressure and heart rate 
(Fig. 3). Arterial and venous NE increased (Table 2 and Figs. 4 and 5), and total-
body NE spillover tended to increase, but not significantly. Baseline levels at the 
start of this LBNP were higher (previous insulin effect), but absolute responses to 
LBNP on both occasions were not different. Here again, the two study groups 
responded similarly. 
Control experiments 
In four young healthy volunteers (aged 23.8±0.3 years, BMI 20.8±0.5 kg-m2), 
control experiments were performed. These individuals were studied with an 
intra-arterial line, but did not undergo any intervention and did not receive any 
infusion. At the respective time periods, blood samples were taken and blood 
flow and blood pressure were measured. During the 3-h experiment, blood flow, 
vascular resistance and arterial and venous plasma NE concentrations remained at 
a fairly constant level (baseline 1 to LBNP 1: FVR 48.2±7.3 to 47.6±8.1, arterial NE 
from 0.82±0.09 to 0.73±0.13 nmolL1; baseline 2 to insulin 90 min: FVR 51.4±7.1 to 
61.7±4.9 AU, arterial NE from 0.77±0.14 to 0.91±0.13 nmolL1; insulin 90 minutes 
to LBNP 2: FVR 71.7±4.9 to 56.3±3.5 AU, arterial NE from 0.91±0.13 to 0.94±0.15 
nmolL')· 
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Discussion 
The major new finding of the present study is that patients who are in the early 
phase of NIDDM show preserved vasodilator and sympathetic responses to 
physiological hyperinsulinemia. Moreover, on top of this preserved cardiovascular 
response to insulin, these NIDDM patients exhibit normal cardiovascular 
responsiveness to an exogenous sympathetic stimulus, this being in our study the 
application of LBNP. In contrast, this group was resistant to the effect of insulin 
on glucose metabolism and hyperinsulinemic after a regular meal. These 
observations imply that NIDDM patients at this early stage of their disease might 
be exposed to insulin-induced vasodilation and sympathetic stimulation because 
of their hyperinsulinemia throughout the day. We speculate that the combination 
of increased skeletal muscle blood flow and increments in heart rate and pulse 
pressure, reflecting a hyperdynamic state, could be important in the development 
of hypertension and/or cardiovascular complications later in the course of the 
disease. 
Metabolic effects of insulin 
Most NIDDM patients pass through prediabetic and early diabetic stages (20), 
characterized by high fasting and postprandial insulin levels (19,29) with 
concomitant existence of insulin resistance (30). In this study, we tried to select a 
group with very early NIDDM, making it as homogeneous as possible by using 
strict selection criteria. This patient group is exceptional from a clinical point of 
view; in most patients, the diabetic state is more advanced and patients are obese 
and have complications or comorbidity. Our nonobese NIDDM subjects were 
indeed insulin resistant, as has been reported before (31). Insulin sensitivity was 
assessed before the second LBNP and a sufficient time after the first LBNP to 
allow all parameters to return to baseline; hence, the determination of insulin 
sensitivity could not be influenced by these sympathetic stimulatory procedures. 
In NIDDM, proinsulin and proinsulin-split products have been found to be 
elevated (32,33), and may explain part of the measured hyperinsulinemia (27,34). 
However, using a specific insulin assay, we were still able to demonstrate that our 
NIDDM group showed true hyperinsulinemia, as were others (19). 
Vasodilator response to insulin 
Since 1990, a number of groups have demonstrated the vasodilatory effect of 
systemic hyperinsulinemia (10,11,35). In NIDDM patients, Laakso et al (17) have 
reported a decrease in insulin-induced vasodilation, partly reversible by improving 
metabolic control with insulin therapy (18). The reported studies, however, 
concern individuals with longstanding established diabetes who are in poor 
metabolic control and are considerably obese. This may be an important 
drawback because, as mentioned above, in NIDDM, endogenous hyperinsulinemia 
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can be found especially in the early phase of the disease. Furthermore insulin-
induced vasodilation is attenuated in obesity itself (10,36). Recently it has also 
been reported that insulin-induced vasodilation was preserved in NIDDM subjects 
(37), findings that are thus compatible with our results. 
Sympathetic stimulant effects of insulin 
The relationship between insulin and the sympathetic nervous system has been 
studied using variable techniques. Some studies have reported an increase in 
venous plasma NE concentrations during insulin infusion (8,9,11), with the earliest 
report being from Gundersen and Christensen (38). The venous NE concentration, 
however, results from total NE production and clearance on the one hand, local 
production and removal on the other hand, and blood flow. By measuring not 
only venous but also arterial blood samples and by using tracer NE infusion (21), a 
far more detailed estimate of sympathetic neural activity is possible. It is, 
however, important to realize that the [3H]NE kinetic tracer technique represents 
only the rate by which NE is entering the plasma compartment, which is not 
necessarily the same as the rate of NE release from sympathetic nerve endings. 
With the use of microneurographic readings (MSNA), the insulin-induced increase 
in sympathetic nervous system activity has been quite consistently reported 
(11,12,36,39). The MSNA technique has drawbacks as well as advantages. It is 
technically demanding and is unsuccessful! in a proportion of cases. Moreover, 
neural outflow at only one location is measured, which does not necessarily 
reflect total sympathetic activity. Until now, data on sympathetic responses in 
NIDDM patients have been sparse. As we show in our study, 90 min of 
physiological hyperinsulinemia induced an increase of total-body NE spillover. 
Since this spillover is an index of sympathoneural activity, our data indicate that 
hyperinsulinemia induces sympathoneural stimulation. This sympathetic 
stimulation was of a moderate degree, around the same magnitude as stimulation 
induced by LBNP of -15 mmHg. The insulin-induced sympathetic stimulation was 
clearly similar in both experimental groups. 
Insulin concentrations during the clamp were, nevertheless, slightly higher in the 
NIDDM group, which is probably caused by a diminished insulin clearance, a 
feature coupled with insulin resistance (26,41,42). The difference in insulin level 
between the groups was small, however; furthermore, not only concentration but 
also duration of hyperinsulinemia seems to be important with respect to 
sympathetic stimulation (11). Finally, the relationship between insulin 
concentration and sympathetic stimulation is not linear; Vollenweider et al. (36) 
found comparable increases in sympathetic nerve activity (MSNA) despite 
threefold differences in insulin concentrations. Probably sympathetic stimulation 
is already maximal at low insulin doses. Therefore, it is highly unlikely that 
sympathetic responses in diabetic subjects would have been less if insulin 
concentrations would have been more similar. 
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Response to sympathetic stimuli 
The diabetic subjects in our study had normal responses to the non-insulin-
sympathetic stimulus LBNP, despite higher prevailing glucose levels (fasting state, 
diabetes vs. control). Also, insulin-resistant obese subjects have been reported to 
be normally responsive to sympathetic stimuli (Valsalva maneuvre, cold pressor 
test, and barorecepter activation and deactivation) (36,40), as have IDDM subjects 
(cold pressor test) (39). Recent work showed an increased response to 
hypoglycemia (to be considered as an intense sympathetic stimulation) in NIDDM 
(43). Thus, there is considerable evidence that nonobese NIDDM patients have at 
least normal responses to sympathetic stimuli. 
The response to the sympathetic stimulus LBNP was not affected by acute 
hyperinsulinemia; baseline values just before the second test were indeed higher, 
but absolute changes were similar. These findings are in complete agreement with 
the aforementioned studies of Vollenweider et al. (36), Grassi et al. (40), and 
Hoffman et al. (39). 
Mechanisms of sympathetic activation 
While we confirm the vasodilatory and sympathetic stimulant effects of insulin, 
we are not able to explain the mechanism of these effects. It has been 
demonstrated previously that activation of the sympathetic nervous system is due 
to hyperinsulinemia and not to glucose infusion (44,45). Hypoglycemic episodes 
were avoided, so sympathetic activation cannot be due to glycopenia. The 
observed sympathetic activation could be based on a baroreceptor reflex to a 
slight insulin-induced decline of blood pressure. This concept, in which 
vasodilation and sympathetic stimulation are coupled, is supported by the fact 
that in autonomous failure, insulin induces hypotension (46,47). From our data, it 
seems, however, that most of the sympathetic stimulation had already been 
established after 45 min of insulin infusion, suggesting that the activation of the 
sympathetic nervous system is merely a predecessor than a consequence of the 
insulin-induced vasodilation. 
Pathophysiological implications 
Since endogenous hyperinsulinemia is indeed present in the fasting as well as in 
the postprandial state in our patients, we hypothesize that daily life 
hyperinsulinemia could induce a chronic stimulation of the sympathetic nervous 
system. An increased sympathetic drive has been related to an increase in 
cardiovascular disease (15) and might in particular be relevant to the 
development of hypertension. 
Endogenous insulin levels are indeed linked to cardiovascular risk in NIDDM 
subjects (48). On might speculate that as the disease proceeds, the chronic 
endogenous hyperinsulinemia could lead to an adaptive mechanism in which 
vascular and neurogenic responses are blunted. In support of this hypothesis are 
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recent epidemiological studies (13,14) in which a hyperdynamic circulation was 
predictive for the development of NIDDM (13). Also, in essential hypertension, an 
established state of insulin resistance and concomitant hyperinsulinemia (1), it is 
presumed that the initial hyperdynamic (hyperkinetic) circulation (15,49) evolves 
into established hypertension with increased peripheral resistance (50). With the 
use of [3H]NE kinetic tracer technique, an increased sympathetic activation in 
response to insulin in hypertensive compared with normal subjects has been 
reported (51), which may indicate that this group is at least not resistant to the 
sympathoexcitory effect of insulin. 
However, we are not able to actually show this postulated increased sympathetic 
activity in our patients; nor can it be proved that hypertension eventually will 
develop. The alternative interpretation could be that insulin-stimulated 
sympathetic neural activity is not involved in the pathogenesis of hypertension in 
NIDDM. 
In conclusion, we report that nonobese patients in the early phase of NIDDM, 
who are hyperinsulinemic and resistant to the metabolic effect of insulin, are 
normally responsive to the effects of insulin on vascular tone and sympathetic 
activity. Furthermore, the sympathetic nervous system is normally responsive to 
stimuli. This means that during daily life an excessive sympathetic neural outflow 
could exist. This fact could be an explanation for the increased incidence of 
hypertension and/or cardiovascular disease in this group and contribute to a 
hyperdynamic circulation, probably inducing secondary changes in time. 
Hyperinsulinemia did not change the absolute responses to sympathetic 
stimulation. The cardiovascular effects of insulin warrant further investigation. 
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Abstract 
Familial combined hyperlipidemia (FCH) is a heterogeneous lipid disorder, caused 
by overproduction of very low density lipoproteins and characterized by the 
occurrence of small dense low density protein (LDL) particles, all features that are 
also associated with insulin resistance. Therefore, insulin sensitivity was examined 
directly by means of the euglycemic hyperinsulinemic clamp technique in male 
nonobese, normotensive FCH patients and compared with that of their 
nonaffected relatives, matched for age and body mass index (BMI). In addition, an 
oral 75 gram glucose tolerance test (OGTT) was performed and lipid values, 
including the LDL subfraction profile, were determined. During the clamp, 
forearm blood flow (FBF) was measured by venous occlusion plethysmography. All 
participants had a normal glucose response after the glucose load, whereas FCH 
patients showed hyperinsulinemia after OGTT and higher fasting C-peptide levels. 
During the clamp insulin concentrations increased equally in both groups. Mean 
whole-body glucose uptake (M) (120-180 minutes) was lower in FCH patients 
compared with the nonaffected relatives (6.89±0.31 vs. 8.94±0.76 nig-kg'-min', 
P=0.01). Also the glucose uptake per unit insulin (I) was lower in FCH patients (M/l 
7.46±0.50 vs. 9.51±0.53; P=0.009). Whole-body glucose uptake significantly 
correlated with BMI, plasma cholesterol and triglyceride concentrations and the 
individual LDL density. The FBF correlated with insulin sensitivity and increased 
significantly in non-affected relatives (1.9±0.12 to 2.5±0.4 mldL'min 1 , P=0.025), 
but not in patients. Thus, FCH patients characterized by a predominance of small 
dense LDL are insulin resistant as compared with their non-affected relatives. This 
insulin resistance may partly be explained by a decreased insulin-induced 
vasodilation in skeletal muscle. Disturbances in the insulin action may contribute 
to the pathogenesis of FCH. 
Introduction 
Familial combined hyperlipidemia (FCH) is a common heritable and heterogeneous 
lipid disorder, characterized by the presence of a multiple type hyperlipidemia 
with elevated plasma cholesterol and/or plasma triglyceride levels, and the 
frequent occurrence of premature cardiovascular disease in first-degree relatives 
(1-3). Originally, FCH was supposed to be caused by the variable expression of a 
single autosomal dominant gene primarily regulating plasma triglyceride levels 
and secondarily affecting cholesterol levels (1). However, several metabolic and 
biochemical defects that have recently been related to the trait suggest that the 
genetic basis of FCH is more heterogeneous. As a consequence, the spectrum of 
FCH also comprises other related phenotypes such as hyperapobeta-
lipoproteinemia (4), the low density lipoprotein (LDL) subclass pattern В 
phenotype (5), familial dyslipidemic hypertension (6) and some features of the 
insulin resistance syndrome (7-9). 
INSULIN RESISTANCC IN FCH 
Insulin resistance, defined as a decreased ability of insulin to stimulate glucose 
uptake, is increasingly recognized as a common factor underlying various 
conditions, all of which predispose to coronary heart disease (10). Resistance to 
normal action of insulin is related to alterations in lipid metabolism such as an 
excessive postprandial release of non esterified fatty acids (NEFA), due to 
impaired suppression of hormone sensitive lipase activity (11). An increased supply 
of fatty acids to liver cells is associated with very low density lipoproteins (VLDL) 
overproduction (12,13). In addition, insulin resistance may coincide with a 
predominance of small dense LDL particles (6,14,15), although countered by 
others (16). Since these features (i.e., VLDL overproduction, impaired lipoprotein 
lipase activity and a predominance of small dense LDL), are also characteristics of 
FCH, the existence of insulin resistance may be an important factor modulating 
FCH phenotypes. The interpretation of data concerning the association between 
insulin sensitivity and lipid disturbances is, however, hampered by the fact that 
several features related to lipid disorders, as visceral obesity, age, gender, 
hypertension and existence of cardiovascular disease themselves also are 
associated with insulin resistance. Furthermore, hyperinsulinemia, as a 
consequence of insulin resistance, has been directly associated with cardiovascular 
disease (17). 
Recent reports hypothesized that diminished glucose uptake may partly be 
explained by a decreased insulin-induced vasodilation in skeletal muscle (18,19). 
Furthermore, insulin's effect on vascular tone has been reported to be nitric oxide 
dependent (20). Interestingly, in dyslipidemic patients, endothelium-dependent 
vasodilation has been shown to be diminished (21,22). 
Several earlier reports have suggested the presence of insulin resistance in various 
forms of hyperlipidemia. However, these findings were either based on rather 
indirect measurements such as determination of plasma concentrations of glucose, 
insulin and NEFA (8), possible confounded by obesity of the study group (9), or 
obtained by steady-state plasma glucose (SSPG) and insulin (SSPI) concentration 
determinations after somatostatin administration (7). Somatostatin in itself may 
exhibit vascular effects. Therefore, in this study we have determined the 
sensitivity to the metabolic and hemodynamic effects of insulin directly by means 
of the euglycemic hyperinsulinemic clamp technique in combination with skeletal 
blood flow measurements. The studies were performed in a careful selected 
sample of well defined non-obese normotensive male FCH patients, which were 
compared with each of their matched non-affected relative. 
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Methods 
Subjects 
For this study, initially 12 unrelated nonobese normotensive male FCH patients, 
selected from an available sample of well defined Dutch FCH families, were 
compared with one of their nonaffected male relatives. To anticipate 
environmental influences we carefully matched related individuals (i.e., affected 
and unaffected) for age, body mass index and waist to hip ratio. In addition, all 
subjects were apparently healthy and met the following inclusion criteria: a body 
mass index below 27 kgm2, blood pressure below 165/90 mmHg (measured in the 
supine position after 5 minutes rest), absence of diabetes mellitus, a medical 
history of vascular disease, and use of any medication, except lipid-lowering 
drugs, which were discontinued at least 1 month before participation. Two FCH 
patients and 2 relatives were habitual smokers. 
The FCH diagnosis was based on the following criteria: (i) the presence of a 
multiple type hyperlipemia in first-degree relatives, with at least two first-
degree relatives with a different hyperlipidemia (i.e., hypertriglyceridemia, 
hypercholesterolemia or a combined hyperlipidemia). The assessment of 
hyperlipidemia was based on the presence of constant elevated cholesterol and/or 
triglyceride levels above the 90th percentile, in spite of dietary advice (23); (ii) a 
family history positive for premature cardiovascular disease before the age of 60 
years. 
Participating FCH patients had both total plasma cholesterol and triglyceride 
concentration above the 90th percentile for age and gender, following dietary 
advice and after withdrawal of lipid-lowering drugs for at least 4 weeks. In 
contrast, unaffected relatives (9 were brothers, 2 were cousins) had both total 
plasma cholesterol and triglyceride concentration below the 75th percentile for 
age and gender. None of the subjects was homozygous for the apo E2 allele. 
Protocol and Procedures 
All participants visited the department twice after an overnight fast. During a 
first visit, a questionnaire was filled out in order to collect information on their 
medical status, and supine blood pressure, body mass index as well as the waist-
hip ratio were measured. Further, blood was sampled for determination of 
baseline values for lipids, lipoproteins, HbAic and C-peptide and for determination 
of the individual distribution of LDL subfractions in the LDL subfraction profile. 
Moreover, a 75 gram oral glucose tolerance test (OGTT) was performed to exclude 
impaired glucose tolerance or overt diabetes mellitus. In these tests glucose and 
insulin concentrations were determined at baseline and 30, 60, 90 and 120 
minutes after the glucose load. Only when participants showed 2-hour post-load 
glucose levels below 7.8 mmolL', a hyperinsulinemic euglycemic clamp was 
performed, combined with hemodynamic measurement of blood pressure, heart 
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rate and forearm blood flow, during a second visit, one to two weeks later. After 
OGTT, one FCH patient and his related control were excluded from further 
analyses due to impaired glucose tolerance of this FCH patient (2-h glucose level 
of 10.2 mmolL-1). The experimental protocol was approved by the ethical 
committee of our hospital, and all participants gave their written informed 
consent. 
Euglycemic Hyperinsulinemic Clamp 
Experiments were performed with the participants in the supine position in a 
quiet, temperature-controlled room (24-25°C). Under local anaesthesia (0.3-0.4 mL 
lidocaine HCL 20 rngmL1), a 20-gauge catheter (Angiocath·, Deserei Medical Inc., 
Becton Dickinson and Сотр., Sandy, Utah, USA) was inserted into the left brachial 
artery and connected with an arterial pressure monitoring line (Viggo 
Spectramed, No 992399A/14368, Bilthoven, The Netherlands) to a Hewlett Packard 
monitor (type 78353B, Hewlett Packard GmbH, Böblingen, Germany). Mean 
arterial blood pressure (MAP) was determined by electronically integrated area 
under the brachial arterial pulse-wave form. The arterial line was kept patent 
with saline infusion (with 2 U heparinmL' added). On the contralateral side an 
identical venous catheter was inserted into a large forearm vein for infusion of 
insulin and glucose. Insulin (Actrapid·, Novo-Nordisk, Denmark) was infused in a 
dose of 60 mUm2min' for 180 minutes. Insulin was diluted in 50 ml 0.9% NaCI 
with addition of 2 mL albumin, to a concentration of 1 UmL1. According to the 
clamp technique (24), plasma glucose concentration was kept at an euglycemic 
level by a variable infusion of glucose 20% solution, adjusted by arterial plasma 
glucose levels measured at 5-min intervals. All subjects were clamped at fasting 
glucose levels minus 0.3 mmolL'. The glucose infusion rate was calculated as the 
given amount of glucose in mL per kg body weight per minute, which equals the 
whole body glucose uptake (M). The glucose uptake per plasma unit of insulin (I) 
(insulin sensitivity index, M/l) was calculated as an additional measure of insulin 
sensitivity. In addition, the concentrations of non-esterified fatty acids (NEFA) 
were determined before and at the end. 
Forearm Blood Flow Measurement 
Forearm blood flow (FBF) was measured using mercury-in-silastic strain-gauge 
venous occlusion plethysmography on both arms as previously described (25). One 
minute before the start of the measurements (every 30 minutes), a wrist cuff was 
inflated to 100 mmHg above the systolic blood pressure, to be sure that the 
measurement only referred to the forearm skeletal muscle vascular bed (26). The 
collecting cuff around the upper arm was inflated to a pressure of 45 mmHg 
during 8-10 heart cycles using a rapid cuff inflator (Hokanson E20 rapid cuff 
inflator, Hokanson Inc., Issaquah, Wa, USA). The strain gauges were connected to 
a Plethysmograph (Hokanson EC4 Plethysmograph, Hokanson Inc., Issaquah, WA, 
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USA). Changes ¡η FBF during the clamp procedure were calculated with the means 
of the left and right FBF. 
Analytical Methods 
Glucose concentrations were measured in duplicate using the oxidation method 
(Beekman·, Glucose Analyser2, Beekman Instruments Inc., Fullerton, CA 92634, 
USA). Plasma insulin concentrations were determined using an "in house" assay 
(double antibody method) with an inter assay variability of 6%. C-peptide was 
determined using a commercially double antibody kit (Diagnostic Products 
Cooperation, cat no KPED1 double antibody, CA 900455597, USA), with an inter 
assay variability of 4.3%. Hemoglobin A)C was determined with a HPLC technique 
(BIORAD Laboratories B.V. Veenendaal, The Netherlands), with a reference range 
of 4.8-6.2%. The concentrations of NEFA's were determined using a commercially 
available ACS-ACOD method (Waco Chemicals GmbH cat. no. 994-75409, Neuss, 
Germany). Total plasma cholesterol and triglyceride concentrations were 
determined by commercially available, enzymatic reagents (Boerhinger-
Mannheim, FRG, cat. no. 237574 and Sera Pak, Tournai, Belgium cat. no. 6639, 
respectively). VLDL was isolated from whole plasma by sequential 
ultracentrifugation at density 1.019 g/ml for 16 hours at 36,000 rpm in a fixed 
angle rotor (TFT 45.6 rotor, Kontron, Zürich, Switserland) in a Beekman L7-55 
ultracentrifuge (Beekman, Palo Alto, USA). High density lipoprotein (HDL) 
cholesterol was determined with the polyethylene glycol 6000 method (27). LDL 
cholesterol was calculated by subtraction of VLDL and HDL cholesterol from total 
plasma cholesterol. Total plasma apolipoprotein-B was determined by immuno-
nephelometry (28). To achieve accurate results in relation to the Center for 
Disease Control Standardization Program, the obtained plasma apo-B results were 
recalculated on the basis of exchange of sera with Dr. S. Marcovina (Northwest 
Lipid Research Laboratory, Seattle, WA, USA). LDL subfractions were detected by 
single spin density gradient ultracentrifugation according to a previously 
described method (29). LDL subfractions were detected by single spin density 
gradient ultracentrifugation, according to a method described elsewhere (30). 
After ultracentrifugation up to five LDL subfractions, stained with Coomassie 
Brilliant Blue R, were visible as distinct bands in the middle of the tube. Accurate 
documentation of the different LDL subfraction patterns was obtained by 
scanning slides of the tubes in triplicate on a LKB 2202 ultrascan laser 
densitometer (Pharmacia LKB). The mean peak heights (h1-h5) of the LDL 
subfractions (LDL1-LDL5) on the three scans were used to calculate the continous 
variable К (-1<K<1), as described elsewhere (31). This continuous variable К 
appeared to reflect appropriately the individual LDL subfraction profiles (31,32). 
A negative K-value (-1<K<0) reflects a LDL subfraction profile more or less 
predominated by small dense subfractions. A profile with a predominance of 
buoyant LDL subfractions reveals a positive К value (0<K<1). 
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Statistical Analysis 
Differences in baseline characteristics and baseline values for lipid, lipoproteins, 
glucose and НЬАк were tested by the nonparametric two-sample Wilcoxon signed 
rank test. The results of the glucose tolerance test were tested by comparing 
areas under the curve of both the glucose excursion curve and the insulin 
response. To compare the whole body glucose uptake and the insulin sensitivity 
index of the affected with that of the unaffected subjects, controlling for possible 
influence of confounding variables, an analysis of variance (ANOVA) was 
performed with age, body mass index and waist to hip ratio as covariates. Pearson 
correlation coefficients using the combined data of both groups were calculated 
to determine the relationship between measurements of the glucose and lipid 
metabolism, the individual LDL subfraction distribution (i.e., K-value) and the 
insulin-induced vascular effects. To investigate differences in the time action of 
insulin on hemodynamic parameters between the two groups, the time/group 
interaction was calculated by repeated measures ANOVA with insulin as the 
independent factor. All statistical analysis were performed using the SPSS/PC+ 
program (SPSS Ine, Chicago, III, USA). Results in Tables and Figures are presented 
as mean±SEM unless otherwise indicated. Differences with a test value less than 
0.05 were considered to be significant. 
Results 
Baseline Characteristics 
Baseline characteristics at inclusion of both FCH patients and their non-affected 
relatives are presented in Table 1. Age, BMI, waist to hip ratio and blood pressure 
were not different between both groups. As a consequence of the selection 
procedure, all lipid and lipoprotein concentrations (except the LDL cholesterol 
concentration) were significantly higher in FCH patients compared with the 
unaffected relatives. Total plasma apo-B was also higher in FCH patients than in 
unaffected relatives. The K-value, as a description of the LDL subfraction profile, 
was more negative in FCH patients than in unaffected relatives, corresponding 
with the predominance of small dense LDL particles in FCH patients. 
Responses to Oral 75 gram Glucose Load 
Baseline values of fasting glucose, fasting insulin, НЬАк, C-peptide, and the 
calculated insulin to glucose ratio are presented in Table 2. C-peptide 
concentrations were significantly higher in FCH patients compared with their 
unaffected relatives. Concentrations of glucose, insulin, НЬАк, and insulin to 
glucose ratio all tended to be higher in FCH patients than in the unaffected, but 
these differences did not reach significant levels. Glucose excursions after oral 
glucose load were comparable in both groups (Fig. 1), although a significant 
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Table 1: Baseline anthropometric measurements, blood pressure, lipid, lipoprotein and 
apolipoprotein-B levels of the FCH patients and their non-affected relatives. 
Number 
Age (years) 
Body mass index (kgm2) 
Waist/hip ratio 
Systolic blood pressure (mmHg) 
Diastolic blood pressure (mmHg) 
Total cholesterol (mmol-L') 
Total triglycerides (mmol-L1) 
VLDL cholesterol (mmol-L') 
VLDL triglycerides (mmol-L') 
LDL cholesterol (mmol-L') 
HDL cholesterol (mmol-L') 
Apo-B (mg-dL') 
K-value 
Affected 
11 
41.9 ±9.0 
24.9 ± 1 . 
0.99 ± 0.05 
122.7 ±11.7 
79.5 ±6.9 
7.70 ± 1.01 
3.73 ± 2.50 
1.90 ±1.40 
2.80 ±2.14 
4.90 ± 1.39 
0.89 ± 0.17 
178.9 ±45.3 
-0.62 ± 0.13 
Unaffected 
11 
44.9 ± 11.5 
24.3 ± 1.5 
1.00 ±0.04 
132.7 ±16.5 
81.8 ±8.4 
5.59 ± 0.85 
1.24 ±0.43 
0.50 ± 0.29 
0.71 ± 0.41 
4.03 ± 0.88 
1.20 ±0.15 
122.8 ±26.8 
-0.08 ± 0.24 
p-value 
ns 
ns 
ns 
ns 
ns 
0.003 
0.003 
0.003 
0.003 
ns 
0.006 
0.003 
0.004 
All values are presented as means ± SD; VLDL, very low density lipoproteins; LDL, low 
density lipoproteins; HDL, high density lipoproteins; Apo-B, apolipoprotein-B; ns, not 
significant 
Table 2: Baseline concentrations of parameters of glucose metabolism in 11 FCH patients 
and 11 non-affected relatives. 
Glucose (mmol-L') 
Insulin (mU-L') 
HbA,c (%) 
C-peptide (nmol-L') 
Insulin to glucose ratio 
NEFA 
Affected 
5.45 ±0.12 
8.55 ± 0.95 
5.45 ±0.10 
0.65 ± 0.03 
1.57 ±0.18 
0.86 ±0.16 
Unaffected 
5.22 ±0.15 
7.00 ± 0.98 
5.36 ± 0.08 
0.47 ± 0.04 
1.35 ±0.18 
0.75 ± 0.05 
p-value 
ns 
ns 
ns 
0.02 
ns 
ns 
All values, except the insulin to glucose ratio, are presented as means ± SEM; NEFA, non 
esterified fatty acids; ns, not significant 
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higher glucose concentration after 2 hours was observed in FCH patients as 
compared with the controls (5.73±0.52 mmol-L' vs. 4.36±0.29 mmol-L', P=0.019). 
Plasma insulin responses during 2 h after the oral glucose load, also presented in 
Fig 1, were significantly higher in patients than controls. None of the participants 
had plasma glucose above 7.8 mmol-L', 2 h after an oral 75 gram glucose load. 
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Fig. 1. Plasma glucose (top) and insulin concentrations (bottom) in response to oral 75 
glucose tolerance test in 11 FCH patients and 11 unaffected relatives. 
Metabolic Response to Clamp Procedure 
Plasma glucose values during the last 60 min of the clamp procedure were stable 
in patients and unaffected relatives (coefficient of variation 3.4±0.3% and 
4.1±0.3%, respectively). Plasma insulin concentrations increased in all subjects and 
were similar after 3 h of insulin infusion in both groups (94.6±4.3 mUL' in FCH 
patients and 93.8±4.8 mUL1 in unaffected relatives). Whole-body glucose uptake 
(M), calculated from the glucose infusion rate of both groups during the clamp 
procedure, is presented in Fig. 2, and was significantly different over the last 60 
min between FCH patients and unaffected relatives (6.89±0.31 vs. 8.94±0.76 
mg-kg 1min ', respectively; P=0.01 ANOVA). 
The mean M-value of the control relatives was very similar to previous obtained 
values of healthy volunteers (8.8±1.3 mgkg'min') (33). The glucose uptake 
during the last 60 min of the clamp procedure per plasma unit of insulin (insulin 
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Fig. 2. Results of the euglycemic hyperinsulinemic clamp procedure during 3 hours in 11 
FCH patients and 11 unaffected relatives. Lines (left Y-axis): Mean glucose 
concentrations of FCH patients and unaffected controls during the clamp. Bars 
(right Y-axis): Glucose infusion rate in affected (closed bars) and unaffected (open 
bars) subjects. 
sensitivity index) also differed between both groups (M/l 7.46±0.50 vs. 9.51±0.53, 
respectively; P=0.009 ANOVA). When the results of the related couples were 
compared it was found that in 9 FCH patients whole-body glucose uptake was 
lower, in 1 FCH patient it was equal and in 1 FCH patient it was higher than in 
their respective normolipidemic relatives (Fig. 3). To avoid the possible 
confounding effect of smoking, the rates of uptake were also compared in 
nonsmokers. In nonsmokers the rates of whole body glucose uptake were also 
significantly lower in FCH patients (n=9) than in unaffected relatives (n=9) 
(6.90±0.66 vs. 9.00±0.93 mgkg'min' , respectively; P=0.019 ANOVA). Although 
fasting plasma NEFA concentrations were higher in the FCH patients than in 
controls, this difference appeared not to be significant (Table 2). Both NEFA 
concentrations were suppressed in a similar manner during the clamp procedure 
(from 0.86±0.16 to 0.12±0.04 mmolL' in FCH patients, P=0.003 and from 
0.75±0.12 to 0.10±0.05 mmolL' in unaffected relatives, P=0.003), without 
differences between both groups. 
Effects on Forearm Blood Flow 
At baseline, the mean values of hemodynamic parameters (FBF and MAP) of both 
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Fig. 3. Comparison of whole-body glucose uptake of related couples (FCH patients and 
relatives) connected by lines. 
groups were similar. Only unaffected relatives exhibited a significant increase of 
31.8±14.3% in FBF (from 1.85±0.16 to 2.45±0.35 mldL'min', ANOVA /»=0.025), 
whereas FCH patients showed no significant change in FBF (from 1.87±0.15 to 
2.06±0.24). MAP did not change in either group (FCH patients: 92.7±2.3 to 
93.0±3.6 and relatives: 95.3±3.0 to 98.4±2.7 mmHg). The time course of the 
changes in FBF showed the major and statistically significant changes during the 
last hour of the clamp reflecting a phenomenon with slow-onset. 
Relationship between LDL subfraction distribution, whole-body glucose 
uptake and skeletal blood flow 
The individual LDL subfraction profile, described as parameter K, correlated 
significantly with the glucose uptake during the clamp procedure (r=0.51, 
P=0.008) (Fig. 4). When the groups were compared separately, FCH patients were 
more insulin resistant and exhibited a predominance of small dense LDL 
subfractions. The unaffected relatives, with the exception of one individual, were 
characterized by the presence of more buoyant LDL particles. Noteworthy, the 
alteration in FBF during insulin administration was correlated with the insulin 
sensitivity index (r=0.40, P<0.05). However, in this sample FBF showed no 
correlation with parameters of lipid metabolism. 
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Fig. 4. Correlation between whole-body glucose uptake and LDL density as determined 
by density gradient ultracentrifugation and described by parameter K. FCH 
patients are depicted by a closed box (•) and unaffected relatives by an open box 
(Ü) (r=0.51, P=0.008). 
Discussion 
In this study, we demonstrated by means of the euglycemic clamp technique 
directly a reduced insulin sensitivity in well-defined male FCH patients as 
compared with one of their normolipidemic relatives. Since it has been 
established that insulin resistance is also associated with obesity, age and gender 
alone (34,35), it is important to emphasize that these observations were not 
confounded by differences in gender or age, and were registered in the absence 
of obesity, hypertension and impaired glucose tolerance in the participants. 
Furthermore, we selected the affected and the unaffected participants in 
genetically related pairs, presuming that by this study design differences in 
environmental or genetic influences were reduced. Apart from the metabolic 
resistance to insulin (reduced glucose uptake), FCH patients also exhibited 
resistance to the vasodilator effects of insulin. Finally, diminished whole-body 
glucose uptake correlated with the presence of small dense LDL subfractions. 
Because of the similarity in presenting lipid disturbances and the association with 
increased cardiovascular risk, diminished insulin sensitivity may be related to FCH. 
This observation is further supported by the finding that insulin resistance affects 
both hepatic VLDL production and lipoprotein lipase action features also met in 
FCH. Previous studies indicate that insulin resistance is associated with elevated 
concentrations of VLDL triglyceride (7,36,37). Recent studies, however, showed no 
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improvement in insulin sensitivity after substantial reduction of plasma 
triglyceride levels with fibrate treatment in both non-diabetic men with type lib 
hyperlipidemia and in type II diabetic patients with hypertriglyceridemia (38,39). 
This may indicate that in some patients insulin resistance is of an inherited 
nature, not depending on plasma triglyceride concentrations, but probably 
preceding VLDL triglyceride overproduction. 
A proposed mechanism responsible for VLDL overproduction is the impaired 
postprandial suppression of NEFA release in adipose tissue due to resistance to 
the normal suppressive effect of insulin on hormone sensitive lipase (11,40). An 
elevated concentration of NEFA is associated with increased hepatic VLDL 
triglyceride secretion, possibly due to reduced intracellular apo-B degradation 
(12). Furthermore, when normal insulin mediated activation of lipoprotein lipase 
in adipose tissue is diminished, an impaired postprandial clearance of triglyceride-
rich lipoproteins may occur (41). Several reports mentioned an impaired 
lipoprotein lipase activity as one of the factors contributing to FCH (42,43). 
A postprandial status with prolonged circulating triglyceride-rich lipoproteins is a 
provocating situation for the formation of small dense LDL particles (44). In the 
Kaiser Permanente Women Twin study and other studies small dense LDL was 
found to be an integral feature of the insulin resistance syndrome (14,15). Others, 
however, showed a significant correlation between LDL particle size and 
triglyceride levels, but not to insulin resistance in mildly hypertriglyceridemic 
subjects (16). Here, the authors considered small dense LDL a feature of the 
insulin resistance syndrome more as a consequence of abnormalities in VLDL 
metabolism. Our observed correlation between glucose uptake as a measure of 
insulin sensitivity and LDL density is in accordance to these reports, but cannot 
discriminate between metabolic influences, such as the correlation with 
hypertriglyceridemia, causing a dense LDL subfraction profile, or primarily genetic 
effects related to diminished insulin sensitivity and small dense LDL in FCH. The 
recently reported major gene effect on LDL subfraction size in FCH (5,32), may 
possibly be found in mutations causing insulin resistance underlying 
hypertriglyceridemia and the formation of small dense LDL. On the other hand, 
reported linkage of small dense LDL to a locus near the LDL receptor and the 
insulin receptor gene on chromosome 19p (45) may indicate that the allele 
responsible for expression of small dense LDL also predisposes to insulin 
resistance. 
Disorders related to insulin resistance seem to exhibit their major defect on the 
level of glucose uptake in skeletal muscle, rather than at the level of the liver or 
the adipose tissue (46-48). Furthermore, several groups including ourselves have 
demonstrated the vasodilator effect of systemic hyperinsulinemia (18,33,49), 
which was reduced in non-insulin-dependent diabetes (NIDDM) (50). It is 
hypotesized that decreased insulin sensitivity in humans may not only be due to 
lower insulin-mediated glucose extraction in insulin-sensitive tissues, but also to a 
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lower blood flow to these tissues, due to a decreased ability of insulin to 
stimulate skeletal muscle blood flow (19). In accordance with other studies in 
which comparable systemic insulin concentrations were reached, we observed a 
30% increase in FBF in non-affected, but not in FCH patients. Although part of 
the present reported insulin resistance may be related to this diminished insulin-
induced vasodilation, this could in fact only account for the last 60 to 80 minutes 
of the clamp, since differences in FBF between the groups became statistically 
significant in this period. 
The insulin-induced vasodilation seems to be endothelium-dependent (20). 
Noteworthy, reduced insulin-induced vasodilation may be due to direct 
endothelium disturbing action of elevated lipid levels (22). Therefore, in FCH 
patients the elevated lipoprotein concentration may directly influence the 
endothelium function, resulting in decreased nitric oxid release during 
hyperinsulinemia. Because insulin resistance itself may underlie VLDL 
overproduction, the reduced hemodynamic effects of insulin in hyperlipemia 
can amplify metabolic disturbance as found in FCH patients. 
In conclusion, this study suggests that FCH patients do exhibit a diminished insulin 
sensitivity. This insulin resistance may underlie the observed hyperlipidemia, 
characterized by elevated concentrations of VLDL cholesterol and triglycerides 
and a predominance of small dense LDL in the affected subjects, and may be 
partly explained by a reduced capacity of insulin to induce vasodilation in skeletal 
muscle of the patients. Therefore, interactions between insulin-action and lipid 
metabolism in FCH warrant further investigation. 
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Abstract 
Insulin resistance is an important pathogenetic factor in non-insulin-dependent 
diabetes mellitus (NIDDM), and a prominent feature of obesity. The vasodilator 
response to insulin, is diminished in NIDDM as well as in obesity, which may 
further impair insulin-mediated glucose uptake. Because insulin-induced 
vasodilation seems to be nitric oxide dependent, impaired vasodilation might 
reflect endothelial dysfunction. Troglitazone, a thiazolidine-dione derivative, has 
been shown to improve insulin resistance in diabetic and obese animal models, as 
well as in human diabetes and obesity. We hypothesized that improvement of 
insulin sensitivity by troglitazone might thus improve insulin-dependent and/or 
endothelium-dependent vascular function in insulin resistant obese subjects. 
To test this hypothesis, thirteen obese subjects (7M:6F, age 37.9±4.0 yr, body mass 
index (BMI) 32.1±3.1 kgm2) were treated with 400 mg troglitazone odd for 8 
weeks, or placebo in a randomised, double-blind cross-over design. At the end of 
each treatment period we investigated forearm vasodilator responses [venous-
occlusion plethysmography] to intra-arterial administered acetylcholine (0.5, 2.0 
and 8.0 /jg-dL 'min ', 5 minutes per dose) and sodium nitroprusside (0.06, 0.20 and 
0.60 μg·dL1·m¡n'). Further, we measured insulin sensitivity, insulin-induced 
vasodilation [euglycemic hyperinsulinemic clamp], and vasoconstrictor responses 
to the specific inhibitor of nitric oxide synthase /VG-monomethyl-L-arginine 
(L-NMMA; 0.05, 0.1 and 0.2 mgdL'min') during hyperinsulinemia. Baseline data 
(placebo) of obese subjects were compared with that of a sex- and age-matched 
group of 13 lean individuals (BMI 21.9±0.б к д т г ) . 
Results: Obese subjects were clearly insulin resistant when compared with leans 
(Glucose infusion rate (GIR) during last 30 min of clamp: 53.9±4.3 vs. 27.2±3.3 
^mol-kg^min', P<0.001). Troglitazone improved insulin sensitivity (n=11, GIR from 
27.4±3.6 to ЗІ. іЗ.ОдтоІ-гіи-тіп', P=0.035). Insulin-stimulated forearm glucose-
uptake increased from 1.09±0.54to 2.31±0.69 д т о І г і І Л т і п 1 during troglitazone 
(P=0.006). However insulin-induced vasodilation in the forearm skeletal muscle 
vascular bed, that was blunted in obese subjects (percent increase in forearm 
blood flow in the lean group 66.5±23.0%, vs. 10.1±11.3% in obese, P=0.04), did 
not improve during troglitazone (n=12, from 11.3±12.3% during placebo to 
2.2±4.9% during troglitazone, P=0.39). Vasodilator responses to acetylcholine 
(endothelium-dependent) and sodium nitroprusside (endothelium-independent) 
did not differ between the obese and lean group, nor between both treatment 
periods in the obese individuals. Vasoconstrictor responses to L-NMMA were 
similar between both groups and treatment periods. 
In conclusion, we confirm that troglitazone can improve insulin sensitivity in non-
diabetic obese subjects. Insulin-induced vasodilation is impaired in obesity, but 
troglitazone had no additional effects on insulin-induced vasodilator action 
and/or endothelial function under these conditions. This may indicate that the 
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changes in insulin sensitivity obtained in this group were too moderate, or that 
other mechanisms are involved. 
Introduction 
Insulin has besides a key role in the regulation of carbohydrate metabolism (1) 
also important cardiovascular effects. Several authors including ourselves have 
shown that systemic hyperinsulinemia induces vasodilation in skeletal muscle (2-
6). This vasodilation further enhances the delivery of glucose to insulin-sensitive 
tissues, thus supporting insulin-induced glucose uptake (7). Insulin-mediated 
vasodilation is diminished in insulin resistant states, such as obesity (8), 
hypertension (9) and NIDDM (10). The vasodilator effect of insulin seems to be 
mediated by endothelial release of nitric oxide (11,12); hence a diminished 
insulin-induced vasodilation suggests a disturbed endothelial function. Indeed, in 
NIDDM (13,14) and hypertension (15,16), both considered to be characterized by 
insulin resistance, an impaired endothelial function has been reported. These 
findings seem to imply that insulin resistance may be linked to endothelial 
dysfunction, either as a cause or as a consequence (7). Recently, indeed, a reduced 
vasodilator response to metacholine (but not to sodium nitroprusside), was 
described in insulin resistant obese individuals, indicating a specific defect in 
endothelial-dependent vasodilation (17). Furthermore a correlation between 
insulin sensitivity and the vasoconstrictor response to the nitric oxide inhibitor 
WG-monomethyl-L-arginine (L-NMMA) has been noticed (18). 
Troglitazone is a newly developed compound that belongs to the group of the 
thiazolidine-diones, a class of drugs capable of improving insulin sensitivity. 
Troglitazone improved insulin resistance in animal models of diabetes (19) and 
obesity (20), as well as in human diabetes (21) and obesity (22). The exact 
mechanism of action is not known up to now, but may be related to the specific 
binding to nuclear receptors (23). Assuming that insulin resistance is coupled to 
endothelial function, we hypothesize that pharmacological improvement of 
insulin sensitivity by troglitazone would also improve endothelial function and 
hence vasodilator responses to insulin, in obesity. 
To address this hypothesis, we performed a randomised, placebo-controlled, 
double-blind cross-over trial with troglitazone, in obese individuals, characterised 
by insulin resistance. 
Methods 
Subjects 
The study group consisted of 13 obese, healthy volunteers. All met the inclusion 
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criteria: age between 25 and 50 years, nonsmoking, absence of hypertension 
(office blood pressure <140/90 mmHg, measured after 5 min rest in the supine 
position), body mass index between 27 and 36 kg-rrr2. Participants used no 
medication; two women used oral contraceptives. Further history, physical 
examination and laboratory analyses showed no evidence of disease. All subjects 
had a normal fasting glucose concentration, and a stable weight. Baseline data 
obtained during the use of placebo (which was known after the completion of 
the trial) were compared with that of an additionally selected group of 13 age-
and sex-matched lean individuals. Study participants were selected by 
advertisement and received a payment. All gave written informed consent. The 
experimental protocol was approved by the hospital ethics committee. 
One of the obese subjects underwent minor surgery during the second part of the 
trial which was however followed by complications and a subsequent weight loss 
of 6.4 kg. This subject was excluded from the troglitazone study part. After 
breaking of the code, it turned out that this individual had used placebo during 
the first study period. Therefore, these data were included for comparison with 
the lean group. 
Protocol 
After inclusion in the study, obese subjects received either troglitazone (2 tablets 
of 200 mg once a day with or after breakfast), or placebo for 8 weeks, in a 
randomised, double-blind, crossover design. The subjects, pharmacists and 
investigators were not aware of the treatment code which was broken only after 
completion of all analyses. Participants were strictly advised to maintain their 
weight. At the end of the two treatment periods, 24-hour ambulatory blood 
pressure monitoring was performed, followed 2 days later by an intra-arterial test 
with administration of vasoactive drugs into the brachial artery, in combination 
with the euglycemic hyperinsulinemic clamp technique (see below). In addition, 
body weight, waist-hip measurements, ECG, fat skinfold thickness, possible side-
effects, and serum safety chemical and hematologic profiles were determined. 
Between both treatment periods there was a two week wash-out period. 
Compliance was monitored by pill counts, in combination with diary records. 
Lean control subjects underwent the investigational protocol only once, a few 
days after baseline investigations. 
Experimental procedures 
Intra-arterial experiments were performed after an overnight fast, with the 
subjects in supine position in a quiet temperature-controlled room (23°-24°C). A 
20-gauge catheter (AngiocathR, Becton Dickinson, Sandy, Utah) was inserted into 
the left brachial artery [local anesthesia with 0.3-0.4 mL lidocaine HCl 20 mg-mL'], 
and connected with an arterial pressure monitoring line to a Hewlett Packard 
78353B Monitor. The arterial line was kept patent with NaCI 0.9%+heparin 
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infusion (2 U heparin IDL1 NaCI, 3 mlh') . In the ¡psilateral arm a catheter 
(Venflon", 20 G, 32 mm) was inserted retrogradely into a deep forearm vein to 
obtain venous blood samples. On the contralateral side an identical catheter was 
inserted into a large forearm vein for the infusion of insulin and glucose 20%. 
Forearm blood flow (FBF) was measured using mercury-in-silastic strain-gauge, 
venous occlusion plethysmography as previously described (24). One minute 
before the start of the measurements, a wrist cuff was inflated to 100 mm Hg 
above systolic blood pressure. The collecting cuff around the upper arm was 
inflated to a pressure of 40 mmHg during 8 heart cycles using a Hokanson E20 
rapid cuff inflator. The strain gauges were connected with the Hokanson EC4 
Plethysmographs (D.E. Hokanson Ine, Bellevue, WA 98005, US). Forearm volume 
was measured with the water displacement method, and all drugs were dosed per 
100 ml forearm tissue (infusion rate 100 ^LdL'min '). 
For the calculation of net uptake or release of glucose and potassium, arterial and 
venous blood was sampled simultaneously at relevant time points (see 
calculations). Venous blood was sampled with inflated wrist cuffs. 
Ambulatory 24 hour blood pressure was measured with an ausculatory method 
(Profilomat, USA), on an average working day, at least two days before the 
experimental procedures. The device was programmed to measure every 15 min 
during the day (7.00 am to 24.00 pm, and every 30 min during the night (24.00 
pm to 7.00 am). 
Measurements 
After complete instrumentation, 30 min of rest were included, after which 
baseline measurements were performed. Subsequently, three doses of 
acetylcholine (0.5, 2.0 and 8.0 μg·dL,·m¡n,), an endothelium-dependent 
vasodilator, were infused into the brachial artery. Each dose was administered 
during 5 min; during the last 2 min FBF measurements were performed. 
Following, 30 min of equilibration were included. Subsequently sodium 
nitroprusside, an endothelium-indepent vasodilator, was infused intra-arterially in 
three doses (0.06, 0.20 and 0.60 μg•dL-'·m¡n '), each during 5 min, with FBF 
measurements during the last 2 min (16). Next, the euglycemic hyperinsulinemic 
clamp was started: Insulin (Actrapid, Novo-Nordisk) was infused intravenously in a 
dose of 430 р т о І т 2 т і п - ' (60 mUdl 'min1), during 120 min. Insulin 50 UmL' was 
diluted in 47.5 mL 0.9% NaCI with the addition of 2 mL human albumin 20% 
(Central Laboratory of Bloodtransfusion, Amsterdam) to a concentration of 1 
UmL'. Euglycemia was maintained by a variable infusion of glucose 20% solution, 
adjusted by arterial glucose measurements at 7 min intervals. Arterial blood 
glucose concentrations of all participants were clamped at fasting level minus 0.2-
0.5 mmolL1. When subjects underwent the second clamp procedure, the glucose 
clamp level was chosen identical to that of the first clamp procedure. 
Finally, to evaluate the contribution of endothelial NO release to the prevailing 
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blood flow during hyperinsulinemia (11,12), three ¡ntra-arterial doses of the 
specific NO synthase inhibitor /v^-monomethyl-L-arginine (L-NMMA, 0.05, 0.1 and 
0.2 mgdL'min ') were administered for 5 min each, with measurements during 
the last 2 minutes. During L-NMMA, insulin (and glucose) infusions were 
continued. 
After the experiment, the glucose infusion was continued for a while and the 
participants were served a carbohydrate-rich meal in order to avoid post-test 
hypoglycemic events. 
A schedule of the study protocol is shown in Fig. 1. 
DRUGS and dosages (in pg.dL.min ): 
Acetylcholine (ACH) 
0.5-2.0-8.0 Ц 
Forearm 
blood How 
NitroprussJde (SNP) 
0.06-0.20-0.60 • 
L-NMMA 
0.05-0.10-0.20 
ψψψ VVVv ν ψ ψ V YV νψ 
art. cath 
180 210 240 
time (min) 
Fig. 1. Schedule of the study protocol. 
Drugs used 
Acetylcholinechloride 100 mg/ampoule, dry powder (Dispersa AG, Winterthur) was 
dissolved to its final concentration with normal saline, and sodium nitroprusside 
50 mg/ampoule, dry powder (Roche, Mijdrecht, The Netherlands) with glucose 5% 
solution. 
/Vo- L-NMMA-acetate was obtained from Sigma and stored as a dry powder after 
manufacturing. The solution was freshly diluted with NaCI 0.9% to its final 
concentration just prior to the experiment. 
Analytical methods 
Blood samples for assessment of glucose were immediately centrifuged during 20 
seconds, in a Microcen 13 (Herolab, Leidschendam, the Netherlands). Plasma 
glucose was measured in duplicate, in arterial (and venous) blood samples by the 
glucose oxidation method (Beekman Glucose Analyzer 2, Beekman Instruments Ine, 
Fullerton, CA 92634, USA). Plasma insulin was measured with a double antibody 
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radioimmunoassay (Interassay coefficient of variation (CV) 6.2%). Plasma C-
peptide was measured with a commercially available double antibody 
radioimmunoassay (Diagnostic Products Corporation, LA, CA 90045 5597, 
interassay CV 4.3%). Hemoglobin A)c was measured using a HPLC technique (BIO-
RAD Laboratories B.V. Veenendaal, the Netherlands) with reference values of 4.8-
6.2 %. 
Free fatty acids (non-esterified fatty acids=NEFA) were analysed with an 
enzymatic method (ACS-ACOD, NEFA C-kit, Waco Chemicals GmbH). Triglycerides 
(Triglycerides GPO-PAP method), cholesterol (Cholesterin CHOD - PAP method) and 
HDL-cholesterol (After addition of Cholesterin precipitation reagens) were all 
determined on a Hitachi 747 auto-analyser (Boehringer Mannheim). 
Blood samples for measurement of plasma norepinephrine were collected in 
prechilled tubes on melting ice, containing glutathione (0.2 mol-L1) and EGTA 
(0.25 mol-L-1) and centrifuged at 4°C. Norepinephrine concentration was 
determined by high performance liquid chromatography (HPLC) with fluorometric 
detection (25). 
Calculations and data analysis 
Forearm Vascular Resistance (FVR) was calculated by dividing intra-arterial mean 
arterial pressure (MAP) and FBF, and expressed in arbitrary units (AU). Assuming 
that whole blood glucose = (1 - 0.3 χ hematocrit) χ plasma blood glucose (26), 
glucose uptake was calculated as: 
AGIucoseArt«,i.iv.i,ou. χ ( 1 - 0.3 χ hematocrit) χ FBF. 
During the last 30 min of the clamp, mean plasma glucose concentration and 
coefficient of plasma glucose variation was calculated. Whole-body glucose 
uptake was defined as the glucose infusion rate during the last 30 minutes of the 
clamp and expressed in дтоі-кд 'min ° (27). 
Statistical analyses were only performed after prior verification of 
appropriateness, by exclusion of period or sequence effects (28). Comparison of 
insulin sensitivity between placebo and troglitazone was performed by paired 
f test of the differences in aera under the curves of the glucose infusion rate of 
the two experiments. Increase in forearm glucose uptake during placebo and 
troglitazone was compared by paired t test as well. 
Effects of insulin on forearm blood flow was calculated using the FBF 
measurements of the control arm, to avoid interference with the previously 
administered vasodilator drugs in the experimental arm. Mean of the last two FBF 
measurements at the time of contralateral SNP infusion (just before the start of 
insulin) were compared with the mean of the last two measurements at the time 
of contralateral L-NMMA administration (after 115 minutes insulin 
administration). Effects were statistically evaluated using paired ί tests. Although 
baseline FBF was not significantly different between both groups, FBF tended to 
be higher in the obese group. To compensate for these possible changes in 
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baseline flow, responses to drugs were also expressed as percentage increase 
above baseline (29). Effects of insulin on blood pressure and heart rate were 
evaluated using repeated measures ANOVA. 
Results of 24 hour ambulatory blood pressure monitoring were averaged to 
hourly values. From each subject only data of which two sets were available, were 
used for further analyses. One mean value was than calculated for the whole 24 
hour period (between 9.00 am and 7.00 am the next morning). These results were 
statistically compared by paired Student's t tests. 
Other metabolic data were statistically analyzed by use of the Student's t test. 
Comparison between the two groups was performed using unpaired t tests. 
Correlations were calculated using Spearman's rank correlation tests. All statistical 
analyses were performed using the SPSS personal computer software package. 
Results in tables and figures are expressed as mean ± SEM, unless otherwise 
indicated. Statistical significance was set at a value less than 0.05. 
Results 
Characteristics of the two groups at baseline are shown in Table 1. They were 
properly matched for age and sex; due to selection, they were clearly different 
with respect to weight, fat percentage and also waist/hip ratio. Furthermore, 
despite the fact that all individuals were normotensive during measurement, 
Table 1. Baseline characteristics (meantSD) 
Obese Lean Ρ 
Number (M:F) 
Age (yr) 
Weight (kg) 
BMI(kgm2) 
Waist/Hip 
Fat (%) 
Cholesterol (mmol-L') 
HDL-Chol(mmolL') 
Triglycerides 
NEFA(mmolL') 
SYS BP (mmHg) 
DIAS BP 
Heart Rate (bpm) 
Forearm blood flow 
(mLdL'-min') 
13 (7:6) 
37.9±4.0 
95.9±9.0 
32.1±3.1 
0.98±0.09 
36.0±6.7 
5.78±1.14 
1.16±0.31 
1.72±0.94 
0.65±0.08 
124±11 
82±5 
69.5±7 
2.74±0.19 
13 (7:6) 
38.3±7.6 
69.Ш0.5 
21.9±0.6 
0.86±0.06 
22.6±6.2 
4.84±1.06 
1.28±0.26 
0.80±0.40 
0.38±0.06 
118±9 
73±10 
70.3±13 
2.25±0.75 
0.87 
<0.001 
<0.001 
<0.001 
<0.001 
0.04 
0.31 
0.004 
0.01 
0.14 
0.01 
0.09 
0.09 
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mean office diastolic blood pressure was higher in the obese group. Finally, obese 
subjects had higher mean cholesterol, triglyceride and NEFA levels. 
Troglitazone was well tolerated by all subjects, with only mild side effects 
(headache, looser stool, dry skin), equally distributed between placebo and active 
drug treatment. Drug compliance was measured by tablet counting and diaries. 
There were no sequence or period effects of the trial; mean weight change, 
fasting plasma glucose/insulin, lipid levels, insulin sensitivity and blood pressure 
were comparable during the first and second period of the trial. 
Effect of troglitazone on fasting metabolic parameters 
During the use of troglitazone, fasting plasma glucose did not differ from that 
during placebo (5.6±0.2 during placebo vs. 5.4±0.2 mmol-L1 during troglitazone, 
P=0.25). Fasting insulin concentration decreased from 84.6±10.0 during placebo to 
65.2±7.9 pmol-L' during troglitazone (P=0.11), and was elevated as compared to 
the fasting levels in lean subjects (40.9±5.0 pmol-L1, P<0.001 vs. obese (placebo)). 
Fasting C-peptide concentration did not change (0.90±0.11 during placebo vs. 
0.88±0.07 nmol-L1 during troglitazone, P=0.76). Surprisingly, HbAu level increased 
significantly from 4.85±0.11 during placebo to 5.12±0.07% during troglitazone 
(P=0.01). Body weight did not significantly change during both treatment periods 
(during placebo +0.55±0.54 kg, during troglitazone +0.48±0.50 kg, P=0.94) 
Troglitazone treatment was associated with slight decrements in NEFA, and 
triglyceride concentration, but these changes did not reach statistical significance 
(Table 2). 
Table 2. Effect of troglitazone on lipids 
Placebo Troglitazone P-value 
Total Cholesterol 
HDL-Cholesterol 
Triglycerides 
NEFA 
5.0±0.3 
1.06±0.07 
2.08±0.72 
0.65±0.08 
5.3±0.3 
1.07±0.08 
1.66±0.41 
0.48±0.06 
0.31 
0.82 
0.50 
0.08 
Mean±SEM, all parameters in mmol-L1 
Effect of troglitazone on baseline hemodynamic parameters 
Table 3 shows the effects of troglitazone on blood pressure and heart rate. 
Baseline FBF, systolic and diastolic (intra-arterially measured) blood pressure were 
not affected by troglitazone treatment. (Baseline FBF with placebo 2.81±0.28 
mL-dL'-min1, with troglitazone 2.99±0.47 mL-dL'-min', P=0.69). Heart rate 
increased significantly by 8.3±2.7% (P=0.016). 
Ambulant 24 hour blood pressure measurements showed a decrease in mean 24 
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Table 3. Effect of troglitazone on blood pressure and heart rate 
Systolic BP (mmHg) 
intra-arterial 
ABPM - 24 hour 
Diastolic BP (mmHg) 
intra-arterial 
ABPM - 24 hour 
Heart Rate (bpm) 
intra-arterial 
ABPM - 24 hour 
Placebo 
129.2±3.1 
114.1±2.1 
71.2±1.6 
84.4±1.3 
59.8±3.1 
70.8±2.3 
Troglitazone 
128.3*3.2 
113.2±3.2 
71.0±1.8 
81.1*1.8 
64.1±2.2 
73.6±1.9 
P-value 
0.71 
0.71 
0.90 
0.049 
0.021 
0.085 
hour diastolic blood pressure during treatment with troglitazone as compared 
with placebo (84.4±1.3 during placebo vs. 81.1*1.8 mmHg during troglitazone, 
P<0.05). Systolic blood pressure did not change (114.1±2.1 during placebo vs. 
113.2±3.2 mmHg during troglitazone, P=0.71). Over the 24 hour period the 
decrease in diastolic blood pressure was during both day and night period (see 
Fig. 2). Ambulatory heart rate increased from 70.8±2.3 to 73.6±1.9 bpm (P=0.085). 
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Fig. 2. Twentyfour hour ambulatory blood pressure profiles, during placebo (A) or 
troglitazone (Δ). 
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Metabolie response to euglycemic hyperinsulinemic clamping 
Blood glucose values during the clamp procedure were not different between 
obese and lean, nor between troglitazone and placebo (lean: 5.23±0.08, obese: 
5.22±0.04 [placebo] and 5.23±0.06 mmol L1 [troglitazone]). Plasma glucose 
concentrations during the euglycemic clamp procedure were stable in all 
individuals (coefficient of variation during the last 30 min: Lean 4.4±0.7%, obese 
3.1 ±0.4 (placebo) and 3.1*0.3% (troglitazone). One obese subject nearly collapsed 
during one of the two clamps [placebo], but her data were included in further 
analyses. Steady state plasma insulin concentrations during the clamp were 
587±22 pmol-L-1 in the lean, 676±19 pmol L' In the obese during placebo (P<0.01 
vs. lean), and 681±27 pmol-L1 during troglitazone (P=0.88 vs. placebo). 
Obese subjects were clearly insulin resistant as compared with lean; mean whole-
body glucose uptake was 53.9±4.3 (range 32.7-92.2) in lean, vs 27.2±3.3 (range 
11.9-46.1) д т о і к д ' min' in obese (placebo, P<0.001 vs. lean). During troglitazone, 
insulin sensitivity improved (whole-body glucose uptake from 26.2±3.4 during 
placebo to 29.9±3.4 /imolkg 'min ' during troglitazone (P=0.07, 95% confidence 
interval -0.40 to +7.47 д т о і к д ' min1)· If the collapsed individual was excluded 
from analysis, whole body glucose uptake improved from 27.4±3.6 during placebo 
to 31.9±3.0 д т о і к д ^ т і п 1 during troglitazone (P=0.035). Individual responses are 
deligned in Fig. 3. 
Glucose Infusion Rate (umol.kg.min ) 
100-
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• 
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Placebo 
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troglitazone 
Fig. 3. Distribution of insulin sensitivity in both lean and obese subjects, and individual 
response of the obese subjects to troglitazone. The individual indicated with G 
had syncopal symptoms during the clamp (troglitazone treatment). 
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Forearm glucose uptake under fasting conditions was not different between 
obese and lean subjects (0.88±0.20 in obese vs. 0.48±0.10 jumoldL'-min·1 in lean, 
P=0.09). Insulin induced an obvious increase in forearm glucose uptake in both 
groups, but the increase was larger in the lean group compared with the obese 
(placebo period): 1.03±0.45 in obese vs. 3.23±0.47 дгпоІ^ ІЛтіп ' in lean, P=0.003). 
During troglitazone, insulin-induced increase in forearm glucose uptake was 
higher compared to placebo (respectively 1.09±0.54 and 2.31±0.69 
/imol-dM-min-l, />=0.0Ό6). 
Effect of troglitazone on vascular responses to vaso-active drugs 
Acetylcholine induced a dose-dependent increase in FBF at the experimental arm, 
but the absolute or relative vascular responses were not different between lean 
and obese, nor were they affected by troglitazone, as is shown in Fig. 4 (top). FBF 
at the control arm did not change significantly during acetylcholine. After 30 min 
of equilibration, FBF was returned towards baseline values. 
Infusion of sodium nitroprusside induced a dose-dependent increase in FBF at the 
experimental arm, which was of a lesser magnitude than the response to 
acetylcholine. Again, troglitazone did not affect the absolute or relative vascular 
responses to nitroprusside, as is shown in Fig. 4 (bottom). FBF at the control arm 
was not affected by the infusions. 
The results were similar when the data were expressed in FVR or in ratio 
rDleiperimental arm/r DlcoMrol *rm. 
Δ Forearm Blood Flow (%) 
SNP 1 SNP 2 SNP3 
Fig. 4: Percentage increase in FBF in response to three subsequent doses of acetylcholine 
(top panel) and sodium nitroprusside (lower panel). 
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Effect of troglitazone on cardiovascular effects of insulin 
Insulin infusion induced a significant increase in systolic blood pressure in both 
groups (from 121.6±1.4 to 127.0±2.2 mmHg in the lean group, and from 131.9±2.8 
to 138.0±3.3 mmHg in the obese group, ANOVA P<0.001 for both). During insulin 
infusion diastolic blood pressure did not change (from 63.8±0.8 to 63.3±1.3 mmHg 
[lean], and from 72.8±1.5 to 73.1±1.2 mmHg [obese], ANOVA /»=0.56 and 0.57 
respectively). Pulse pressure increased (from 57.8±1.2 to 63.7±1.6 mmHg [lean, 
ANOVA P=0.003], and from 59.2±1.8 to 64.9±2.4 mmHg [obese, ANOVA />=0.001]). 
During insulin infusion heart rate increased (from 56.4±2.9 to 58.7±3.3 bpm in 
lean, ANOVA P=0.19, and from 60.8±3.0 to 66.1±3.9 bpm in obese, ANOVA 
P=0.005). Responses in blood pressure and heart rate were not different between 
the two groups. Troglitazone had no influence on the cardiovascular responses to 
insulin. 
Baseline arterial plasma norepinephrine concentrations were similar in obese 
(0.92±0.08 nmol-L·1) and lean subjects (0.80±0.06 nmol-L·1, P=0.26). During insulin 
infusion, arterial norepinephrine concentrations increased significantly, both in 
obese (to 1.15±0.09, percentage increase 33.4±7.6%, P=0.006 vs. baseline) and in 
leans (to 1.06±0.10 nmol-L'1, percentage increase 31.7±9.6%, P=0.001 vs. baseline), 
but the increases were not different between both groups (P=0.89). Treatment 
with troglitazone did not change baseline arterial norepinephrine concentration 
(0.84±0.06 nmol-L ', P=0.43 vs. placebo), nor the insulin-induced increase in 
norepinephrine levels (to 1.14±0.08 nmol-L·1, P=0.79 vs. placebo, percentage 
increase 39.1±9.0%, />=0.67 vs. placebo). 
Δ F o r e a r m b l o o d f l o w d u r i n g i n s u l i n (%) 
300 
200 
100 
o-
LEAN OBESE 
Fig. 5. Individual responses in percentage increase in FBF above baseline during insulin 
administration of lean (left) and obese subjects (right). 
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Intravenous insulin infusion induced a gradual increase in FBF in the control arm, 
see Fig. 5 for individual responses. FBF increased from 1.33±0.14 to 2.15±0.32 
mLdL-'min'1 (P=0.014) in the lean group, percentage increase 66.5±23.0%. Insulin-
induced vasodilation was completely blunted in the obese group; FBF from 
1.87±0.22 to 1.95±0.19 (P=0.63), percentage increase in FBF 10.1±11.3% (/>=0.04 
vs. lean). The lack of effect of insulin on vascular tone in the obese was not 
reversed by troglitazone (percentage increase in FBF from 11.3±12.3% during 
placebo to 2.2±4.9% during troglitazone, P=0.39). Identical changes occurred 
when FVR instead of FBF was used for analysis. 
The percentage increase in forearm blood flow was not significantly correlated 
with insulin sensitivity (r=0.24, P=0.25) or insulin sensitivity index (r=0.22, P=0.30). 
However, insulin-induced vasodilation showed significant correlations with age 
(r=-0.41, />=0.042), fasting insulin concentration (r=-0.42, P=0.038), and plasma 
HDL-cholesterol (r=0.43, P=0.033). 
Response to L-NMMA during hyperinsulinemia 
L-NMMA infusion during systemic hyperinsulinemia induced a dose-dependent 
vasoconstrictor response in the experimental arm, both in the obese and in the 
lean control group. Responses in the obese group were not different from those 
in lean subjects, and were not affected by troglitazone. Absolute and relative 
responses are denoted in Fig. 6. FBF at the control arm was not affected by L-
NMMA infusion. 
FBF (ml.dLlmin1) AFFJF (%) 
2-
1 • 
o-
— •— • OBESE- placebo 
— •— • OBESE-troglitazone 
- · - • LEAN 
p-NS 
Base L-NMMA1 L-NMMA2 L-NMMA3 
Fig. 6. Absolute (top panel) and relative (in percentage, bottom panel) changes in FBF 
during three subsequent doses of L-NMMA. 
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Correlations between metabolic parameters and vascular responses to 
vasodilators/constrictors. 
If data of both obese (placebo period) and lean subjects were combined, insulin 
sensitivity was correlated with other metabolic parameters as fasting insulin 
concentration, HDL-cholesterol, and NEFA concentration (r=-0.56, P=0.003), but 
not with responses to acetylcholine, nitroprusside and insulin-induced 
vasodilation. Insulin sensitivity showed a clear correlation with body mass index 
(r=0.67, P<0.001). 
Discussion 
The major new finding of the present study is that obese subjects, although 
exhibiting clearly decreased vasodilator responses to insulin in comparison to lean 
individuals, do show normal responses to acetylcholine, sodium nitroprusside and 
L-NMMA. Furthermore, we confirm that troglitazone improves insulin sensitivity, 
but the changes are moderate, and do not lead to changes in insulin-induced 
vasodilation or endothelium-dependent vasoactive responses. 
Troglitazone and insulin resistance 
In this study, as in many others, we show that obesity is associated with insulin 
resistance. As such, obesity represents a situation of "pure" insulin resistance, and 
changes in this parameter will not be confounded by changes in blood glucose 
concentrations that have been shown to have a direct effect on insulin sensitivity 
itself ("glucose toxicity") (30). Although healthy, normotensive subjects were 
selected, they turned out to have a slightly higher but significantly elevated 
diastolic blood pressure as compared with the lean group, and clearly elevated 
plasma triglyceride and NEFA concentrations, all factors consistent with the 
insulin resistance syndrome, or syndrome X (31). Notwithstanding a slight overlap, 
there was a clear difference in insulin sensitivity between the two groups, with 
mean glucose infusion rates in the lean group being nearly twice as high as in the 
obese group. Troglitazone improved a number of related parameters: total-body 
as well as forearm insulin-mediated glucose uptake improved, diastolic blood 
pressure decreased, and elevated insulin and lipid levels had a tendency to 
decrease. These treatment results of troglitazone are consistent with the reported 
results of studies in vitro (32) and in animals (19,20), as well as in humans 
(21,22,33-35). However the changes under these strict double blind placebo 
controlled conditions were only mild, and a considerable difference with the 
obtained values in the lean control group remained. It might be that the dose we 
chose was too low, although a recent large multi-centre trial showed no 
difference in effect of a dose range of 200-800 mg daily (36). In the latter 
placebo-controlled study, the effects of troglitazone on glycémie parameters were 
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modest too (36). Our study duration might be relatively short to exhibit a full 
effect; significant effects of the drug on metabolic parameters have however 
been reported after 4-8 weeks (34,35). In addition, a long treatment period would 
in this crossover design probably induce more extra-treatment bias. More studies 
will be needed to characterize the full effect of troglitazone. 
Troglitazone did not change fasting glucose concentration, and fasting insulin 
concentrations (if anything) decreased, which is in line with improvements of 
glucose uptake and insulin sensitivity. In this regard, the slight but significant 
increase in HbA,c-levels is surprising. It suggests that this increase is not due to 
changes in glycémie level, but probably due to an intrinsic effect of troglitazone 
on red blood cell mass, survival or production. A tendency to a slightly lower 
neutrophil count was observed earlier (36), as were decreases in red blood cell 
count, hemoglobin/hematocrit, and increases in LDH (33). Other studies did not 
report these effects (21,34-36). In our group of subjects hemoglobin concentration 
decreased from 8.1±0.2 to 7.9±0.2 mmol-L', P=0.19, whereas hematocrit remained 
equal. The putative interaction of troglitazone with hematological parameters 
might be of high clinical significance, because such an effect, may mask the effect 
of troglitazone on glucose metabolism (37). Probably, this effect explains part of 
the modest changes in HbAu levels in response to troglitazone, despite more 
pronounced improvement in glycemia, reported so far (36). Clearly this aspect 
deserves more investigation. 
Insulin-induced vasodilation 
It has been reported by several investigators that insulin induces vasodilation in 
skeletal muscle (2,6), an effect that is impaired under conditions of insulin 
resistance (8-10,38). Insulin-induced vasodilation may enhance glucose uptake in 
insulin-sensitive tissues, and, further along that line, a diminished insulin-induced 
vasodilation may thus explain part of the insulin resistance (8,9). Therefore, the 
mechanism of insulin's vasodilator effect is an issue of significant scientific 
importance, and improvement of insulin-induced vasodilation may be an 
important factor in improvement of insulin sensitivity as a whole. 
In this study we confirm the results of Laakso showing that obese subjects have 
blunted vasodilator responses to insulin (8). Improvement of metabolic control by 
insulin treatment of NIDDM patients in poor metabolic control was capable of 
improving insulin sensitivity, but also of vasodilatory response to insulin (39), 
suggesting that the defect may be reversed by reversion of insulin resistance. In 
our study however, we were not able to show any beneficial effect of 
troglitazone on insulin-induced increase in forearm blood flow, despite an 
improvement of insulin sensitivity. It may be that the slight improvement in 
insulin sensitivity was clearly insufficient to improve vascular function; indeed, 
even during troglitazone, insulin sensitivity was still considerably diminished in 
obese subjects, compared with leans. 
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We cannot exclude that the lack of insulin-induced vasodilation is based on 
structural changes in vascular function in obese subjects, which has been 
suggested before (40). However in our obese group, responses to endothelium-
dependent as well as in-dependent vasodilators were absolutely similar with that 
in the lean, arguing against this possibility. 
In this study we were not able to construct a full dose response curve of the 
effect of insulin on blood flow, but the insulin concentrations during the clamp 
were in the high physiological range. At these insulin levels, the discrimination 
between lean and obese should be maximal (8). Therefore, if changes in 
vasodilatory effects of insulin might occur, we expected that changes would be 
most pronounced within this dose range. 
Blood flow was measured at the forearm, with a noninvasive Plethysmographie 
technique. Although some investigators have used leg blood flow and dye 
dilution techniques to measure blood flow (8,10,12), in general, studies that use 
plethysmography have shown reproducible results, in agreement with earlier 
findings (16,41,42). Therefore we feel that the lack of effect of troglitazone does 
not seem to be related to the investigational methods we have used. 
Endothelial function and insulin resistance 
The last decade an overwhelming amount of data has pointed to the importance 
of the vascular endothelium under physiological and pathophysiological 
conditions (43,44). It has been reported by two groups of investigators that the 
vasodilator action of insulin can be blocked by the inhibitor of nitric oxide 
synthase L-NMMA, thus suggesting an endothelium-dependent mechanism of 
action (11,12). This implies that a diminished vasodilatory response to insulin 
might reflect a disturbed function of the endothelium. In a number of insulin 
resistant disorders both a diminished insulin-mediated vasodilation and an 
impaired endothelial function have been described, indeed suggesting a coupling 
between insulin resistance and endothelial function (7). However, in our study we 
were not able to reproduce the recently reported significant relationship between 
responses to L-NMMA and insulin sensitivity (18). If any, we found a tendency 
towards a negative correlation. In the referred study, there was no similar 
relationship between insulin resistance and responses to acetylcholine (18), which 
is in complete accordance with our findings. Recently, attenuated vasodilator 
responses to metacholine were described by Steinberg et al in insulin resistant 
obese subjects (17). This defect did exist already under baseline conditions, but 
was more pronounced during hyperinsulinemia. Responses to the endothelium-
dependent vasodilator acetylcholine and to the NO-inhibitor L-NMMA in our 
study were however absolutely similar between obese and lean groups of 
subjects, despite large differences in insulin sensitivity between both groups. We 
did not measure responses to acetylcholine during hyperinsulinemia, and thus 
cannot exclude that a difference under these conditions may exist. A significant 
CHAPTER 8 
correlation between insulin-sensitivity index and the maximal vasodilator 
response to metacholine and not with insulin sensitivity itself has been reported 
(17), but was not confirmed in our study. The study of Steinberg and our study 
show small, but probably relevant differences. Although strictly spoken 
normotensive, their study population had higher blood pressure values (MAP 
approximately 100 mmHg, vs. approximately 92.5 mmHg in our study), possibly 
explaining part of the observed differences (15). The vascular beds in which the 
investigations were performed were different. Steinberg et al used metacholine 
as endothelial-dependent vasodilator, and it has been reported that this may not 
be 100% nitric oxide dependent (45). Further studies will be required to gain 
more insight in this controversial area. 
The fact that we did not detect a specific defect in vascular endothelial function 
in obese insulin resistant subjects, despite a clear diminished insulin-induced 
vasodilation, suggests that alternative mechanisms might be responsible for 
insulin-mediated vasodilation. A recent in-vitro study supports our findings; in 
arterial strips, insulin caused decreases in vascular tone, that was however not 
inhibited by L-NMMA, but definitively by inhibitors of ATP-dependent potassium 
channels (46). These findings suggest thus an alternative pathway for insulin's 
vascular effects. We have demonstrated that ouabain is also capable of inhibiting 
insulin-induced vasodilation, hence suggesting that the enzyme Na*-K*-ATPase is 
involved (6). Consequently, alternative mechanisms for insulin-induced 
vasodilation seem to emerge, although these in itself do not rule out eventual 
involvement of the vascular endothelium. 
Since we did not detect a specific endothelium-related defect (our à priori 
hypothesis), the lack of effect of troglitazone treatment on this parameter is 
hardly surprising. 
In conclusion, we report that obese, normotensive individuals, with insulin 
resistance show a blunted vasodilator response to insulin, despite preserved 
endothelium-dependent and -independent vascular responses. Troglitazone 
improved metabolic parameters related to insulin sensitivy, but did not change 
the effect of insulin on vascular tone, nor on endothelial function. 
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Non-insulin-dependent diabetes mellitus (NIDDM), a disease with a very high 
prevalence in western society, is in the large majority of cases accompanied by a 
reduced biological effect of insulin. This reduced metabolic action of insulin is 
termed insulin resistance. During the last decade it has become clear that insulin 
resistance is not restricted to NIDDM, but is also a prominent feature of numerous 
related disorders like hypertension, obesity and dyslipidemia; disorders that are 
all known risk factors for the development of cardiovascular diseases. As such it 
has been postulated that insulin resistance might be a common pathogenetic 
factor. 
Under normal conditions, insulin resistance will be compensated by extra 
secretion of insulin, hence leading to hyperinsulinemia. Earlier scarce and more 
recent data have pointed to direct "cardiovascular" effects of insulin, apart from 
the well known metabolic actions. Some of these effects might play a role in the 
development of hypertension or cardiovascular disease. In this thesis some of 
these "non-metabolic" effects are investigated, both in healthy normal 
individuals, and in human diseases characterized by insulin resistance. 
The first chapter provides an overview of the effects of insulin on vascular tone 
and on the sympathetic nervous system; those two actions of insulin that form the 
topic of this thesis. At the end of chapter one, a number of items are listed, that 
have subsequently been issued in the subsequent chapters. 
While it seems generally accepted that systemic hyperinsulinemia induces 
vasodilation in skeletal muscle, controversy exists whether insulin acts also at a 
local level. Therefore we investigated whether local administration of insulin, 
leading to regional plasma insulin concentrations in the physiological range, 
would also be capable to induce vasodilation in skeletal muscle vascular bed. In 
chapter two we demonstrated that local insulin infusion induces a vasodilator 
action in the forearm vascular bed in healthy individuals. However, this effect was 
of moderate magnitude, slow in onset and gradually increasing. Even after 3 
hours the effect appeared not to be maximal. Part of the controversy in the 
literature could therefore be based on the time course of the vasodilator effect; 
an effect that was of similar magnitude as in reports in which insulin was infused 
intravenously (systemic hyperinsulinemia). Although insulin induced a parallel 
increase in forearm glucose uptake, that preceded vasodilation, further 
stimulation of glucose metabolism by extra infusion of glucose did not augment 
the vascular effect. Based on these results, we conclude that the vasodilator 
response to insulin can at least partly be explained by a direct vascular effect. 
Insulin-mediated glucose uptake precedes this effect, but does not seem to be an 
important determinant of the effect. 
After we had shown a direct vasodilator effect of insulin, we questioned whether 
this action could be mediated by a modulation of insulin on a- or ß-adrenoceptor 
sensitivity. In an extensive number of studies in healthy young individuals, it could 
be demonstrated that insulin in itself did not affect the vasoconstrictor responses 
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to norepinephrine ¡η combination with propranolol (pure α-receptor agonism), 
norepinephrine alone (a- + ß-receptor effect) or the vasodilator responses to 
isoproterenol (pure ß-receptor agonism). As such we state in chapter three that 
regional hyperinsulinemia does induce vasodilation, but this is not due to insulin-
induced modulation of a- or ß-adrenoceptor responsiveness. 
In chapter four, we demonstrate that vasodilation in the skeletal muscle vascular 
bed, as a result of systemic hyperinsulinemia, can be inhibited by locally 
administered оиаЬаіл. Because ouabain is a specific inhibitor of the sodium-
potassium pump, these results strongly imply that stimulation of the enzyme 
Na*-K*-ATPase is involved in insulin's vasodilator effect. However we also provided 
evidence that activation of Na*-K>ATPase could occur at the level of the 
endothelial cell rather than at the vascular smooth muscle cell. This latter finding 
could explain why insulin-induced vasodilation can also be suppressed by 
inhibition of nitric oxide release by WG-monomethyl L-arginine (L-NMMA), as 
described by others. 
The effects of insulin on adrenomedullary function represent an area of research 
that has received little attention up to now. By means of epinephrine tracer 
kinetic studies, we were able to show that insulin in itself stimulates adrenal 
epinephrine secretion. The results of these studies are described in chapter five. 
Although the effect of insulin on adrenomedullary function is small, it might play 
a role in insulin's influence on vascular tone. 
Further studies were performed in insulin resistant subjects. In chapter six the 
effects of insulin on vascular tone and sympathetic nervous system were studied 
in non-obese NIDDM patients, who had only mild glycémie intolerance. These 
subjects indeed were resistant to the effect of insulin on glucose metabolism as 
determined by the euglycemic hyperinsulinemic clamp procedure, and showed 
hyperinsulinemic responses to an oral glucose load. However the vasodilator and 
sympatho-activator effects of insulin were not different between NIDDM and 
control subjects. Also responses to other sympathetic stimuli were preserved. 
These findings imply that the NIDDM subjects, being chronically hyperinsulinemic, 
could endure chronic stimulation of the sympathetic system. This might 
subsequently induce cardiovascular sequelae. 
In chapter seven a homogenous group of patients suffering from familial 
combined hyperlipidemia (FCH) were studied. Based on surrogate measurements 
this disorder was earlier suggested to represent an insulin resistant state. By 
studying non-obese normotensive subjects, and comparing them with their non-
affected relatives, we were able to avoid a number of confounding factors. We 
demonstrated that this group indeed was insulin resistant as determined by 
euglycemic hyperinsulinemic clamp. In addition, a diminished vasodilator response 
to insulin was observed, which is in line with findings in other insulin resistant 
states. 
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Finally, in chapter eight, obese subjects, clearly demonstrated to be insulin 
resistant as compared to lean control subjects, were treated with troglitazone. 
Troglitazone is a representative of a new class of drugs; thiazolidine-diones, a 
group that acts as "insulin sensitizer". We were able to confirm earlier reports 
that insulin-induced vasodilation was blunted in obese subjects. Although 
troglitazone indeed improved insulin sensitivity, the changes were only moderate, 
and the compound did not restore the vasodilator responses to insulin. No 
associations were established between insulin sensitivity and endothelial function. 
In conclusion, these studies demonstrate that insulin has besides its well known 
action on human metabolism, several effects on cardiovascular function. Insulin 
induces vasodilation in the skeletal muscle vascular bed by a direct action on the 
vessel wall. This direct effect is at least partly mediated by stimulation of Na*-K*-
ATPase, and not by modulation of a- or ß-adrenoceptor responsiveness. Insulin's 
vasodilator action is diminished or absent in most insulin resistant states, and not 
reversed by drugs that stimulate the metabolic actions of insulin, such as 
troglitazone. 
Besides vasodilation, insulin stimulates the sympathetic nervous system. This 
activation of the sympatho-adrenal system seems, however, not caused by the 
insulin-mediated vasodilation. In addition, responses to stimulation of the 
sympathetic nervous system were not diminished in insulin resistant states as 
NIDDM, obesity and dyslipidemia. Therefore resistance to the metabolic effects of 
insulin, does not necessarily imply resistance to the insulin-induced sympathetic 
stimulation. This "selective insulin resistance" may play an important role in the 
development of hypertension and/or cardiovascular complications in patients 
exhibiting hyperinsulinemia in response to insulin resistance. 
Studies in humans are hampered by the difficulties in assessing vascular and 
sympathetic functions in-vivo. Additional work will therefore be needed to 
further unravel the different aspects of insulin action in human health and 
disease. 
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Type 2 diabetes mellitus (suikerziekte), ook wel ouderdomsdiabetes of niet van 
insuline afhankelijke diabetes mellitus genoemd, is een frequent voorkomende 
ziekte in onze bevolking. Bij deze ziekte bestaat er enerzijds een tekort aan 
insuline, terwijl anderzijds de werkzaamheid van insuline is verminderd. Deze 
afname in de gevoeligheid van de weefsels voor het hormoon insuline wordt ook 
wel aangeduid als insulineresistentie. Door de insulineresistentie is in feite méér 
insuline nodig om de bloedglucosewaardén binnen normale grenzen te houden. 
Dit verklaart waarom bij een deel van de mensen met type 2 diabetes zelfs meer 
insuline in het bloed circuleert dan bij mensen zonder diabetes. Desondanks is er 
echter nog steeds te weinig insuline om de glucoseconcentratie op een normaal 
niveau te kunnen handhaven. 
Insulineresistentie komt niet alleen bij patiënten met suikerziekte voor, maar ook 
bij mensen met overgewicht, hoge bloeddruk en bepaalde vetstofwisseling-
stoornissen. In al die gevallen is er tevens sprake van verhoogde ¡nsuline-
concentraties in het bloed, waardoor de glucosestofwisseling toch normaal kan 
blijven. Bij de genoemde aandoeningen, die gepaard gaan met insulineresistentie, 
blijkt er een verhoogde kans op het optreden van hart- en vaatziekten te 
bestaan. Men veronderstelt nu dat het bestaan van insulineresistentie een 
gemeenschappelijke factor is, die van betekenis zou kunnen zijn bij het ontstaan 
van deze hart- en vaatziekten. De mogelijke rol die verhoogde bloedconcentraties 
van insuline daarbij zouden kunnen spelen vormt het hoofdthema van dit 
proefschrift. In de hoofdstukken twee tot en met acht worden verschillende 
directe effecten van insuline op de functie van het hart- en vaatstelsel 
beschreven. 
In hoofdstuk één staan de feiten weergegeven zoals die op het moment van het 
schrijven van dit proefschrift bekend waren. Een van de opvallende effecten van 
insuline is de directe werking op bloedvaten. Insuline veroorzaakt vooral in het 
spierweefsel een duidelijke bloedvatverwijding. In principe is dit een nuttig 
effect, omdat daarmee de doorbloeding toeneemt en daarmee de aanvoer van 
voedingsstoffen (glucose). In hoofdstuk twee wordt aangetoond dat de 
vaatverwijdende werking van insuline berust op een rechtstreeks effect op de 
bloedvaten. Deze conclusie berust op experimenten waarbij insuline direct in de 
slagader van de onderarm werd toegediend. Uit latere experimenten bleek dat 
het vaatverwijdend effect van insuline niet berust op een verandering in de 
gevoeligheid voor vaatverwijdende of vernauwende stoffen die normaal in het 
lichaam circuleren (hoofdstuk drie). De verklaring voor het vaatverwijdend 
vermogen van insuline ligt mogelijk in de stimulatie van de uitwisseling van 
natrium en kalium over de celmembraan. Wellicht werkt insuline op een 
enzymsysteem dat in de wand van de cel zit en zorgt voor het in- en uitpompen 
van deze ionen. Het was al langer bekend dat insuline deze zogenaamde natrium-
kalium pomp stimuleerde. In dit proefschrift wordt nu beschreven dat remming 
van de activatie van die pomp de normaal optredende vaatverwijding onder 
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invloed van insuline in de spieren kan voorkomen (hoofdstuk vier). 
Insuline leidt niet alleen tot bloedvatverwijding, maar blijkt ook activatie van het 
onwillekeurig zenuwstelsel (in medische termen: het sympathisch zenuwstelsel) te 
veroorzaken (toegenomen afgifte van stresshormonen in het lichaam). Het 
nauwkeurig meten van de activiteit van dit zenuwstelsel is overigens erg moeilijk. 
Hiervoor werd een methode gebruikt met radio-actief gemerkt stresshormoon. 
Daarmee kon overtuigend worden aangetoond dat insuline de afgifte van het 
stresshormoon noradrenaline stimuleert, hetgeen ook al eerder door anderen was 
gesuggereerd. Een nieuwe bevinding van ons onderzoek was, dat insuline ook de 
afgifte van het stresshormoon adrenaline door de bijnier stimuleerde, hetgeen 
staat beschreven in hoofdstuk vijf. 
Het effect van insuline op de bloedvaten en op het onwillekeurige zenuwstelsel 
werd tevens onderzocht bij mensen met type 2 diabetes mellitus (hoofdstuk zes). 
Zoals verwacht was de gevoeligheid voor de werking van insuline op de 
glucosehuishouding verminderd (insulineresistentie). Daarentegen bleek het 
stimulerend effect op het sympathisch zenuwstelsel normaal. Dit is mogelijk 
ongunstig, aangezien de continu verhoogde insulineconcentratie ¡n het bloed tot 
een aanhoudende verhoogde afgifte van stresshormonen zou kunnen leiden, 
hetgeen hoge bloeddruk of hart- en vaatziekten zou kunnen veroorzaken. In ons 
onderzoek konden wij aantonen dat het bovenbeschreven fenomeen zich ook 
voordoet bij mensen met insulineresistentie op basis van overgewicht of 
vetstofwisselingsstoornissen (hoofdstuk zeven). 
In eerder onderzoek was al aangetoond dat het bloedvatverwijdende effect van 
insuline bij mensen met overgewicht sterk was verminderd (zie ook hoofdstuk 
acht). Dit was eveneens het geval bij mensen met een erfelijke 
vetstofwisselingstoornis, gepaard gaande met insulineresistentie (hoofdstuk 
zeven). In hoofdstuk acht staat beschreven dat behandeling van mensen met 
overgewicht met een nieuw geneesmiddel dat de insulineresistentie enigszins 
vermindert (troglitazone), niet leidde tot een verbetering van de vaatverwijdende 
werking van insuline. 
Samenvattend: Insuline heeft niet alleen een duidelijke invloed op de (glucose-) 
stofwisseling, maar ook op de bloedvaten en de activiteit van het onwillekeurig 
zenuwstelsel. Een verminderde werking op de stofwisseling hoeft niet altijd 
gepaard te gaan met een vermindering van de andere effecten van insuline. Een 
dergelijke dissociatie van de verschillende effecten van insuline zou een rol 
kunnen spelen bij het ontstaan van hoge bloeddruk of hart- en vaatziekten bij de 
bovenbeschreven aandoeningen, die gepaard gaan met insulineresistentie. 
174 CHAPTER 10 
175 
176 
Dankwoord 
De voltooing van een proefschrift is een moment van voldoening, opluchting en 
dankbaarheid. Voldoening vanwege het bereikte resultaat, opluchting omdat 
deze klus geklaard is, en dankbaarheid om de steun van zovelen. Een aantal wil 
ik nog met name bedanken. De vele vrijwilligers en patiënten voor hun inzet, 
doorzettingsvermogen en opgewektheid tijdens de verschillende onderzoeken. De 
research verpleegkundigen Eugenie Olde Riekerink en Arnoud Jansen van 
Rosendaal, en de physicus Joost den Arend, niet alleen voor hun hulp, maar zeker 
ook voor hun warme menselijke belangstelling voor onderzoeker en onderzochte. 
De medewerkers van het laboratorium voor Voortplanting en Endocrinologie 
(hoofd: Dr. F. Sweep), met name Sjaak Willemsen, dankzij wiens inzet de 
bepalingen van de catecholamine-concentraties ongekend nauwkeurig waren, en 
Rob Hermsen die zorg droeg voor de constantheid van de insulinebepalingen. De 
medewerkers van het centraal klinisch-chemisch laboratorium (hoofd: Dr. J. 
Willems) en algemene interne geneeskunde (hoofd: Dr. P. Demacker) voor de 
zorgvuldige verwerking van de diverse bloedmonsters. De medewerkers van de 
keuken van ЕЮ en de diëtisten Ricky Lamers en Hilde van Koolwijk voor de vele 
koolhydraatrijke maaltijden, en met name voor het enthousiasme waarmee ze 
hielpen. De laboranten van de afdeling nucleaire geneeskunde (hoofd: Prof. Dr. F. 
Corstens), met name Emile Koenders voor de hulp bij de bereiding van de radio-
actieve oplossingen. De keuzevakkers Jan-Willem Meijer, Marian Scheepers, Annet 
Schefman, Alphons den Broeder, Walter Brookelmans, Marian Heeremans, en 
Maya Ong voor hun inzet. Jacques Lenders mijn co-promoter dank ik voor zijn 
stimulerende opmerkingen, zijn optimisme en zijn integriteit. Tevens dank ik hem 
voor het vertrouwen dat hij in mij stelde door mij voor te dragen voor een 
fellowship in het National Institute of Health (Bethesda, USA), en de hulp bij de 
voorbereidingen hiervoor. Theo Thien voor zijn warme belangstelling en 
enthousiasme. Jos Lutterman voor de belangrijke rol die hij speelde bij mijn 
verdere bekwaming in de diabetologie en voor zijn relativerende opmerkingen. 
Jos van der Meer voor zijn in mij gestelde vertrouwen. Mijn medepromovendi 
voor hulp, samenwerking, en met name gezelligheid. Mijn collega's van de 
diabeteswerkgroep, die altijd bereid waren bij te springen en het werken tot een 
plezier maakten. Mijn ouders waarvan ik plichtsbesef en zelfstandigheid leerde, 
en afmaken waaraan je begint. Paul Smits, mijn promotor, maar ook steun en 
toeverlaat. Met hem kon ik alles bespreken inclusief frustaties. Zonder hem zou 
dit proefschrift er echt niet gekomen zijn. Hij was ook degeen die mij enthousiast 
maakte voor wetenschappelijk onderzoek in het algemeen. Johanna tenslotte, 
voor haar voortdurende kritische toon, maar desondanks onvoorwaardelijke 
steun. 
177 
178 
Curriculum Vitae 
De schrijver van dit proefschrift werd op 8 maart 1960 geboren aan boord van het 
moterschip "Johanna". Tot zijn zevende jaar bleef hij meevaren met zijn ouders. 
De lagere school werd voltooid in vijf jaar, in Beneden-Leeuwen, alwaar hij 
inwoonde bij zijn tante Anna. In 1978 werd het Atheneum В diploma (cum laude) 
aan het Pax Christi College te Druten behaald. In datzelfde jaar werd een 
aanvang gemaakt met de studie geneeskunde aan de Katholieke Universiteit te 
Nijmegen. Het doctoraal examen werd cum laude behaald in 1983, het 
artsexamen op 15 maart 1985. Vanaf 1 april 1985 was hij in opleiding tot 
internist, aanvankelijk in het St Elizabeth Ziekenhuis te Amersfoort (opleider Dr. 
D. Bonte), per 1 mei 1987 in het academisch ziekenhuis St Radboud te Nijmegen 
(opleider Prof Dr. A. van 't Laar). Vanaf 1 mei 1990 werkt hij als internist op de 
afdeling algemene interne geneeskunde met als specifiek aandachtsveldsveld de 
zorg voor mensen met diabetes mellitus. Vanaf oktober 1992 heeft hij gewerkt op 
een project van dr. P. Smits; de daarbij verkregen resultaten hebben ondermeer 
geleid tot dit proefschrift. Teneinde het diabetesonderzoek in de toekomst verder 
te kunnen ondersteunen, zal hij zich in eerste instantie aansluitend 
wetenschappelijk bekwamen dankzij een beurs voor een verblijf als "visiting 
associate" aan het National Institute of Health (Bethesda, Maryland, USA, 
begeleider Dr. D.S. Goldstein), vanaf 1 maart 1997. De vereiste amerikaanse 
artsexamens (ECFMG) werden daartoe inmiddels behaald. De auteur van het 
proefschrift is gehuwd met Johanna van den Berg, samen hebben ze drie 
kinderen, Hedwig, Reinier en Laura. 
179 
1801 CHAPTER 1 
CHAPTER ONE \181 
182 I CHAPTER 1 
Stellingen 
behorende bij het proefschrift 
Cardiovascular effects of insulin. 
Studies in normal and insulin resistant subjects. 
Cees J.J. Tack 
19 februari 1997 
Insuline heeft een direct vaatverwijdend effect, dat langzaam tot stand 
komt en sterk varieert tussen verschillende personen. 
Dit proefschrift 
Het vaatverwijdend effect van insuline wordt niet veroorzaakt door een 
verandering in de gevoeligheid van de vaatwand voor α- of ß-adrenerge 
stimuli. 
Dit proefschrift 
CJJ Tack, Ρ Smits. Insulin does not modulate ß-adrenergic 
responsiveness. Circulation (letter) 1997; 95:532-534. 
Insuline kan worden beschouwd als een stressor van het sympathisch 
zenuwstelsel, omdat het leidt tot een toename van de afgifte van de 
stresshormonen noradrenaline en adrenaline. 
Dit proefschrift 
Het vaatverwijdend effect van insuline lijkt, tenminste voor een deel, te 
berusten op activatie van de natrium-kalium pomp in de celmembraan. 
Dit proefschrift 
De verminderde insuline-geïnduceerde vaatverwijding bij mensen met 
overgewicht berust niet op een functionele stoornis van het endotheel. 
Dit proefschrift 
Er bestaan talloze verschillende vormen van suikerziekte die worden 
geschaard onder de term type 2 diabetes. 
Maturity onset diabetes of the young (MODY) is een autosomaal dominant 
overervende vorm van type 2 diabetes mellitus, en een uitstekend model 
voor genetisch onderzoek. 
CJJ Tack. Ned Tijdschr Geneeskd 1995; 139:2127-9. 
MJ Dronsfield, CJJ Tack, ADR Mackie, JD Baird, SC Bain, AT Hattersley. 
Submitted. 
Het genetisch defect bij MODY-1 en MODY-3 blijkt gelegen in een mutatie 
van respectievelijk hepatocyte nuclear factor-4ct en -1a. De relatie tussen 
de functie van deze genen en diabetes is momenteel volstrekt onduidelijk, 
maar opheldering daarvan zal belangrijke informatie opleveren. 
К Yamagata, et al. Nature 1996; 384:455-458 en 458-460. 
De hoogte van het HbA,c-gehalte, een veel gebruikte maat voor metabole 
diabetesinstelling, wordt mede bepaald door factoren die van invloed zijn 
op de rode bloedcelkinetiek. 
CJJ Tack, JFM Wetzels. Diabetes Care 1996; 19:775-6. 
CJJ Tack, JA Lutterman. Ned Tijdschr Geneeskd 1995; 139:2278-81. 
Deskundigheid met betrekking tot de diagnostiek en behandeling van 
diabetische voetproblemen is schaars. 
Eigen waarneming 
Voor het reproduceerbaar vaststellen van het bestaan van diabetische 
neuropathie, is een eenvoudig gestandaardiseerd lichamelijk onderzoek zo 
slecht nog niet. 
CJJ Tack, PM Netten, M Scheepers, JW Meijer, Ρ Smits, JA Lutterman. 
Neth J Med 1994; 44:41-49. 
Blauwe verkleuring van tenen kan een van de eerste uitingen zijn van het 
feochromocytoom. 
CJJ Tack, JWM Lenders. Arch Int Med (Letter) 1993; 153:2061. 
Vergeleken met de zorg waarmee een manuscript wordt gemaakt, is de 
keuze van het tijdschrift waaraan het ter publicatie wordt aangeboden, 
relatief subjectief en intuïtief. 
De maatschappelijk toegekende waarde van een betaalde baan 
buitenshuis staat in schril contrast met de opvatting dat kinderen krijgen 
en opvoeden een weloverwogen beslissing van beide ouders is, waarbij het 
belang van het kind voorop dient te staan. 
Het enthousiasme voor een werkstage in de Verenigde Staten wordt sterk 
op de proef gesteld door de eindeloze reeks bureaucratische hindernissen 
die in binnen- en buitenland moeten worden genomen. 
Eigen frustatie 
De introductie van de vaatwasmachine heeft geleid tot een verlies van 
menig goed gesprek. 
Een diabetes patient hoeft niet altijd scherp ingesteld te zijn, een co-
assistent daarentegen wel. 
ALCO-groep 151 
Medisch specialisten hebben een belangrijke achterstand ten opzichte van 
huisartsen waar het gaat om het voeren van een electronisch medisch 
dossier. 
JL van Deursen, huisarts te Zutphen 
De introductie van de intensivist op de intensive care leidt niet tot 
kwaliteitsverbetering indien de collectieve zorg verminderd. 
AIM Soomers, internist/intensivist te Alkmaar 
Wie het eerste knoopsgat heeft gemist, krijgt zijn jas nooit meer goed 
dicht. 
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